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Abstract
Processes leading to the in vitro activation of progeiatinase-A, 
progelatinase-B and procollagenase were examined. Progelatinase-A can be 
activated by treatment with 4-aminophenyl mercuric acetate or by matrilysin and 
collagenase. The former induces an intramolecular self-cleavage before further 
intermolecular cleavages generate the mature enzyme. Whilst matrilysin can 
process progelatinase-A to the mature form, collagenase can only generate an 
intermediate by cleaving after N37 in the bait region. This intermediate is identical 
to that produced by a human tumour cell-line in culture. Gelatinase-A reciprocates 
the action of collagenase by completing the activation of the latter to generate a 
form of collagenase with full collagenolytic activity. This has been described as 
superactivation and is commonly associated with the action of stromelysin. It 
correlates with the appearance of Fsi at the amino-terminus.
The C-terminal domain plays no role in catalysis but may be important for in 
vivo activity. This is particularly evident for collagenase which loses the ability to 
cleave collagen in its absence. The interaction between collagenase and collagen 
was shown to be a potential target for designing inhibitors of collagen breakdown.
The properties of a series of reversible, competitive hydroxamic acid matrix 
metalioproteinase inhibitors were studied. Incorporation of a phenylpropyi group in 
the P 1 ' position produced inhibitors with picomolar affinities for the gelatinases and 
discriminated against collagenase and matrilysin and other classes of zinc 
metallopeptidases. The high affinity of these inhibitors for gelatinase-A was shown 
to derive from a combination of diffusion limited association rates and very slow 
dissociation rates.
Methods were developed to allow the study of the pharmacokinetic 
properties of these inhibitors. Chemical modifications at the P2 ’ and P3 ’ positions 
were shown to result in inhibitors with oral bioavailabilities of greater than 30% in 
the mouse.
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CHAPTER 1
INTRODUCTION 
1.1: Introduction
In cancer the spread of tumour cells from a primary site to colonise 
distant organs is called metastasis. When cancer treatment fails it is the primary 
cause of patient death (Liotta, 1992). Proteolytic enzymes belonging to the 
matrix metalioproteinase (MMP) family have been implicated in this process 
and are currently the target of a large pharmaceutical effort to develop novel 
anti-metastatic agents. The work presented in this thesis examines (1) The 
biochemistry of these enzymes and (2) the design of synthetic inhibitors of 
MMPs. An overview of this field of research is presented in this Chapter in order 
to provide a basis for discussion in later Chapters.
1.2: Tumour invasion and metastasis
1.2:1 The stages of tumour invasion and metastasis
Basement membranes play an important role in maintaining the integrity of 
organ structures in the body. The destruction of these membranes is a common 
feature of tumour growth. They are comprised of high molecular weight matrix 
proteins namely, type IV collagen, laminin and proteoglycans together with small 
amounts of nidogen (Kleinman et al., 1982; Hassell et al., 1985). The 
surrounding stroma is also made up of matrix molecules, of which the fibrillar 
collagens are the major structural elements. Tumour invasion is the process by 
which tumour cells disrupt these anatomical barriers and invade the surrounding 
tissues. Some tumour cells also acquire the capability to enter the lymphatic or 
blood system (intravasate) and then to escape the circulation (extravasate) and 
proliferate at a secondary site. This is known as metastasis and it depends on a 
sequence of events, some of which allow the cells to attach to basement 
membranes and others which allow the cells to penetrate these membranes and 
invade the underlying tissue (Fig.1.1). Endopeptidases have been implicated in 
stages which require the dissolution of physical barriers. Additionally, since the 
formation of new blood vessels (angiogenesis) requires the penetration of
Figure 1,1
The metastatic cascade
The steps involved in tumour cell invasion and metastasis
Transfc^mation
Growth
T
Angiogenesis *
^  Detachment ^  '
Invasion * 
intravasation / Release *J
Survival (Host interactions)
ArrestI
Extravasatic^ /  invasion * 
Growth /  Angiogenesi^ /  (Micrometastasis) 
Clinically important metastasis
Tumour cell invasion and metastasis is a sequential process involving many 
celhcell and cel I: matrix interactions.The above diagram (Hart and Saini, 1992) 
illustrates the steps required for a tumour cell to metastasise from a primary 
tumour to a secondary site. Steps where proteinases are presumed to be 
involved are labelled (*)
basement membrane by endothelial cells these same enzymes may contribute to 
the growth of the tumour itself (reviewed in Liotta et al., 1991).
1.2:2 The involvement of proteinases in tumour invasion and metastasis
There are four major classes of proteinase which can be categorised according 
to the amino acid residues involved in catalysis. Elevated levels of all of these 
classes (aspartyl, serine, cysteine and métallo) have been correlated with tumour 
invasiveness (reviewed in Moscatelli and Rifkin,1988; Duffy, 1992). These 
include plasminogen activators (serine) (Quigley et ai, 1987; Reich et al., 1988; 
Dano et al., 1985; Schmitt et al., 1992), cathepsin B (cysteine), cathepsin D 
(aspartyl) (Thorgeirsson et al., 1985; Rochefort, 1990; Sloane et al., 1990; Chen,
1992) and a range of matrix metalloproteinases (Liotta et al., 1980; Ostrowski et 
al., 1988; Templeton et al., 1990; McDonnell and Matrisian, 1990; Stetler- 
Stevenson, 1990).
Increased MMP expression has been correlated with the invasiveness of 
several tumour types and the down regulation of these enzymes reduces the 
invasive properties of manipulated cell lines (Goldberg and Eisen, 1992a). 
Moreover, transfection of the cDNAs encoding several members of this family into 
non-metastatic cell-lines conveyed a metastatic phenotype to these cells 
(Cockett, 1993; Bernhard et al.', 1994; Powell et al., 1993). A matrix 
metalioproteinase inhibitor has been reported to inhibit the lung colonisation of 
B16 F10 melanoma cells in a syngeneic mouse recipient (Reich et al., 1988) and 
recently, a selective inhibitor of gelatinase-A has been shown to block lung 
colonisation by COLO 26 cells (Cockett, 1993).
This thesis provides the background to the design and characterisation of 
such inhibitors, together with a biochemical characterisation of gelatinase-A and 
B and interstitial collagenase.
1.3: The matrix metalloproteinases
1.3:1 General properties of matrix metalloproteinases
The matrix metalloproteinases (MMPs) are thought to orchestrate the 
normal tissue remodelling associated with cell migration, angiogenesis, tissue 
morphogenesis and growth, uterine Involution and cervical softening (reviewed
In Matrisian, 1990). Breakdown of the tight regulation of these enzymes can lead 
to the inappropriate matrix modelling observed in diseases such as the 
arthritides, fibrosis, atherosclerosis, multiple sclerosis and tumour invasion and 
metastasis (Murphy and Reynolds, 1993; Stetler-Stevenson, 1990).
The MMPs are comprised of a multi-gene family of zinc and calcium 
dependent proteinases which are capable of hydrolysing all the major elements 
of both basement membrane and connective tissue matrix at physiological pH 
(Docherty et al.; 1992; Murphy and Reynolds, 1993) (Table 1.1). They are 
modular enzymes comprised of distinct homologous domains two of which, the 
propeptide and the catalytic, are common to the entire family.
MMPs typically hydrolyse the bond between a small neutral amino acid residue 
such as glycine or alanine and a large hydrophobic residue such as leucine or 
phenylalanine. They are secreted as latent proenzymes by connective tissue 
cells as well as by cells of haematopoetic origin. Latency is maintained by the 
presence of an approximately 80 amino acid N-terminal propeptide which is 
removed upon activation. This can be initiated In vitro by the addition of the 
organomercurial, aminophenylmercuric acetate (APMA) in a process leading to 
the auto-catalytic cleavage of the propeptide (Nagase et al., 1991). The 
susceptibility of MMPs to organomercurial initiated activation is a distinguishing 
feature of this family (section 1.3:3).
Once activated the enzymes are thought to be regulated by inhibitors such 
as the general proteinase inhibitor a-2 macroglobulin (a-2M) and also by a family 
of MMP specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs) 
(section 1.4:2) (Cawston, 1986). Although there is a high degree of amino acid 
sequence homology across the family (reviewed in Birkedal-Hansen, 1993), they 
can be conveniently subdivided into three major classes on the basis of structure 
and function.
(I) The collagenases
There are three known members of the collagenase family, interstitial 
collagenase (also known as fibroblast collagenase), neutrophil collagenase and 
a cDNA coding for a third member of the family has recently been cloned from a 
breast tumour derived cDNA library (Freije et al., 1994). Collagenases are the 
most specialised of the known MMPs. Their ability to cleave fibrillar collagen
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(mainly types I ,11 and III) at a single locus within the triple helical domain makes 
them unique amongst mammalian proteinases. Under most circumstances very 
little of the mesenchymal derived enzyme (interstitial collagenase) is synthesised 
but mRNA levels can be significantly increased in response to various cytokines 
and growth factors. The up-regulation of the enzyme in response to interleukin-1 
(IL-1) and tumour necrosis factor (TNF) is of particular interest because of the 
contribution of these cytokines to the progression of inflammatory disorders such 
as rheumatoid arthritis.
A closely related enzyme is synthesised by neutrophils. Unlike the 
fibroblast form it is stored in granules prior to its release in response to neutrophil 
activating agents. The latent and active forms of neutrophil collagenase are 
somewhat higher in molecular mass than their fibroblast counterparts but this is 
largely a result of glycosylation. The two enzymes exhibit similar substrate 
specificities but the neutrophil enzyme is catalytically more efficient and cleavage 
at aryl amino acids occurs more readily (Netzel-Arnett et al., 1991).
The third member contains several residues specific to the collagenases 
as well as the shortened proline-rich hinge region which is also a characteristic of 
this family. The expressed protein justifies its classification as a collagenase by 
its ability to degrade fibrillar collagen.
(ii) The stromelysins
Stromelysins-1 and 2 are secreted from mesenchymal cells as 57 kDa 
proenzymes. Comparison of the enzymic properties of the two enzymes 
(Nicholson et al., 1989) suggest that they have almost identical substrate 
specificities. The production of stromelysin-1 by rheumatoid synovial hypertrophic 
lining cells but not normal synovial cells (Okada et al., 1989a) and the elevated 
level of proteoglycan-degrading activity found in osteoarthritic cartilage 
compared with normal cartilage (Martel-Pelletier et al., 1984; Dean et al., 1989), 
indicate that these enzymes play an important role in the destruction of cartilage. 
The stromelysin-1 gene shows similarities in the promoter/enhancer region to 
interstitial collagenase and consequently is often co-ordinately produced upon 
stimulation with growth factors or tumour promoters (Frisch et al., 1987; Edwards 
et al., 1987). The stromelysins possess the broadest substrate specificity (Table 
1.1) and may play an additional physiological role in the activation of other 
members of the family (Ogata et al., 1992; O’Connell et al., 1994; Murphy et al..
1987). Stromelysin-1 is active on a low molecular mass synthetic substrate 
between pH 4 and pH 10 (Harrison et al., 1992) but it has a very narrow pH 
optimum of pH 5 - 5.5.
(Hi) The gelatlnases
Harris and Krane (1972) first described a metalloproteinase released by 
cultured rheumatoid synovium that was capable of degrading denatured 
interstitial collagen (gelatin). The enzyme was subsequently found to be identical 
to a 72 kDa type IV collagenase isolated from cultures of rabbit bone calvaria by 
Murphy at al. (1985). This enzyme (gelatinase-A) is constituitively expressed by 
a number of normal and transformed cells (Seltzer eta!., 1981; Salo et a!., 1991; 
Lefebvre et a!., 1991; Overall and Sodek, 1987) and is the most widely distributed 
of all the MMPs. Transcriptional control of gelatinase-A is different to that of 
collagenase and stromelysin. Low levels of the enzyme are expressed by most 
cells and these levels are not regulated by agents such as IL-1 and TNF 
(reviewed in Matrisian,1990).
Gelatinase-A is effective against type V and type VII collagens (Seltzer et 
a!., 1989) in addition to type IV collagen, the major structural component of 
basement membrane. It may also act co-ordinately with collagenase to complete 
the degradation of fibrillar collagen and thus aid in its elimination from the body.
Progelatinase-B is a 92 kDa enzyme that was originally recognised as a 
gelatinolytic metalloproteinase of PMN leukocytes by Sopata and Dancewicz 
(1974). Whilst it is secreted by many cell types in culture the same gene product 
is produced in a storable form in PMNs. Although the two gelatlnases share 
structural homology and substrate specificity they differ at the transcriptional level 
since the gelatinase-B gene possesses elements in common with the 
stromelysins and interstitial collagenase (reviewed in Birkedal-Hansen eta!., 
1993).
(iv) Other MMPs 
Matrilysin
Matrilysin is the smallest member of the MMPs consisting of a catalytic and 
a propeptide domain only. It is expressed in developing monocytes (Busiek et 
a!., 1992) and gingival fibroblasts (Overall and Sodek, 1990) as a 28 kDa 
proenzyme which reduces to 20 kDa upon activation. Like the stromelysins, with
which it is sometimes classified it has a broad substrate specificity but it is 
distinguishable from the former by its broad pH optimum (pH 6 - 8) (Crabbe etal.,
1992).
Metalloelastase
A metalloelastase, sharing about 50% homolgy with collagenase and 
stromelysin, has been identified in human alveolar macrophages (Shapiro et al.,
1993). The deduced amino acid sequence predicts a 54 kDa proenzyme. In the 
absence of EDTA, this readily undergoes amino- and carboxy-terminal 
processing to a mature 22 kDa form. Partially purified native metalloelastase 
degrades insoluble elastin.
Stromely sin-3
Stromelysin-3 was first identified in the stromal cells surrounding invasive 
breast carcinomas by Basset et al. (1990). Its name is rather misleading since it 
shares no greater sequence homology with stromelysin than with collagenase 
and on this basis cannot be classified with either group. To date, insufficient 
quantities of the active human enzyme have been isolated to enable its substrate 
specificity to be determined although the mouse homologue is reported to 
degrade laminin and fibronectin (Murphy etal, 1993).
MT-MMP
Stromelysin-3 shares a region of homology located between the end of the 
propeptide and the start of the catalytic domain with a membrane bound MMP 
(MT-MMP) recently isolated from a human placental cDNA library (Sato et 
a/.,1994). The latter enzyme was shown to be expressed in lung carcinomas and 
to a lesser extent in normal lung. Its most striking feature is the presence of a 
hydrophobic tail which may be involved in anchoring it to the cell membrane. Its 
only known substrate to date is progelatinase-A
1.3:2 The structure and function of MMP domains
Inspection of MMP structures reveals that they can be divided into discrete 
functional domains (Fig. 1.2).
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The domain structures of matrix 
metaiioproteinases
CoUagen-like domain
O
Fibronectin-hke 
domain
PRCGV/NPD
Vitronectin-iike
domain
Propeptide HEF/L/IGH
Cataiytic domain
O
Proime rich 
regionLatent MMP 
N-terminus Active MMP C-terminus of
N-terminus matriiysin
(site of 10 amino acid 
insertion in stromeiysin 3) 
and MT-MMP
Putative membrane
spanning sequence 
in MT-MMP
Matnlysm
Stromelysm~1
Gelatmase A
Gelatinase B
Domain 1 (Propeptide)
Domain 1 comprises the first 80 amino acid residues or so of the secreted 
enzyme. After secretion the main function of this peptide is to maintain the 
enzyme in a latent form. This is discussed in detail in section 1.3:3. In common 
with the propeptide of other enzymes (Zhu et al., 1989) it may also have a role in 
promoting the intracellular folding of these enzymes.
Domain 2 (Catalytic domain)
Domain 2 possesses the catalytic machinery including the substrate 
binding cleft and the active site. This domain can be delineated both genetically 
and functionally from the hinge region of domain 3 by a (L/l) Y G amino acid 
sequence (L260 in human interstitial collagenase). Towards its C-terminus is a 
sequence which shares very strong homology with the sequence VaM^^-V-A-H*" 
E-L-T-H*-A found in the bacterial endopeptidase thermolysin. This 'zinc box' is 
the signature for zinc endopeptidases and includes two histidines (H*) which 
bind to the catalytic zinc. MMPs differ from thermolysin in that the third zinc 
binding residue is also a histidine as opposed to a glutamic acid in the bacterial 
enzyme. The catalytic properties of glutamic acid (E) in the above sequence, 
previously described for thermolysin (Matthews et al., 1988), have been 
confirmed in gelatinase-A by the observed reduction in activity resulting from its 
replacement by A, Q or D (Crabbe et al., 1994a).
The structure of this domain has now been solved by X-ray crystallography 
(Bode etal., 1994; Lovejoy etal., 1994; Stams etal., 1994; Borkakoti etal., 1994; 
Reinemar etal., 1994; Spurlino etal., 1994) and NMR (Gooley etal., 1994). The 
crystal structure of the neutrophil collagenase catalytic domain showing the 
substrate binding cleft and a bound inhibitor is presented in Figure 1.3. This 
structure is representative of the MMP structures described to date. The crystal 
structure reveals a spherical molecule with a shallow active site cleft. The cleft 
separates a small C-terminal region from a larger N-terminal region composed of 
two a-helices, a five-stranded p-sheet and bridging loops. The catalytic zinc is 
situated at the bottom of the cleft and is co-ordinated by three histidines in the 
sequence Hisi97_ E-F-G-H-S-L-G-L-A-H. An important feature of these enzymes 
is the presence of a conserved glycine (G) (above) which plays an important role 
in enabling the third histidine to bind to the catalytic zinc. This places the MMPs 
in the same group as astacin (Bode et al., 1992) and the snake
10
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venom metallopeptidase, adamalysin II (Gomis-Ruthef a/., 1993). The name 
'metzincin' has been coined by Bode et al. (1993) to describe this super-family. 
Besides the catalytic zinc, neutrophil collagenase has an additional zinc (bound 
by three histidine residues and an aspartic acid) which together with two calcium 
ions is thought to play a structural role. Only one calcium has been identified in 
other MMPs (Spurlino et a!., 1994). The conserved calcium appears to make 
contacts with residues on either side of the zinc box supporting the view that it 
plays an important structural role. The residues involved in substrate and 
inhibitor recognition are discussed in section 1.4:4 (ii).
Domain 3 (C-terminal /  hemopexin / vitronectin-like domain)
Domain 3 is present in all the MMPs with the exception of matrilysin and is
separated from the catalytic domain by a proline-rich hinge of varying length. It
contains regions of homology with both hemopexin and vitronectin and in 
gelatinase-A alone, there is a sequence of significant homology with the 
immunoglobulin A (IgA) proteinases (unpublished observation). Two conserved 
cysteines can be used to align the primary sequences of this domain for all the 
MMPs (Fig. 1.2). The presence of an intact disulphide bridge between these 
cysteines may be important for maintaining the structure of the domain.
For most of the MMPs the C-terminal domain has been shown to play no 
role in catalysis since domain 2  retains its activity on low molecular mass 
substrates in its absence (Sanchez-Lopez et a!., 1993; Lowry etal., 1992; Murphy 
et al., 1992a). It does, however, possess some important non-catalytic properties. 
Several groups have shown that the C-terminal domain of interstitial collagenase 
(Birkedal-Hansen et al., 1988; Clark and Cawston, 1989; Murphy et al., 1992b) 
and neutrophil collagenase (Schnierer et al., 1993) is essential for the cleavage 
of fibrillar collagen although it plays no role in the activity of these enzymes 
against peptide substrates. Both collagenase and stromelysin have been shown 
to bind to collagen through their C-terminal domains. Interestingly, the presence 
of the propeptide inhibits this interaction in collagenase but not stromelysin 
(Murphy etal., 1992b).
The C-terminal domain of gelatinase-A has been shown to be dispensable 
for catalysis and substrate recognition but it is necessary for activation by cell 
membranes (Murphy et a!., 1992a). This work has been extended by Cockett 
(1993) who has demonstrated that cells transfected with gelatinase-A cDNA have
12
a metastatic phenotype that depends on the expressed gelatinase-A possessing 
an intact C-terminal domain.
The ability of progelatinase-A and B to bind to TIMP-2 and TIMP -1  
respectively, has also been localised to their C-terminal domains (Goldberg et 
al., 1989). Additionally, the presence of this domain increases the strength of 
TIMP binding to the active enzymes (Howard et al., 1991; Murphy et al., 1992a). 
Goldberg et al. (1992b) have suggested that the domain may contribute to the 
activation of progelatinase-B by stromelysin but this is not substantiated by the 
results of other groups (O'Connell et al., 1994). These studies are described in 
Chapter 3.
Domain 4 (gelatin-binding)
Domain 4 is formed by three repeating motifs which share homology with 
the gelatin binding region of fibronectin. It is only present in the two gelatinases 
and may mediate the sequestration of these enzymes within the extracellular 
matrix (Collier et al., 1988; Wilhelm et al., 1989). It is inserted into a conserved 
region of amino acids just prior to the active site and may form a discrete domain 
which juts out from the main body of the enzyme. It is required for both binding to 
type I collagen and to confer specificity for type IV collagen (Murphy et al., 1994)
Domain 5 (collagen-like)
Domain 5 is found in gelatinase-B alone and may simply be an extension 
of the proline hinge region. It shares a weak homology with some types of 
collagen (Wilhelm et al., 1989) but its function is unknown.
Other motifs
Pro/active domain insertion
Stromelysin-3 and MT-MMP possess a 10 amino acid insertion situated 
between the conserved P-R-C-G-(V/N)-P-D sequence of the propeptide and the 
N-terminus of the catalytic domain. Interestingly, it contains the motif, R-X-K-R, 
which is the substrate recognition sequence for subtilisin-like processing 
enzymes (reviewed in Smeekens, 1993): Hosaka e ta l., 1991). Since these 
enzymes act within the cell it is possible that stromelysin-3 and MT-MMP are 
processed intracellularly and then secreted (or inserted into the membrane) in an 
active form.
13
Membrane spanning domain
This is present in MT-MMP only and consists of 24 uncharged hydrophobic 
residues situated at the end of the C-terminal domain. By analogy with such 
motifs in other proteins (Sato et al., 1994) it is presumed to anchor the enzyme to 
the cell membrane.
1.3:3 Activation of MMPs
The activation of MMPs represents a critical point in controlling their 
activity in vivo. The end-point of this process is the removal of the approximately 
80 amino acid propeptide with a concomitant reduction in molecular mass of 
about 10 kDa on SDS-polyacrylamide gels.
The latency of the proenzyme is thought to be maintained by the insertion 
of a conserved sequence of the propeptide, P-R-C-G-(V/N)-P-D, into the active 
site cleft. The unpaired propeptide cysteine (C^^ jp interstitial collagenase) then 
acts as the fourth ligand for the catalytic zinc and displaces a catalytically 
essential water molecule (see section 1.3:4). Theoretically, the propeptide could 
be removed by a single cleavage downstream of the conserved cysteine. The 
fact that this does not occur, suggests that the susceptible bond which marks the 
beginning of the catalytic domain in the active form of the enzyme is masked by 
other regions of the propeptide (Nagase et al., 1991).
Activation is a consequence of the displacement of the cysteine by a water 
molecule in a process that has been called the 'cysteine switch' (Springman et al., 
1990). There are a number of ways of achieving this in vitro but mechanistically 
these may be divided into two categories (1 ) chemical and (2 ) enzymic.
The first category includes organomercurials such as APMA, metal ions, 
reducing agents, SDS, heat and oxidants. They either chemically alter the 
cysteine (eg. APMA) or perturb the structure of the catalytic site sufficiently to 
allow water to enter and displace the cysteine from the zinc (Fig. 1.4 {A}). The 
catalytically competent enzyme then performs an intramolecular cleavage at a 
site 5  - 8  residues upstream of the propeptide cysteine which presumably lies in 
the substrate recognition cleft (Stricklin etal., 1983; Grant et al., 1987; Nagase et 
al., 1990). An intermolecular, concentration dependent autolytic cleavage 
completes the process by removing 0 ^ 3  to form the mature enzyme. Whilst 
chemical activators (oxidants) have been reported to activate PMN derived
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enzymes in vivo (Weiss et al., 1985: Burkhardt et al., 1986) a physiological 
counterpart to APMA has not yet been isolated. A low molecular mass activator 
which might fulfil this role is endothelial cell stimulating angiogenic factor (ESAF) 
which has been reported to activate collagenase and gelatinase-A (Weiss et al., 
1983).
Removal of the propeptide domain may also be accomplished by the 
action of proteinases (Fig. 1.4 {B}). The archetypal serine proteinase, trypsin is 
routinely used for the test-tube activation of the collagenases, matrilysin and the 
stromelysins. The physiological counterparts to trypsin are presumed to be 
plasmin and kallikrein (Werb et al., 1977). Proteinases make an initial cleavage 
in the propeptide at a point located 30-40 residues downstream from the N- 
terminus. This has been termed the 'bait' region although its role is not strictly 
analogous to the role of the bait region in a - 2  macroglobulin (Barrett and Starkey, 
1973). This proteinase sensitive region has an amino acid sequence which 
dictates the class of proteinase able to activate the MMP in question. Thus, the 
procollagenase bait region, Lys34-R-R-N , can be cleaved by enzymes with 
trypsin-like specificity for basic residues. The stromelysin sequence of Phe^^-V- 
R-R-K may in addition be cleaved at the phenylalanine by enzymes with 
chymotrypsin specificity (Nagase et al., 1990; Suzuki et al., 1990). Of particular 
interest, since the MMPs are often co-ordinately expressed is the activation of 
one by another. Whilst the so-called 'superactivation' of interstitial 
procollagenase by stromelysin (Chapter 4) proceeds efficiently only on the 
partially processed enzyme (Murphy et al., 1987) stromelysin activation of 
progelatinase-B is carried out directly by stepwise removal of the propeptide 
(Ogata et al., 1992; O'Connell et al., 1994). Similarly, both matrilysin and 
collagenase have recently been shown to activate progelatinase-A by cleaving a 
sequence which may be a bait region for MMPs (Crabbe et al., 1994b; Crabbe et 
al., 1994c) (Chapter 3). The activation of gelatinase-A by these two MMPs has so 
far only been demonstrated in vitro but the MT-MMP recently described by Sato et 
al. (1994) may assume this role in vivo. The enzyme is structurally related to the 
soluble MMPs and is probably responsible for the well documented activation of 
progelatinase-A by tumour cells (Brown et al., 1993; Azzam et al., 1993) or 
concanavalin-A stimulated fibroblasts (Ward et al., 1991).
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1.3:4 The mechanism of action of MMPs
In order to create the correct chemical environment for hydrolytic attack, 
proteinases have developed a ubiquitous catalytic apparatus. The basic 
elements of this apparatus are a nucleophile, a general base and an electrophile. 
For the MMPs these are water, glutamic acid and zinc, respectively. A 
mechanism for MMP catalysed substrate cleavage can be proposed by 
considering the structural evidence provided by X-ray crystallography. Spurlino 
et al. (1994) and Lovejoy et al. (1994b) have postulated that many features of the 
interstitial collagenase catalytic mechanism (Fig. 1.5) are consistent with the 
mechanism proposed by Matthews (1988) for the action of the structurally related 
bacterial zinc proteinase, thermolysin. In the free enzyme the zinc ion is co­
ordinated to the side chains of and a water molecule (residue
numbers refer to the proenzyme form). Cleavage is initiated by the nucleophilic 
attack of water on the scissile peptide bond. The attack is promoted by E^oo 
situated in the zinc box sequence VaM^e-A-A-H-E-L-G-H. The carbonyl oxygen of 
A163 and the side-chain oxygen of then stabilize the protonated nitrogen of 
the scissile bond. In contrast to thermolysin the carbonyl oxygen of the cleaved 
bond appears to be stabilised by the carbonyl-zinc interaction alone. A 
tetrahedral intermediate is formed from the attack of the activated water molecule 
on the carbonyl group of the scissile bond. The subsequent collapse of this 
intermediate then gives a primary ammonium species and a zinc bound 
carboxylate. Release of the protonated amine and expulsion of the product 
carboxylic acid permit the water molecule to co-ordinate to the zinc to complete 
the cycle.
1.3:5 Cleavage-slte specificity
As noted earlier the MMPs often hydrolyse bonds between small 
uncharged amino acids and large hydrophobic residues. In designing inhibitors, 
however, it is possible to take advantage of subtle differences in selectivity 
between members of the family. A selection of cleavage site sequences are 
presented in Figure 1.6. These are representative of the preferred substrate 
cleavage sites of various MMPs (reviewed in Birkedal-Hansen et al., 1993). By 
convention amino acids to the left of the cleavage site are designated Pi, P2 , P3 
etc. and interact with corresponding sub-sites on the enzyme S i, S2 , S3  and
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Figure 1.6 The substrate cleavage specificities of MMPs
Collagenase collagen (human) a  1 G P Q G 1 A G Q
a2 G P Q G L L G A
collagenase (auto) D A E T L K V M
collagenase (auto) T K L V K Q P
(%2 -Macroglobulin (hum) G P E G L R V G
PZP (hum) Y G A G L G V G
a 2 -Macroglobulin (rat) M D A F L E S S
collagenase (hinge) P V Q P G P Q
Stromelysin stromelysin (auto) D T L E M R K
stromelysin (auto) D V G H F R T F
collagenase D V A Q F V L T
proteoglycan core 1 P E N F F G V
a i -proteinase inhibitor E A 1 P S 1 P
a 2 -Macroglobulin (hum) G P E G L R V G
substance P K P Q Q F F G L
Gelatinase gelatin a l fragment CBS G P Q G R G E
G P S G L Hyp G P
G P A G F A G P
gelatin a l fragment CB7 G P Hyl G R G A
gelatinase-A (auto) D V A N Y N F F
Matrilysin insulin B-chain L V E A L Y L V
E A L Y L V C G
matrilysin (auto) D V A E Y S L F
matrilysin (auto) R V 1 E M Q K
All MMPs fluorescent peptide 1 McA P L G L Dpa A R
fluorescent peptide 2 Dnp P L G L W A R
Fluorescent peptide 1 (Knight etal., 1992)
Fluorescent peptide 2 (Stack and Gray., 1989)
Hyl = Hydroxylysine
Hyp = Hydroxyproilne
PZP = Pregnancy zone protein
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amino acids to the right of the cleavage site are designated Pi', P2', P3' etc. and 
interact with the corresponding Si', S2', S3 sub-sites.
Collagenase invariably cleaves at the amino side of leucine or isoleucine. 
Whilst this cleavage often occurs after a glycine, other residues are not excluded 
(Fields et al., 1987). For example, collagenase cleaves after a phenylalanine 
residue in the bait region of rat a-2M (Sottrup-Jensen etal., 1989) and following a 
proline (Birkedal-Hansen et al., 1988) during the autolytic cleavage of the hinge 
region that may occur during activation or on prolonged storage .
Stromelysin tolerates a range of amino acid residues on either side of the 
cleavage site. Phenylalanine is the preferred Pi' target for its action on both itself 
and other members of the family. Harrison et al. (1989) have shown that 
stromelysin selectively cleaves a Q-F bond in the natural peptide, substance P, at 
a rate sufficient for its use as a substrate for screening assays. Very few amino 
acids including proline are excluded from the left of the cleavage site.
Like stromelysin, gelatinases cleave at a range of Pi ' residues. 
Autocatalytic cleavages occur at tyrosine and phenylalanine suggesting a 
preference for large hydrophobic residues at this position. Gelatinases are more 
selective than stromelysin for residues to the left of the cleavage site. Small 
neutral amino acids are typically found at Pi (Seltzer etal., 1990) and gelatinase- 
A self-cleaves at an asparagine.
Matrilysin has a cleavage site specificity that is intermediate between that 
of collagenase and stromelysin. The activity of five MMPs including matrilysin 
was tested against a series of peptides by Netzel-Arnett et al. (1993). Their 
results indicate that whilst matrilysin can tolerate a wide range of amino acids at 
the Pi position, it is particularly active against alanine containing peptides. Like 
collagenase, aliphatic amino acids such as leucine are preferred at the P i’ 
position. Surprisingly, during activation matrilysin can cleave itself at an E-Y 
bond in addition to the predicted cleavage of E-l and E-L (Crabbe etal., 1992).
The fluorescent peptides developed by Stack and Gray, (1989) and Knight 
et al., (1992) have a common G-L cleavage site for all the MMPs but the enzymes 
differ in their turnover rates of this substrate (Chapters 3 and 4).
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1.4: Inhibition of matrix metaiioproteinases
1.4:1 General aspects of inhibitor design
The efficiency of a competitive peptidase inhibitor may be derived from the 
same combination of structural elements no matter which enzyme class is 
targeted. One element mimics the scissile bond and consequently blocks 
catalysis whilst others provide specificity by mimicking the structure of the 
substrate (Fig. 1.7). As a result of this convergence the majority of peptidase 
inhibitors look superficially similar. This means that a successful feature 
discovered in one area of drug development may be duplicated in the design of 
drugs from other unrelated areas. This is particularly evident in the structure of 
MMP inhibitors (MPIs) in which features of peptidyl-dipeptidase A (ACE), 
neprilysin, otherwise known as neutral endopeptidase (NEP) and renin inhibitors 
can readily be discerned.
In rational drug design the first step is to identify a compound that is active 
against the target enzyme. Early compounds may incorporate features derived 
from a knowledge of the substrate cleavage site, natural inhibitor structure or the 
cleavage mechanism. Having identified a lead compound it is then chemically 
modified to optimise its activity. By making small modifications of one feature at a 
time, for example, extension of a side-chain by one carbon, compounds can be 
assigned to homologous series. At the end of each series an optimised lead 
molecule can then be identified and this is continued until all the optimum 
characteristics have been incorporated. Having optimised the structure for 
potency the process is then repeated for selectivity, bioavailability and so on. In 
practice, the best structure for activity, for example, may conflict with that giving 
good bioavailability. This means that several different “structure-activity 
relationships” (SARs) may have to be constructed.
In addition to the approach outlined above the recent availability of 
crystallographic data for a number of MMP-inhibitor complexes provides 
additional information which may be used to rationalise further inhibitor 
modifications (section 1.4:4).
The concept of inhibiting metaiioproteinases to give therapeutically useful 
compounds has originated in the ACE (Ondetti et al., 1977) and neprilysin areas 
(Roques et al., 1980). Many of the discoveries in these areas have been used to 
increase the potency of MMP inhibitors. Similar sources of information have
23
been used in the design of inhibitors with improved pharmacokinetic properties. 
Additionally, structural features used in the design of renin inhibitors have been 
Incorporated in the design of pharmacokinetically superior MMP inhibitors. Since 
these areas have provided the basis for MMP inhibitor design a brief description 
of each will be presented.
Peptidyl-dipeptidase A (ACE) (EC 3.4.15.1)
ACE Is a membrane-bound zinc metallopeptidase which catalyses the 
release of dipeptides from the carboxy-terminus of oligopeptide substrates. Its 
best known physiological function is the conversion of angiotensin I to 
angiotensin II by removal of the dipeptide H-L. It also catalyses the inactivation of 
the vasodilatory peptide bradykinin and cleaves Leu- and Met-enkephalins. 
Inhibitors are used in the control of hypertension.
Captopril (Fig. 1.8) is an early example of drug design that was based on 
rational modifications to a chemical entity. Its design is derived from the structure 
of the active site of carboxypeptidase A obtained by X-ray crystallography and the 
structure of an ACE substrate, bradykinin (Ondetti et al., 1977; Cushman et al., 
1977). Its success laid the foundation for the design of further ACE inhibitors 
such as enalaprilat (Fig. 1.8) as well as inhibitors of other metaiioproteinases
Neprilysin (NEP) (EC 3.4.24.11)
NEP is a membrane-bound zinc endopeptidase which also displays 
properties consistent with carboxypeptidase activity. It cleaves a broad range of 
substrates at the amino terminal side of hydrophobic residues such as 
phenylalanine, leucine and methionine. Inhibition of the enzyme has been 
shown to result in analgesia.
The first potent synthetic inhibitor of NEP was reported by Roques et al. 
(1980). This compound, thiorphan (Fig. 1.8) was based on captopril. 
Interestingly, NEP does not discriminate between [S]- and [R]- stereoisomers at 
the Pi ' position and the P i'-Pa' peptide bond can even be reversed 
(retrothiorphan) without a reduction in activity. This distinguishes NEP inhibitors 
from those of ACE and the MMPs (see Chapter 5). Carboxylic acid inhibitors of 
NEP were described by Mumford et al. (1982). The estérification of the carboxylic 
acid group to generate a prodrug has been explored by Roques etal. (1993) as a 
means of modifying the distribution of these inhibitors. This approach
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had previously been used successfully in the ACE area with enalapril, which is 
the ester prodrug of the carboxylic acid inhibitor, enalaprilat. The introduction of 
a hydroxamic acid zinc binding ligand separated from the Pf' group by a 
methylene spacer (Bouboutou et al., 1984), provided a structural format for the 
design of MMP inhibitors which is still in use.
Renin
Renin is an aspartyl proteinase which catalyses the production of 
angiotensin from angiotensinogen. Interest in the enzyme stems largely from the 
success of ACE inhibitors which block the action of ACE at a later stage in the 
renin-angiotensin pathway. The poor In vivo characteristics encountered with 
these peptide based drugs has been a major obstacle to the clinical use of renin 
inhibitors. Workers In this area have, therefore, been particularly active in their 
attempts to overcome these problems. The recognition of a need to balance the 
hydrophilic and hydrophobic elements to achieve oral bioavailability has resulted 
in the development of a large number of non-amino acid side-chains. These side- 
chains which include morpholine amides, sulphamylurea and arylsulphonamides 
(Patt et al., 1992; Ashton et al., 1992; Doherty et al., 1992) have now been 
incorporated into a range of MMP inhibitors by several industrial groups.
1.4:2 Natural protein Inhibitors of MMPs
The most important inhibitors of MMPs in vivo are the ubiquitous a - 2  
macroglobulin and a family of specific inhibitors, TIMPs 1, 2 and 3 (Stricklin and 
Welgus, 1983; De Clerck et al., 1989; Uria et al., 1994). The former traps 
enzymes using a proteinase sensitive bait sequence (Barrett and Starkey, 1973). 
Following cleavage of this sequence the inhibitor collapses around the enzyme 
and prevents its access to large substrates.
TIMPs range in size from 20 - 30 kDa but this is largely a result of 
glycosylation. They are highly potent reversible inhibitors of MMPs with inhibition 
constants (Ki's) in the picomolar range (Murphy et al., 1992a). The structure of 
TIMP is maintained by six disulphide bonds. Two distinct domains can be 
distinguished by their relative abilities to bind to active gelatinase and to 
progelatinase (Murphy etal., 1991). The N-terminal domain appears to carry the 
minimum information required for inhibitory activity whereas the C-terminal 
domain is required for binding of TIMP-1 to progelatinase-B and TIMP-2 to
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progelatinase-A. Reduction of the disulphide bonds leads to the complete loss of 
TIMPs ability to inhibit stromelysin in a rat pleural cavity model (Lark et al., 1990) 
suggesting multiple interactions between the inhibitor and enzyme. This places 
severe limitations on TIMP's application to the design of low molecular mass 
inhibitors since its potency derives from the contribution of interactions from 
distant sites of the primary sequence as opposed to a single bait region. 
Nonetheless, TIMPs have been valuable tools in vitro to demonstrate a role for 
MMPs in tumour and endothelial cell invasion of tissue matrices (DeClerck et al., 
1991; Mignatti et al., 1989), angiogenesis (Moses and Langer, 1991) and in vivo 
models of cartilage destruction and metastasis (Carmichael et al., 1989; Alvarez 
etal., 1990).
1.4:3 Inhibitors from naturai sources
Several inhibitors of MMPs have been isolated from the screening of 
microbial broths. Actinomycetes have been a particularly rich source of such 
inhibitors producing the tetracyclines described by Golub et al., 1984 in addition 
to a series of hydroxamic based inhibitors including the matlystatins and 
actinonin.
The matlystatins are a family of low molecular mass MMP inhibitors 
isolated from a strain of actinomycetes by Ogita et al. (1992). The structure of 
matlystatin B is presented in Fig. 1.8. These compounds are active In the low 
micromolar range against a variety of zinc metaiioproteinases including 
thermolysin, aminopeptidase M, interstitial collagenase, gelatinase-A and 
stromelysin for which they are particularly potent (IC50 = 80 nM). Matlystatin A 
inhibits the invasion of the artificial basement membrane, matrigel, by HT 1080 
human fibrosarcoma cells with an IC50 value of 21.6 pM.
Actinonin (Fig. 1,8) is a pseudo-peptide antibiotic. It was identified from 
the anti-collagenase activity (Ki = 1.4 |xM) of actinomycetes by workers at Rhone- 
Poulenc (Faucher et al., 1987). However, actinonin is now known to be a more 
potent inhibitor of the zinc aminopeptidases, particularly aminopeptidase N (AP- 
N; CD13).
There are remarkable structural similarities between the matlystatins, 
actinonin and synthetic inhibitors of MMPs. The former are generally less 
peptidic in nature and so may provide some information to aid the design of non­
peptide analogues of MMP inhibitors.
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1.4:4 The design of MMP inhibitors
(i) Experimental approaches to inhibitor design
In the early 1980's a number of pharmaceutical companies began to 
develop inhibitors of interstitial collagenase. The rationale for this choice of 
enzyme target was based on the unique ability of collagenase to degrade the 
collagen of bone and cartilage which implied an important role in diseases of 
matrix destruction such as arthritis.
The first group to report the synthesis of rationally designed collagenase 
inhibitors was that of Gray et al. (1981). By direct analogy with ACE inhibitors a 
sulphydryl group was attached to a C-terminally blocked peptide which was 
loosely based on the residues to the right-hand side of the collagen cleavage 
site. Early efforts focused on the design of inhibitors based on both the left-hand 
side (LHS) and the right-hand side (RHS) of the cleavage site (reviewed in 
Johnson et al., 1987). These studies demonstrated that modifications to RHS 
inhibitors could produce improved potency. The results of the G.D. Searle group 
are typical of the developments made in the MMP area over the following years. 
The inhibitor side-chains were optimised for collagenase inhibition by 
incorporating a tyrosine derivative at the P2' position and reducing the size of the 
P3' to methylamide. It became evident, however, that the key to potency lay in the 
choice of the zinc-binding group. Early inhibitors included a substituted N- 
carboxymethyl for this purpose (McCullagh et al., 1984). The most potent of 
these (compound 1) had an IC50 of 0.8 p,M (Fig. 1.9). During this period 
improvements in chiral separation lead to the important discovery that 
collagenase preferred R stereochemistry at the Pi ' position and this 
discriminated it from ACE. Replacement of N-carboxylalkyls with thiol zinc 
ligands, produced inhibitors (compound 2) with IC50 values of 0.2 - 0.3 p,M 
(Donald et al., 1985). No further progress was made until the Introduction of 
hydroxamic acid ligands which had been used successfully in the NEP area 
(Fournie-Zaluski., 1985). Introduction of this zinc ligand onto the optimised 
Searle peptide back-bone (compound 3) produced an inhibitor with an IC50 of 
0.02 p,M (Dickens et al., 1986). Investigators at Roche achieved similar
2 8
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0.4 (collagenase) 
0.04 (stromelysin)
potencies (0.03 |xM) with a series of phosphinic acid based compounds 
(Borkakoti et al., 1988). Inhibitors based on a model of collagen provided 
evidence that the P2' and P3' residues could be cyclised in a trans-amide 
conformation without loss in potency. At the same time, selectivity for collagenase 
was provided by the presence of a large cyclic imido group in the Pi position. 
Cyclisation of the P2' and P3' residues was a significant move away from the 
traditional dipeptide arrangement and its incorporation into hydroxamic acid 
based inhibitors produced a non-peptide compound (compound 4) with similar 
potency to the parent compound.
Hydroxamic acid inhibitors represented the state of the art in 1986 and 
indeed since then, there have been few changes to the basic structures of these 
compounds. Many of these early studies, however, were carried out on 
collagenase of questionable purity, isolated in small amounts from natural 
sources such as pig and rabbit. Consequently, the cloning of each of the MMP 
cDNAs leading to a full panel of pure human recombinant enzymes including 
collagenase (Goldberg et a!., 1986), stromelysin (Whitham et al., 1986), 
gelatinase-A (Collier et al., 1988), gelatinase-B (Wilhelm et a/.,1989) and 
matrilysin (Busiek ef a/.,1992) was a significant step fonward. One of the earliest 
examples of an inhibitor that had been screened for selectivity was the ICI 
analogue (compound 5) which showed some preference for stromelysin (Di 
Pasquale et al., 1986). Although inhibitors could now be evaluated against a 
number of Individual enzymes the full potential of this technology was not 
realised until the development of improved peptide screens. The fluorescent 
peptide substrates developed by Stack and Gray, (1989) and Knight etal. (1992) 
formed the basis for fully automated screens which were robust enough to permit 
Ki's to be established. This was particularly important because potencies were 
now in the low nanomolar range. Such potent inhibitors titrate the enzyme at 
concentrations which are required to hydrolyse collagen and the resulting IC50 
value becomes equivalent to 50% of the enzyme concentration (see Chapter 6).
These developments have been exploited at Celltech to produce a 
selection of potent inhibitors with a range of selectivitles. It was recognised that 
the cleavage specificity of collagenase was not representative of the other 
members of the family. Inspection of the substrates led to the development of 
inhibitors with an aryl group at the Pi' position (Porter et al., 1992). This conferred 
gelatinase and stromelysin selectivity over interstitial collagenase together with
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significant improvements in potency (Chapter 5). The studies reported by 
Chapman et al. (1993) confirm these observations. They constructed SARs for a 
series of N-carboxyalkyl inhibitors against stromelysin, collagenase and 
gelatinase-A. The importance of interactions at the Si ' sub-site was revealed by 
the introduction of a phenethyl group at the Pi' position. This produced a 
compound with an affinity against stromelysin (Ki = 6.5 nM) which is normally 
associated with inhibitors possessing a hydroxamic acid zinc ligand. Figure 1.10 
summarises the conclusions of these SAR studies.
(11) MMP inhibitor design from 3-dimensional structures
As described earlier the structures of several MMPs have now been solved 
using X-ray crystallography and NMR spectroscopy. The inclusion of inhibitors in 
some of the studies permits enzyme-inhibitor contacts to be identified and the 
amino acid composition of the enzyme sub-sites to be assigned. Of particular 
relevance to this study are the descriptions of RHS inhibitor binding. Figure T i l  
(A) shows the hydrogen bond contacts of a synthetic hydroxamic acid Inhibitor 
co-crystal I ised with the catalytic domain of interstitial collagenase (Borkakoti et 
al., 1994). Two oxygens from the hydroxamic acid bind to the zinc so that the 
metal ion is penta-co-ordinated (trigonal-bipyramid). Additional hydrogen 
bonding provided by the NH- group to a backbone carbonyl explains the superior 
potency of the hydroxamate ligand over other bi-dentate ligands. All the 
backbone groups are hydrogen bonded which is consistent with the experimental 
observation that inversion of peptide bonds is not tolerated by these enzymes. 
The conformation of the bound synthetic inhibitor has the P2' side-chain directed 
away from the enzyme and on the opposite side of the inhibitor backbone to the 
Pi" side-chain. This confirms the validity of the modelling studies used by Roche 
who arrived at the same conclusion using a repeating tri-peptide template based 
on collagen (reviewed in Johnson et al., 1987) In order to probe the nature of the 
substrate binding pockets Stams et al. (1994) compared the crystal structure of 
the catalytic domain of interstitial collagenase with its neutrophil counterpart. The 
most notable difference was the larger size of the S|' sub-site of the neutrophil 
form. This appears to be a consequence of the replacement of an arginine (R^ S^) 
with a leucine. In the interstitial collagenase R^ s^ points towards the catalytic 
zinc, effectively closing the end of the Si' pocket. In the neutrophil enzyme the 
corresponding residue, leucine, is orientated away from the zinc
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resulting in an enlarged pocket. This is consistent with the observation that 
neutrophil collagenase is active on substrates with aromatic groups in this 
position (Hasty et al., 1987). These studies were complemented by the work of 
Gooley et a i (1994) who used NMR to determine the 3-D structure of a truncated 
stromelysin complexed with an N-carboxyalkyl inhibitor. Amino-acid residues 
involved in substrate/inhibitor recognition were identified and this was extended 
to other metzincins using sequence homologies (Fig.1.11{B}). Amongst the 
MMPs only Interstitial collagenase and matrilysin possess a residue other than 
leucine at position 197 (corresponding to in interstitial collagenase). From 
the description given above we can see that this is consistent with the preference 
of other members of the family for an aromatic residue at the Pi' position and 
stresses the importance of this residue in delineating the Si ' pocket. Only one 
residue (V^^s in stromelysin) can be assigned to the Sg' sub-site suggesting that 
this is a very shallow pocket. Two residues are assigned to the S3' sub-site, one 
of which varies significantly between MMP members. This indicates that 
specificity may be built into the P3' position although the openness of the pocket 
may make the enzymes tolerant to a range of substitutions. These conclusions 
are entirely consistent with the SARs reported by Chapman et a i (1993) and the 
studies conducted at Celltech (Porter et ai, 1992).
1.4:5 The kinetics of MMP inhibition
The potency of MMP inhibitors are typically described in terms of either 
their IC50 value or their inhibition constant (Ki). The former refers to the 
concentration of inhibitor which reduces enzymic activity by fifty percent. This 
form of measurement is commonly employed during the establishment of a study. 
At this stage, inhibitors may be relatively inefficient and the measurement of 
relative inhibitory activity may be of more importance than absolute potency. The 
expression is, however, relatively uninformative since it depends on the type of 
inhibition and the experimental conditions under which it is determined. The 
continuing use of the term in the MMP area derives from the use of collagen in 
assays. This is because collagen exhibits varying degrees of solubility making it 
unsuitable for kinetic studies which require an accurate measurement of 
substrate concentration.
The Ki is a more exact term and defines the dissociation of the 
inhibitor-enzyme complex or the reciprocal of the binding affinity to the enzyme.
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The greater control over the assay conditions afforded by peptide substrates 
permits the kinetics of enzyme-substrate-inhibitor interactions to be studied in 
great detail. In doing so it is likely that investigators assume that the enzyme- 
inhibitor interaction is reversible and indeed the use of the term Ki, presumes this 
to be the case. The absence of any inhibitor group with obvious potential for 
covalent interactions with the enzyme suggests that this may be an accurate 
assumption and indeed the reversibility of stromelysin inhibitors has now been 
demonstrated experimentally (Izquierdo-Martin and Stein, 1992).
Morrison (1982) defined four main classes of inhibitor on the basis of 
reversibility, potency and the rate of inhibitor-enzyme reaction, namely; classical, 
tight-binding, slow-binding and slow, tight-binding.
The Ki value for a classical, competitive inhibitor may be determined using the 
Michaelis-Menten relationship;
v| = Vmax.S
Km (1 + [I]/K0 + S
where vj is the velocity in the presence of inhibitor, Vmax is the maximum velocity, 
Km is the Michaelis constant for the substrate, 8, and [I] is the concentration of 
inhibitor.
Tight-binding inhibition is characterised by Inhibition at inhibitor 
concentrations comparable to those of the enzyme. This means that data cannot 
be analysed using the equation for classical inhibition since this assumes that the 
free inhibitor concentration equates to the total inhibitor concentration. As the 
majority of MMP Inhibitors have nanomolar Ki's they presumably fall into this 
category. Accordingly, the treatment of kinetic data must allow for the mutual 
depletion of enzyme and inhibitor. A general steady-state rate equation that 
accounts for the tight-binding of inhibitor to enzyme was derived by Morrison 
(1969) (reviewed in Williams and Morrison, 1979 and Morrison and Walsh, 1988) 
(see section 2.2:4).
An inhibitor may be considered slow-binding if its potency increases on a 
time-scale (i.e. longer than seconds) that is readily followed by conventional 
assay (Schloss, 1988). Slow, tight-binding inhibition is characterised by a time- 
dependent inhibition of the enzyme at inhibitor concentrations comparable to 
those of the enzyme. Most early references to this phenomenon, reported 
association rates (reviewed in Schloss, 1988) that were considerably lower than
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the diffusion controlled limit of 10  ^-10^ M-Is-1 (Brouwer and Kirsch, 1982; Hardy 
and Kirsch, 1984). The first kinetic treatment of slow, tight-binding inhibition was 
provided by Cha (1975) (also Cha et ai, 1976) who proposed two mechanisms to 
account for the slow establishment of equilibrium assuming no change in 
inhibitor form.
In mechanism A, enzyme and inhibitor bind in a single slow step which is 
defined by an association rate constant {kon) and a dissociation rate constant 
(koff). A progress curve of product formation with time in the presence of enzyme 
and inhibitor can be described by a single steady-state velocity (Vg). The 
substrate concentration may be disregarded at concentrations significantly lower 
than the Km and so this process may be described as follows.
kil
E <=====> El 
k2
I  slow 1
In mechanism B, inhibitor [I] binds rapidly to the active site of the enzyme to 
produce an El collision complex. This now undergoes a relatively slow 
isomerism to produce a modified complex, El* (tightened complex).
kil k3
E <==-=:=> El <=====> El*
k2 k4
{ slow }
These two mechanisms exhibit different characteristics which are discussed in 
Chapter 6.
A number of studies have shown that slow, tight-binding may be a 
common feature of inhibitors with very low Ki's (Morrison and Walsh, 1988). The 
binding of the folate analogue, methotrexate, to dihydrofolate reductase (Williams 
et al., 1979) is a prominent example of such a mechanism. Perhaps, the most
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extensively documented examples in the metalloproteinase field are the 
phosphorus based inhibitors of thermolysin (Bartlett and Marlow, 1987). The 
association rates of these inhibitors are of the order of 10^ M - is - \  Similar 
compounds have also been shown to bind slowly {kon = 10^ M-^s"^) to 
stromelysin (Izquierdo-Martin and Stein, 1992). The slow binding of these so- 
called 'transition-state analogues' is presumed to be a consequence of the slow 
exchange of inhibitor for zinc-bound water. This may not, however, represent the 
mechanism by which simple 'ground-state' substrate analogues bind.
In a study conducted by Izquierdo-Martin and Stein (1994), N-carboxyalkyl 
inhibitors were shown to bind slowly to stromelysin with kon^ of the order of 10^ 
M-Is-1 but this series may, like the phosphorus based inhibitors, be classed as 
transition state analogues. There are no reports of the kinetics of hydroxamate 
inhibitor binding to MMPs.
There are several descriptions of slow, tight-binding inhibitors in the ACE 
area. Bull et al. (1985) compared the slow binding of captopril (thiol), and 
enalaprilat (carboxylate) and lisinopril (carboxylate) to ACE. Whilst these 
compounds exhibit time-dependent inhibition the association rate constants {kon 
= 106 M-Is-1) are arguably within diffusion controlled limits. Similarly, idapril 
(hydroxamic acid) has also been described as slow binding despite a kon of 3 x 
10® M-is"i (Lippi et al., 1993). These compounds are highly active and this 
illustrates another aspect of slow-binding kinetics. For inhibitors with Ki's of the 
order of 1 nM the slow onset of equilibrium can be a consequence of a slow rate 
of dissociation even if the association rate is diffusion limited. Bartlett and 
Marlowe (1987), therefore, suggest an upper limit of 10® M-is-i for a true slow- 
binding mechanism. Experimentally, tight-binding inhibitors may be studied 
using slow-binding kinetics by decreasing the enzyme concentration (which is 
dependent on having a high substrate turnover number). This is an important 
method for determining the values for kon and koff of such inhibitors (Morrison, 
1982). The application of these techniques to MMP inhibitors will be described in 
Chapter 6.
1.4:6 The pharmacokinetics of MMP inhibitors
The efficacy of an orally delivered drug is related to its efficiency in 
traversing the intestinal membrane (absorption), its pre-systemic elimination and 
its systemic half-life. These factors have presented a major challenge to the
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clinical development of peptidic drugs (Humphrey and Ringrose, 1986). Oral 
bioavailability (often expressed as a percentage) is typically defined in terms of 
the ratio of orally administered drug detected in the plasma to that detected after 
administration by the intravenous route.
The design of inhibitors of the renin-angiotensin system have served as 
models for the design of orally active peptidic drugs in general. Three main 
approaches have been employed, namely;
(1) The use of prodrugs that are converted to the active species in vivo.
(2) Depeptidisation
(3) Modifications of the lipophilic/hydrophilic balance
A combination of the first two approaches has proved successful in the 
development of enalaprilat (Figure 1.8). The pharmacokinetic properties of this 
compound were significantly improved by blocking the zinc-binding carboxylate 
group to form the prodrug, enalapril. After absorption from the gastrointestinal 
tract the blocking group is readily removed by esterase action.
Depeptidisation has long been a goal of workers in the MMP area. 
Cyclisation of the P2' and P3' groups without a loss in potency was achieved by 
Roche (section 1.4:4), however, complete depeptidisation has not been 
achieved.
Passive absorption across the gastrointestinal tract requires a correct 
balance of lipophilic and hydrophilic elements. Modification of the 
physiochemical properties of compounds to achieve this balance has been 
extensively studied in the renin area. Boyd et ai. (1992) reported the use of a 
wide variety of basic groups to produce a series of soluble and bioavailable renin 
inhibitors which retained their potency. Other groups achieved oral 
bioavailability by incorporating histidine-like substituents into their structures (Patt 
eta!., 1992)
Kleinert (1992), however, showed that peptide-like inhibitors of renin of 
differing sizes were efficiently absorbed in several animal species (reviewed in 
Kleinert et ai., 1993). They concluded that the major cause of poor bioavailability 
in such drugs was rapid hepatic clearance.
The problems associated with peptide based drugs is particularly evident 
in the MMP area where a lack of oral bioavailability and poor systemic half-life 
have severely hindered progress into the clinic. These obstacles are reflected in 
the notable absence of pharmacokinetic literature on the subject.
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Studies of the Searle collagenase hydroxamic inhibitor (Compound 3, Fig. 
1.9) demonstrated its lack of oral bioavailability in the rat despite its stability over 
24 hours in the blood (Singh et al., 1993). Perfusion using organ baths 
demonstrated that the compound was adequately absorbed across the rat 
intestine but neither the parent nor its major metabolite, the carboxylic acid, 
escaped the liver. The C-terminal region of the drug was then targeted as a 
means of altering its physiochemical properties without affecting potency. The 
result was a series of compounds with oral bioavailabilities ranging from 0 -1 0  % 
and systemic half-lives ranging from 6.9 - 43.7 minutes. A more detailed study of 
the metabolism of a related drug BB94 (batimastat) was undertaken by Yachetti 
et al. (1993). Several metabolites were identified in the biie shortly after 
intravenous administration. The major site of biotransformation was shown to be 
the hydroxamic acid.
Some progress was made by the incorporation of a tertiary butyl group into 
the P2' position of a collagenase inhibitor (Ro31-9790) developed by Roche 
(Meeting report by Lewis et al., 1993). The oral bioavailabilities of this inhibitor 
were estimated to be 7% and 17% in the rat and marmoset, respectively. The 
compound which is a broad spectrum collagenase and gelatinase inhibitor is 
also reported to possess a systemic half-life of about 1 hour in the rat.
Despite its use in clinical trials for the treatment of ascites the British 
Biotech compound, batimastat, is not reported to be orally bioavailable and is 
currently administered by the intraperitoneal (i.p.) route. A series of modifications 
to the compound have been patented (Dickens et ai, 1994) with the claim that 
replacing the a-carbon substituent (see Fig. 5.1) with a hydroxyl group leads to 
improvements in oral bioavailability. The pharmacokinetics of gelatinase-A 
inhibitors is the subject of Chapter 7.
1.5: Experimental approach
The contents of this thesis can be divided into two sections. The first part, 
Chapters 3 and 4, deal largely with the activation of progelatinase-A, 
progelatinase-B and interstitial procollagenase. The second part (Chapters 5, 6 
and 7) covers the processes by which inhibitors to these MMPs were designed.
Methods for activating MMPs are widely reported in the literature 
(reviewed in Birkedal-Hansen et ai, 1993) and indeed activation by APMA is a
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characteristic property of this family. Nevertheless, the activation of 
progelatinase-A, progelatinase-B and procollagenase (enzymes provided by Dr. 
T. Crabbe) has been the subject of extensive debate. Accordingly, chapters 3 
and 4 address the following issues;
(1) The resistance of progelatinase-A to test-tube activation by
proteinases.
(2) The contribution of the C-terminal domain to progelatinase-B activation
(3) The phenomenon of the “superactivation” of collagenase
A combination of SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and fluorescent peptide assay were used to study the activation process. This 
allows the enzymic activity to be related to the enzyme form, since activation is 
generally associated with a reduction in molecular mass. In many cases the 
identities of enzyme species were also determined by N-terminal sequencing. 
This work showed that progelatinase-A may be activated in the test-tube by either 
matrilysin or collagenase. The latter is not able to complete the process and, by 
using a specific inhibitor of gelatinase-A, its cleavage site was identified. It 
proved to be identical to an intermediate arising from the activation of 
progelatinase-A by stimulated human fibrosarcoma cells (Strongin et ai, 1993). 
The action of collagenase was then shown to be reciprocated because 
collagenase became superactivated by co-incubation with progelatinase-A. The 
whole process was stimulated by heparin, which may act as a template for the 
two enzymes by binding to their C-terminal domains.
Superactivation, correlates with the appearance of at the N-terminus of 
collagenase. It was first noted by Murphy et a i (1987) when interstitial 
collagenase was incubated with stromelysin. Work in this thesis demonstrates 
that this phenomenon is limited to increasing the rate at which collagenase 
cleaves collagen and has no effect on the peptidase activity of collagenase. This 
is relevant to the role of F®1 in promoting superactivation, which will be discussed 
in Chapters 4 and 8 in the light of recent crystal log raphic studies.
The contribution of the C-terminal domains to activation and activity was 
examined using genetically engineered proteins that lacked this domain. The 
results show that truncated enzymes demonstrate identical activities to the parent 
enzymes apart from the inability of truncated collagenase to cleave collagen. 
This was expected since similar results have been described by other groups 
(Birkedal-Hansen et ai, 1988; Clark and Cawston, 1989). The observation was
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taken a step further, however, by demonstrating that a monoclonal antibody 
(MAC065), directed against the C-terminal domain of collagenase, specifically 
blocked collagenolysls. Collagen binding may, therefore, provide an additional 
target for the design of collagenase inhibitors.
Fluorescent peptide assays were developed for gelatinase-A, gelatinase- 
B, collagenase, stromelysin and matrilysin. Appropriate assays were also 
established for two zinc peptidases, ACE and AP-N. Chapter 5 shows how these 
assays can be used to construct a series of inhibitor SARs, which are important to 
the rational design of new chemical entities. Optimisation of inhibitor side-chains 
led the Celltech Chemistry Department to synthesise compounds with Ki's of less 
than 10‘11 M against the target enzyme, gelatinase-A, and which are of the order 
of 50,000 fold more potent against this enzyme than interstitial collagenase. 
These experimentally derived SARs may be further rationalised using the 
enzyme structure data that has since become available (see section 1.4:4 {ii}).
A kinetic treatment of the binding of phosphorus-based inhibitors and N- 
carboxyalkyl inhibitors to stromelysin has been reported by Izquierdo-Martin and 
Stein, (1992; 1994). These inhibitors exhibit association rate constants (kon) of 
the order of 10^ M -is"\ which is a characteristic of slow-binding kinetics. There 
are, however, no reports on the binding of hydroxamic acid inhibitors to MMPs, 
although the ACE literature does contain examples of such compounds (Lippi et 
a/., 1993). Complex formation between MMP inhibitors and gelatinase-A was 
analysed under pre-steady-state conditions (Chapter 6). The time-dependency 
of inhibition, which arises from the use of low reactant concentrations, allowed 
the data to be analysed using slow-binding equations. The kon for a number of 
inhibitors was in the range of 10® - 10  ^ M“‘ls"'' which is consistent with diffusion 
limited association. These values are comparable to that reported for the ACE 
hydroxamic acid inhibitor, Idapril (Lippi etal., 1993). The dissociation half-lives of 
all the compounds tested were of the order of minutes to hours so the high affinity 
of hydroxamic acid inhibitors for gelatinase-A is the product of a slow rate of 
dissociation and a fast rate of association.
There is little published data concerning the pharmacokinetics of MMP 
inhibitors. The data that is available (section 1.4:6) suggest that the systemic 
half-lives and oral bioavailability of hydroxamic inhibitors are poor in the rat. The 
same principles apply to the design of pharmacokinetically active drugs as for the 
design of good in vitro properties so in order to construct SARs, a high-
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throughput screen is necessary. This was provided by a mouse pleural cavity 
assay (section 2.4:3), which was developed In collaboration with the Dr. P. 
Antoniw, Dr. S. Chander and Dr. N. Willmott of the Celltech Oncology 
Pharmacology Department. This assay identified a series of systemically active 
and orally active inhibitors but its narrow concentration-effect range meant that it 
was not quantitative (Chapter 7). Phamacokinetic properties were, therefore, 
determined by the standard practice of measuring inhibitor levels in the blood. 
The lack of a distinguishable chromophore, ruled out the direct measurement of 
inhibitor concentration. Instead, the inhibitor was extracted from the blood and its 
inhibitory activity measured either by titration against gelatinase-A (section 2.4:2
(i)) or by Capillary Electrophoresis (2.4:2 {ii}). These studies resulted in the 
identification of inhibitors with oral bioavailabilities of about 40% in the mouse 
and 7% in the rat.
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CHAPTER 2
MATERIALS AND METHODS
2.1 : General materials
2.1:1 Reagents, stock solutions and equipment 
General chemicals
General chemicals were purchased from B.D.H Ltd., Poole, Dorset, or 
Sigma Chemical Co., Poole, Dorset, unless stated otherwise. Methanol, 
acetonitrile and HPLC grade water were obtained from Fisons, Loughborough. 
Radioisotopes were purchased from Amersham International, Little Chalfont, 
Bucks.
APMA (Sigma A-8514) Stock solution of 20 mM in DMSO. Stored at room 
temperature.
Bacterial collagenase (Sigma C-9891) type 1A from Clostridium  
histolyticum. Stock solution is 10 mg/ml in water. Stored at -20®C.
Brij 35 (Pierce 28316) 10% aqueous solution stored at room temperature.
BrI] 35 (Sigma Diagnostics 430AG-6) 30% solution (w/v) stored at room 
temperature.
Heparin (Sigma H-3125) Sodium salt, grade I from porcine intestinal 
mucosa. Stored as powder at room temperature.
p-Dloxane Dried over Molecular sieve 4A (stored in fume cupboard)
1,10-Phenanthrollne solution 16 mg of 1,10-phenanthroline monohydrate 
dissolved in 0.5 ml p-dioxane and diluted to 1 ml with deionised water. 
(Prepared fresh for each experiment)
PMSF (Sigma P-7626) Stock solution of 100 mM in propan-2-ol stored at 
room temperature.
SBTI (Boehringer Mannheim 109 886) Stock solution is 4.5 mg/ml in 
peptide assay buffer. Stored in 50 pi aliquots at-20°C
Scintillation fluid Aqua luma plus (Lumac LSC)
TOA Stock solution is 90% (w/v) in water.
Trypsin (Sigma T-8642) Type XIII :TPCK-treated trypsin from bovine 
pancreas. Stock solution of 0.1 mg/ml in 10 mM HCI, 10 mM CaCl2. Stored in 0.1 
ml aliquots at -20°C.
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Immobilon membrane for western blotting (Millipore) Membranes are 
presoaked in methanol for a few seconds and then washed in transfer buffer prior 
to use.
Polymethyacrylate fluorlmeter cuvettes (sigma C-0793)
Sep-pak ci8 reverse phase cartridges (Waters) part no. 51910 
Sterile plastic syringes (Becton Dickinson) Plastipak 
Ultrafree-MC 10,000 NMWLfliter units (Millipore) (To process 400 pi 
volumes)
Western blotting apparatus (Biorad) Transblot cell 
2.1:2 Enzymes
ACE (Sigma A-6778; rabbit lung) Stock is 1 pM in 2 mM TRIS-HCI, pH8.0, 
100 mM NaCI, 10 pM EDTA
AP-N (Boehringer, 20 units/0.4 ml) (Stock solution is diluted 1/200 for 
assay)
MMPs Recombinant human progelatinase-A, progelatinase-B, 
procollagenase, prostromelysin and promatrilysin were purified from medium 
conditioned by the relevant transfected mouse myeloma cell line as described 
previously (Murphy et ai, 1992a; O'Connell etal., 1994; Murphy etal., 1992b; 
Kocklitis etal., 1991; Crabbe etal., 1992)
2.1:3 Substrates
ACE substrate (Sigma F-7131) N-(3-[2-furyl]acryloyl)-F-G-G. Stock 
solution is 1 mM in assay buffer
AP-N substrate L-leucine para-nitroanilide (Sigma ) Stock is 20 mM in 
methanol/PBS (1:1 v:v)
Preparation of casein [i^sij-iabelled p-casein is stored in 100 pi aliquots 
at -20°C. Prior to assay it may be purified by the addition of 20 pi of an 18% 
solution of TCA. Intact casein then forms a precipitate which may be isolated by 
centrifuging at 15,000 rpm for 10 minutes. The precipitate is dissolved in 0.5 ml 
of tetraborate buffer and then diluted to a final specific activity of 2 x 10® counts 
per ml.
collagen (type I prepared from rat skin). Acid soluble collagen was 
extracted and purified from rat skin as described by Cawston and Murphy, (1981). 
The final product is stored lyophilised at 4°C. The collagen content is determined
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by amino-acid analysis and calculated from the hydroxproline content which 
makes up 13% of the total weight of collagen. Prior to assay collagen is 
dissolved at 1 mg/ml in 0.2 M acetic acid by slowly stirring for several hours at 
room temperature. The solubilsed collagen is then dialysed against collagen 
dialysis buffer for 16 - 32 hours. The pH of the final solution is retained at about 
pH 6.5 to prevent precipitation. For assay the pH is adjusted to 7.5 - 8.0 using 5 
N sodium hydroxide.
[i^C]-labelled collagen Approximately 30 ml of unlabelled collagen (1 
mg/ml) is dialysed against tetraborate buffer for 16 hrs. This is then transferred to 
a conical flask on ice. The total contents of 1 vial of [i^cj-acetic anhydride (250 
pCi) are mixed with the collagen solution for 30 mins at 4°C. This is then 
dialysed for several days against 0.2 M acetic acid until the radioactivity in the 
dialysate has reached background levels. The radioactivity of the collagen is 
reduced to about 10® cpm/ml using unlabelled collagen solution and this is 
dialysed for 48 hrs in collagen dialysis buffer.
[i4C]-labelled gelatin [“'^Cj-labelled collagen (1 mg/ml) In 0.2 M acetic 
acid (above) is diluted into cold collagen (1 mg/ml, 10® cpm/mg) in collagen 
dialysis buffer to give a final specific activity of 10® cpm/mg. The collagen is 
converted to gelatin by heating to 55 - 60°C for 60 minutes. The pH of this 
solution is then adjusted to pH 8 by the addition of a few drops of sodium 
hydroxide.
Heat appropriate mixture of collagen and [^^Cj-labelled collagen in collagen 
dialysis buffer to 60°C for 1 hour. Store at 4°C. For assay adjust pH to pH 7.5 - 
8.0.
Dnp-PLGLWAR (Stack and Gray, 1989) (Purchased from Nova biochem, 
A08563) E372 = 16,000 M-^cm'’*. For a 25 mM solution add 25 mg to 1 ml of 
DMSO. Measure the absorbance at 372 nm and adjust the volume accordingly. 
Store in the dark at -20°C. For assay this stock solution is diluted to 4 mM with 
DMSO. Additional dilutions are carried out in peptide asay buffer. The final 
concentration of DMSO should be no greater than 0.5% (v/v) in the assay.
QF24 (Purchased from Dr. G.Knight, Strangeways research laboratory, 
Cambridge) E410 = 7,500 M“lcm‘T Dissolve 0.9 mg in I ml of DMSO. Measure 
the absorbance of a 1:10 solution (sample:assay buffer) at 410 nm. Adjust the 
volume with DMSO to give a stock concentration of 350 - 390 pM. Store in the 
dark at 4°C. For assay this solution is diluted 250 fold in peptide assay buffer.
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2.1:4 Buffers
ACE assay buffer 50 mM HEPES, pH7.5, 0.3 M NaCI, 10 pM zinc 
chloride
AP-N assay buffer Sterile phosphate buffered saline (PBS)
Caseinase assay buffer 25 mM TRIS-HCI, pH 7.6, 10 mM CaCl2,
0.05%Brij 35, 0.05% sodium azide (w/v)
Collagen dialysis buffer 50mM TRIS-HCI, pH 7.6, 200 mM NaCI, 0.003% 
sodium azide (w/v)
Diffuse fibril Assay buffer lOOmM TRIS-HCI, pH 7.9 at r/t, 15 mM CaCl2,
0.02% sodium azide (w/v)
Enzyme dilution buffer 50 mM TRIS-HCI, pH 7.9 at r/t, 0.02 sodium azide
(w/v)
Gelatinase activation buffer 63 mM TRIS-HCI, pH 7.5, 65 mM NaCI, 10 
mM CaCl2, 0.025%Brij 35 (This is made up by combining equal volumes of 
peptide assay buffer and low salt enzyme buffer).
Low salt enzyme buffer 26 mM TRIS-HCI, pH 7.5, 30 mM NaCI, 10 mM
CaCl2,
Peptide assay buffer 100 mM TRIS-HCI, pH 7.5 at r/t, 100 mM NaCI, 10 
mM CaCl2, 0.05% Brij 35 (v/v)
Pleural cavity lavage buffer PBS containing 50 mM EDTA 
SDS-PAGE sample buffer (x5 concentrated) 2.5 M Tris-HCI, pH 6.8 
(3.75 ml), glycerol (15 ml), SDS (4.5 g), deinonised water (8.5 ml). Stored at 4°C 
and heated for use.
Solution phase assay buffer 100 mM TRIS-HCI, pH 7.9 at r/t, 250 mM 
NaCI, 30 mM CaCl2, 750 mM glucose, 0.02 % sodium azide (w/v)
Solution phase enzyme dilution buffer 50 mM TRIS-HCI, pH 7.9 at r/t, 5 
mM CaCl2, 0.05 Brij 35, 0.02% sodium azide (w/v)
Stopping buffer 100 mM sodium acetate pH 4.0
Tetraborate buffer 10 mM disodium tetraborate, pH 9.5, 200 mM CaCl2
6.H2O
Western blotting transfer buffer 100 mM CAPS buffer pH 11 (22.13g/L) 
was stored as a x 10 concentrated solution. For use 300 ml of CAPS is mixed 
with 300 ml of methanol and the volume is adjusted to 3 L with deionised water.
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Western blotting iow salt wash buffer 20 mM TRIS-HCI, pH 7.6, 0.9% 
NaCI (w/v), 0.05% triton X-100 (v/v).
Western blotting low salt blocking buffer Low salt wash buffer 
containing 0.5% casein hammersten (w/v) (BDH).
Western biotting high salt blocking buffer 20 mM Tris-HCI, pH 7.6,1 M 
NaCI, 0.4% lauroyl sarcosine (w/v).
2.2: Enzyme assays
2.2:1 MMP activation
Prior to their use in assays all MMPs have to be activated. The following 
methods of activation were developed using human recombinant enzymes. 
However, enzymes from other sources may be activated in a similar manner.
(i) Interstitial procollagenase
Interstitial procollagenase (1 - 4 pM) is incubated for 45 minutes at 35°C 
together with TPCK-treated trypsin (5 pg/ml) and prostromelysin (4 pg/ml). At the 
end of the incubation period the trypsin activity is terminated by the addition of 
SBTI (50 pg/ml) or PMSF (ImM). The activated collagenase is commonly 
allowed to stand for at least 15 minutes at 23°C (room temperature) prior to 
assay. Although this solution may be stable for several days at 4°C fresh batches 
are generally prepared for each assay.
This process is also used for the activation of truncated procollagenase 
which lacks the C-terminal domain and for neutrophil procollagenase.
(Ii) Prostromelysin
Prostromelysin (1 - 2 pM) is incubated with TPCK-treated trypsin (0.01 
mg/ml) for 15 - 30 minutes at 23°C. The trypsin activity is then terminated with 
SBTI (0.1 mg/ml). The activated enzyme is stable for at least a week at 4°C, 
although like collagenase, fresh reagent is generally prepared prior to assay.
(ill) Progelatinase-A
Progelatinase-A (1.6 pM) is incubated in the presence of APMA (1 mM) in 
peptide assay buffer which includes 5% DMSO (i.e. APMA:gelatinase solution 
1:20 v/v) for 16 hours at 23°C. The incubation period may be shortened by 
omitting Brij 35 from the assay buffer. Generally the APMA is not removed prior
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to assay and this solution is stable at 4°C for 3 - 4 weeks. Approximately 90% 
activation is achieved by this method.
(iv) Progelatinase-B
Progelatinase-B (2 pM) is incubated in the presence of APMA (2 mM) in 
peptide assay buffer which includes 10% DMSO for 23 hours at 37°C. This 
solution is generally stored at -20°C prior to assay.
Alternatively, progelatinase-B (2 pM) may be activated by the addition of 
active stromelysin (0.17 pM) for 6 hours at 37°G. This produces a more stable 
species but the presence of stromelysin may interfere with the assay of inhibitors.
(v) Promatrilysin
Promatrilysin is activated by heating for 5 hours at 53°C (Crabbe et al., 
1992). This solution is stable for several weeks at 4°C.
2.2:2 Peptide assays for MMPs
The activity of MMPs is routinely measured using two fluoresecent 
peptides
1. Dinitrophenyl Pro-Leu-Gly-Leu-Trp-Ala- D-ArgNH2 (Dnp-PLGLWAR; Stack 
and Gray, 1989).
2. 7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3 
diaminopropionyl]-Ala-ArgNH2 (Mca-PLGL Dpa AR; Knight etal., 1992). This is 
referred to as QF24 throughout this study.
The fluorescence associated with tryptophan, W, (peptide 1) and Mca 
(peptide 2) is quenched by the presence of Dnp and Dpa, respectively. 
Cleavage of the G-L bond separates the two groups resulting in a corresponding 
increase in fluorescence. The rate of fluorescence increase (FU/min) is 
proportional to the rate of enzymic reaction.
(I) Dnp-PLGLWAR assay
Dnp-PLGLWAR assays are generally performed using a substrate 
concentration of 20 pM in 0.1 M Tris-HCI, pH 7.5, containing 0.1 M NaCI, 0.01 M 
CaCl2, 0.05% Brij 35 (peptide assay buffer) and 0.5% DMSO (Crabbe eta l ,  
1992). Assays are routinely conducted at 37°C for all the MMPs except 
gelatinase-A, which is assayed at 26®C due to its instability at the higher
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temperature. Hydrolysis of the G-L bond is followed fluorometrically by 
measuring the increase in tryptophan (W) fluorescence (Xqx 280, Xem 346) using 
a Perkin Elmer LS 30 luminescence spectrometer.
A stopped assay is commonly employed, in which 20 pi of the reaction 
mixture is removed to 0.78 ml stopping buffer. Samples are then placed in an 
autosampler and the fluorescence measured using a flow cell. Fluorimeter 
settings are as follows;
Excitation wavelength 
Emission wavelength 
Monochromator scan mode 
Ordinate mode 
Scale factor 
Response 
Abscissa mode 
Sample time /  sec 
Delay / sec 
Purge time
280 nm 
346 nm 
Emission 
Fluorescence 
1 
2
Scan
5
3
0
The data is displayed using an LS 30 handler programme.
(ii) QF24 assay
MMP activity is measured using the substrate QF24 (1.4 -1.6 pM) in a total 
reaction volume of 2.5 ml of peptide assay buffer. Hydrolysis of the G-L bond is 
followed fluorometrically by measuring the increase in Mca fluorescence (A,ex 
328, Xem 393) associated with the removal of the quenching Dpa group (Knight 
et al., 1992). Fluorescence is monitored continuously using a Perkin Elmer LS 
5B luminescence spectrometer with slit widths set at 5 mm. Rates are graphically 
displayed using the FLUSYS programme (Rawlings and Barrett, 1990). 
Reactions are calibrated at the start of each experiment using Mca-P-L (10 nM). 
The fluorimeter set-up Is programmed as follows;
Excitation wavelength 
Emission wavelength 
Autozero 
Autoconcentration 
Response time
328
393
Yes
Yes (factor 100) 
3
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Generally, 10 pi of substrate solution in DMSO is mixed with 2.465 ml of 
buffer in a quartz or polymethacrylate cuvette (Sigma) suitable for fluorescent 
measurements. The total volume is then adjusted to 2.5 ml with enzyme solution 
(25 pi). In the absence of a temperature controlled sample holder reactions are 
carried out at room temperature (22 - 25 °C).
2.2:3 Determination of Km and kca/Km vaiues
The Michaelis constant (Km) is the dissociation constant for the enzyme- 
substrate complex and it refers to the substrate concentration required to produce 
half-maximal velocity (Vmax)- It is experimentally determined by measuring 
enzymic rates in the presence of a range of substrate concentrations, ideally of 
the order of 0.1 - 10 times the Km value. The enzfitter programme (Michaelis- 
Menten kinetics) can be used to determine the Km from a plot of substrate 
concentration (x-axis) versus rate (y-axis). The insolubility of QF24 and 
fluorescence quenching at higher concentrations precluded an accurate 
estimation of Km for any MMP although a lower limit can be established. 
Similarly, because of the insolubility of the Dnp-PLGLWAR substrate, accurate 
Km values were only determined for the gelatinases.
The kca/Km is a useful term for comparing the specificity of an enzyme
towards a substrate and is an indication of the overall efficiency of an enzyme. It
may be derived from the standard Michaelis-Menten equation;
Vj  = Vmax. S 
Km + S
where V| is the initial rate and 8 is the substrate concentration. When 8 is not 
substantially lower than Km the value for k^a/Km cannot be determined directly. 
Under conditions of 8 «  Km, however, the denominator, 8, term becomes 
insignificant and the equation may be rearranged to give,
Vmax = yi 
Km S
Since Vmax is equivalent to the product of kcat and the enzyme concentration [E] 
this becomes;
„ kcat=  vi 
Km S.[E]
The kca/ZKm may, therefore, be determined directly using a substrate 
concentration at least 10 fold lower than the Km- On occasions when this 
condition cannot be satisfied the Km may be determined using the Vmax value.
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Since, the /cca^ /Km is often expressed in units of IVI-is-\ rates such as FU/min, 
must be converted into substrate concentration terms. This conversion is 
routinely carried out for the QF24 assay during the process of calibration. Dnp- 
PLGLWAR fluorescence may be calibrated using a range of tryptophan 
concentrations. The precise relationship between fluorescence units and the 
exposure of tryptophan, changes according to the age of the fluorimeter lamp, but 
it is commonly in the range of 1 FU = 0.005 - 0.006 pM.
2.2:4 Determination of Ki values
(i) Dnp-PLGLWAR assay 
Preparation of inhibitor
Inhibitors are commonly dissolved in methanol at a concentration of 10 
mM. Prior to assay, samples are diluted 100 fold in methanol after which further 
dilutions may be performed using assay buffer. Between eight and ten inhibitor 
concentrations (double-dilutions) are frequently tested. Ideally, the Ki should lie 
close to the middle concentration. A suitable concentration range may be 
established by performing a preliminary “siter” assay using four inhibitor 
concentrations, for example 1, 10, 100 and 1000 nM. Except in exceptional 
circumstances (such as the measurement of very weak inhibitors) the final 
concentration of methanol should be lower than 1% of the total assay volume. 
Method
All MMP inhibitors are initially screened with the Dnp-PLGLWAR substrate 
using assay conditions described previously. The final assay mixture contains 
enzyme (12 pi), inhibitor (12 pi), substrate (10 pi) and is adjusted to 120 pi with 
peptide assay buffer.
Briefly, gelatinase-A (0.05 nM), gelatinase-B (0.04 nM), stromelysin (3 nM), 
collagenase (2.5 nM) or matrilysin (0.25 nM) and a range of inhibitor 
concentrations (0.1 - 50 x Ki) are incubated for 1 - 4 hours at 23°C in peptide 
assay buffer. The reaction is started by the addition of substrate to a final 
concentration of 20 pM. After 16 hours at an appropriate temperature the 
reaction is terminated by removing 20 pi and adding this to stopping buffer and 
measuring the resulting fluorescence.
Apparent Ki (Kigpp) values are determined using Enzfitter (Leatherbarrow,
1987) by a non-linear regression of the following equation (Morrison and Walsh,
1988) for tight-binding, reversible inhibition;
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2E,
where Vq is the initial rate in the absence of inhibitor, Vq is the initial rate in the 
presence of inhibitor, Et is the total enzyme concentration and It the total inhibitor 
concentration in the reaction mixture. The enzfitter programme for high affinity 
Inhibition is essentially as follows;
High affinity inhibition
■Equation Name*
■Y Axis Name-
Initial rate ][
"X Axis Name-
[Inhibitor]
■VARm^
1 Inhibition constant Ki 5
2 Uninhibited rate VO 6
3 7
4 8
n ["^Prompted Constant^^ F— VA»— 1
FEnzyme concentration Eo 34 n
'Equation Definitions
Tempi
<vo/(2*Eo))*((Ea-r-Ki)+SQRT(SQR(Ki+I-Eo)44*Ei*Eo))
True Ki values may be determined using the relationship for competitive 
inhibition, j .  Collagenase, stromelysin and matrilysin assays
are performed under first order conditions of S «  Km and, therefore, Kiapp 
approaches the true Ki. Substitution of the appropriate Km value in the above 
equation permits the Ki vaiues of inhibitors of gelatinase-A and gelatinase-B to 
be calculated.
(ii) QF24 assay
The Dnp-PLGLWAR assay cannot be used to determine the potency of 
inhibitors with Ki values lower than 100 pM against gelatinase-A. In such cases, 
the QF24 assay is commonly used as a secondary screen, since the superior
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sensitivity of this substrate (chapter 3) permits a reduction in the concentration of 
the enzyme.
Method
Gelatinase-A (20 pM) and a range of inhibitor concentrations (0.1 - 50 x Ki) 
are incubated in a volume of 2.49 ml of peptide assay buffer for 1 - 4 hours at 
23°G. The reaction is started by the addition of substrate (10 pi) to a final 
concentration of about 1.4 pM. Hydrolysis rates are then determined over the first 
1 - 2  minutes of the reaction using the flusys programme (Rawlings and Barrett, 
1990). Kiapp is calculated as described above. The substrate concentration of 
1.4 pM is presumed to be significantly lower than the Km and, therefore, the Kiapp 
approximates to the Ki.
2.2:5 Titration of enzymic activity
The concentration of active MMP can be determined by titrating its activity 
against a high affinity inhibitor that binds to the enzyme with a 1:1 stoichiometry, 
under conditions in which the dissociation of the enzyme-inhibitor complex is 
negligible. TIMPs which are the natural inhibitors of MMPs were often used for 
this purpose. Whilst TIMP-1 is the most commonly employed titrant, TIMP-2 is 
preferable for the determination of gelatinase-B activity, since TIMP-1 can bind to 
the C-terminal domain of its proenzyme form. The concentrations of TIMP-1 and 
TIMP-2 were determined by titration against a standard solution of stromelysin, as 
described by Willenbrock et ah, (1993).
Method
Titrations are performed using an enzyme concentration of 20 - 50 nM and 
TIMP concentrations in the range of 2.5 - 100 nM. Enzyme and inhibitor are 
incubated at room temperature in a total volume of 50 pi of peptide assay buffer. 
After 1 - 2  hours aliquots are removed and then diluted appropriately for assay 
against either of the two fluorescent peptide substrates. Dnp-PLGLWAR assays 
are routinely performed at 37°C (except gelatinase-A) and samples are taken at 
intervals up to 30 minutes and analysed as described above. QF24 assays are 
performed at room temperature with continuous monitoring of the hydrolysis rate. 
In both cases only the linear portion of the progress curve is used, to avoid effects 
due to the dissociation of the TIMP-enzyme complex.
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The active enzyme concentration is determined form the x-axis intercept of 
a plot of the Initial rate of substrate hydrolysis (y-axis) versus TIMP concentration 
(x-axis).
2.2:6 High molecular mass substrate assays
The following high molecular substrate assays (diffuse fibril, soluble 
collagen, gelatin , casein) are all based on differential centrifugation. In each 
case soluble radiolabelled material, formed as a result of enzyme action, is 
separated from uncleaved substrate by centrifugation. The amount of 
radioactivity in the supernatant is proportional to enzymic activity.
(1) The determination of IC50 values using the diffuse-flbrll assay for 
collagenase (Cawston and Barrett, 1979)
The collagenolytic activity of collagenase is commonly measured against 
collagen of three physical forms, namely fibrillar, semi-soluble (diffuse-fibril) or 
soluble (reviewed in Cawston and Murphy, 1981). The former, which uses 
preformed fibrils is closest to mimicking the natural substrate but it is limited by 
the poor specific activity of collagenase. Collagenase is most active against 
soluble collagen but artifacts may be introduced by the solubilising agent. The 
most frequently employed assay is the diffuse-fibril type since it incorporates 
properties of both the other assays.
The IC50 value is the concentration of inhibitor required to inhibit enzymic 
activity by 50%. It is calculated by plotting the Logic inhibitor concentration (x- 
axis) versus percentage inhibition of the activity of an enzyme control. The IC50 
may then be determined manually from the resulting sigmoidal plot or using an 
appropriate enzfitter programme.
The following controls should also be included,
1. No enzyme blank (This value is subtracted from all other results)
2. Enzyme without inhibitor (Eo) (This represents 0% inhibition)
3. Total digestion by bacterial collagenase (This gives an indication as to whether
(2) is on the linear portion of the concentration-activity curve)
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Method
A range of inhibitor concentrations are prepared based upon the criteria 
described for Ki assays. Assays (triplicate) are then performed in a total volume 
of 300 pi using 0.4 ml eppendorf tubes as follows;
Inhibitor in a volume of 10 pi of methanol or DMSO is added to 70 pi of 
enzyme dilution buffer. The volume is then adjusted to 200 pi with 100 pi of 
collagenase assay buffer and 20 pi of activated collagenase (100 nM). This 
solution is allowed to stand at room temperature for 30 - 60 mins. The reaction is 
started by adding 100 pi ['•^Cj-acetylated collagen (1 mg/ml, 10® cpm/mg). After 
whirli-mixing, samples are incubated for a further 100 mins at 35°C. The tubes 
are flicked in order to cause the collagen to condense into a ball of fibrils. They 
are then centrifuged for at 12,000 rpm for 10 minutes to precipitate the intact 
collagen. 100 pi of the supernatant is then immediately removed and mixed with 
3 ml of an aqueous compatible scintillation fluid. Cpms are counted using the 
i^C-channel of a scintillation counter (eg. Packard)
(ii) The solution phase assay for collagenase
The property of collagen to form insoluble fibrils at neutral pH at 
concentrations in excess of 100 pg/ml precludes the use of the diffuse fibril assay 
for obtaining kinetic parameters by classical enzymologlcal methods. Fibril 
formation may, however, be inhibited by the inclusion of glucose so that assays 
can be performed in a “total-solution-phase” system. The procedure described 
here is based on an assay method first developed by Terato et al. (1976). Assays 
(triplicate) are performed in a total volume of 300 pi in 1 ml eppendorf tubes. 
Method
Collagenase made up in 100 pi of enzyme dilution buffer is added to 100 
pi of glucose assay buffer. The temperature of the reaction mixture is then raised 
to 35®C prior to the addition of 100 pi of [i4C]-labelled collagen (1 mg/ml, 10® 
cpm/ml). The reaction proceeds for 60 minutes at 35°C and then enzymic activity 
is quenched by the addition of 15 pi of 1,10-phenanthroline. Samples are then 
allowed to stand at 35°G for a further 60 minutes to encourage unfolding of the 
cleaved collagen. After cooling to room temperature, intact collagen is 
precipitated by the addition of an equal volume of dioxane solution followed by 
centrifugation in a microfuge (about 12,000 rpm) for 10 minutes. Radioactivity in 
the supernatant is measured by removing 400 pi to 4 ml of scintillation fluid and
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counting on a channel. Control assays are similar to those described for the 
diffuse fibril assay.
(iii) Gelatin assay for gelatinase
Denatured fibrillar collagen is thought to be a physiological substrate for 
members of the gelatinase family. Whilst, in vivo, it is likely to be produced as a 
result of collagenase action, gelatin may be formed artificially by incubating type I 
collagen at elevated temperatures. The following procedure is based on the 
method described by Sellers et ai. (1978).
Method
[i^C]-labelled gelatin substrate is prepared as described in section 2.1:3. 
A range of inhibitor concentrations are prepared by doubling dilution as 
described for Ki determination. Assays (triplicate) are then performed in a total 
volume of 300 \i\ using 1 ml eppendorf tubes as follows;
Gelatinase-A (0.5 nM) and a range of inhibitor concentrations are 
incubated for 2 hours in a final volume of 200 pi peptide assay buffer. Enzyme 
only (Eo), blank and total hydrolysis samples are treated similarly. The reaction 
is started by the addition of [i^Cj-gelatin (100 pi). After 100 minutes at 26°C the 
enzymic activity is terminated by the addition of 60 pi of 90% solution of TCA. 
Prior to processing, samples are stored at 4°C overnight or on ice for 1 hour. The 
tubes are subsequently centrifuged at 12,000 rpm for 10 minutes at 4°C to 
precipitate the uncleaved gelatin. 200 pi of supernatant is then added to 3ml of 
scintillation fluid and the radioactivity is measured on the [‘‘^C] channel of a 
Packard scintillation counter or equivalent instrument. I C 5 0  values are 
determined as described for the diffuse fibril assay.
In a variation on the above procedure the incubation time may be increased to 16 
hours to permit the gelatinase concentration to be decreased. This assay is 
limited, however, by an increase in the level of cpm in the blank supernatant.
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(iv) Caseinase assay for stromelysin (based on Cawston e t a/. (1981)
The hydrolysis of casein is commonly employed for the detection of non­
specific proteinase activity. Whilst all MMPs tested, possess some caseinase 
activity (collagenase has poor activity) it is most frequently used for the 
measurement of stromelysin.
Method
[I25|].|abelled p-casein substrate is prepared for assay as described in 
section 2.1:3. A range of inhibitor solutions are prepared as described above. 
Assays (triplicate) are performed using stromelysin at a final concentration of 30 - 
35 nM in a total volume of 100 pi in 0.4 ml eppendorf tubes as follows;
Stromelysin (20 pi) is added to a solution containing inhibitor (5 pi) mixed 
with 65 pi of caseinase assay buffer. Samples are incubated for 60 minutes at 
room temperature prior to the addition of 10 pi of radiolabelled casein substrate 
to initiate the reaction. After 60 minutes at 37°C the reaction is terminated by 
adding 20 pi of unlabelled carrier g-casein (1 mg/ml) followed by a solution of 
18% TCA (24 pi). Samples are whirli-mixed and then placed on ice for 60 
minutes. Undigested casein Is precipitated by centrifugation at 15,000 rpm, for 
15 minutes at 4°C. 100 pi of the supernatant Is then placed in an LP4 tube and 
counted using an LKB gamma counter. IC50 values are determined as described 
previously,
2.2:7 Other assays 
(Î) Peptidyl-dipeptidase A
Inhibitors were tested against AGE using the substrate furylacroyl-F-G-G 
essentially as described by Gunning et al. (1983). Enzymic activity is followed by 
measuring the decrease in absorbance at a wavelength of 328 nm using an HP 
8452A spectrophotometer.
Prior to assay, the enzyme, which is stored with EDTA is incubated in ACE assay 
buffer at room temperature for 60 minutes.
Method
For assay, ACE (20 nM) is mixed with inhibitor (100 pM) in a total volume 
of 0.9 ml of assay buffer in a 1 ml quartz cuvette. The reaction is started by the 
addition of 100 pi of substrate (final concentration 100 pM) and the resulting 
decrease in absorbance is measured using a 1 cm light path. Control samples.
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including enzyme without inhibitor and an inhibitor vehicle blank, are scanned 
simultaneously. Reactions are monitored for 20 minutes and then the initial rates 
(AU/min) are established from the linear part of the progress curve (1 - 6 
minutes).
(ri) Aminopeptidase-N (AP-N)
Inhibition of AP-N activity was tested using the substrate L-leucine p- 
nitroanilide as described by Tieku and Hooper (1992). Hydrolysis of the 
substrate causes the release of the p-nitroanilide group which results in an 
increase in absorbance at 405 nm. Assays are performed in 96 well microtitre 
plates (NUNC) using a UVmax microtitre plate reader.
Method
Inhibitor is dissolved in methanol to a concentration of 1 mM. This solution 
is then diluted appropriately (doubling dilutions) to provide a range of 
concentrations giving 0 -100% Inhibition in the assay (see IC50 determination).
Inhibitor solution (10 pi) is mixed with 170 pi of PBS in a microtitre plate 
prior to the addition of 10 pi of enzyme. After 1 hour at 37°C the reaction is 
started by adding 10 pi of substrate to give a final concentration of 1 mM. 
Reaction rates may be followed using the soft max programme set to the 
following parameters.
MODE: kinetics AUTOMIX: ON
Wavelength: 405 RUNTIME: 15:00 (mins)
CALIBRATION: ON LAG TIME: 0
OD LIMIT 2.2
Initial rates (mOD/min) are determined from the linear portion of the progress 
curve and IC50 values may be determined as described previously.
2.3: Protein characterisation
2.3:1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE analysis was routinely performed using precast 10 - 20% 
polyacrylamide gels purchased from Daiichi Pure Chemical company Ltd., Tokyo, 
Japan. Samples to be analysed typically contained 1 pg of protein and were 
prepared by boiling for three minutes in standard sample buffer (Laemnli, 1970) 
which included 2% (v:v) p-mercaptoethanol for reducing conditions. Samples
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were typically electrophoresed at a constant current of 35 - 40 mA until the dye 
front reached the bottom of the gel. Completed gels were stained for protein by 
placing them in Coomassie-blue R-250 stain for 1 hour. Gels were then 
destained using a solution of 7.5% (v/v) acetic acid or 10% (v/v) acetic acid and 
40% (v/v) methanol. Molecular masses (kDa) were generally estimated using a 
range of molecular mass standards purchased from Pharmacia Fine Chemicals, 
Uppsala, Sweden.
2.3:2 Electroblotting and N-terminal sequencing
Protein samples were N-terminally sequenced either directly or after 
electroblotting as described by Crabbe et al. (1992). In the latter method the 
sample is first subjected to SDS-PAGE according to the method of Hunkerpiller 
(1983). Protein is then electroblotted onto a poly(vinylidene) membrane 
(Matsudaira, 1987) and stained using 0.1% (w/v) Ponceau S dye in 1% (v/v) 
aqueous acetic acid (Aebersold et a/., 1987) and the relevant band is then 
excised. The blotted sample is applied to Bioprene-treated glass fibre discs 
which are loaded onto an Applied Biosystems 470A gas-phase sequencer and 
N-terminally sequenced by Edman degradation. The resulting 
phenylthiohydantoin-derivatised amino-acids are analysed with an Applied 
Biosystems 120A HPLC.
2.3:3 Western blotting
Western blotting was used to identify the collagenase domain recognised 
by the monoclonal antibody, MAC065.
Transfer
Samples were loading symmetrically onto both halves of a 10 - 20% SDS- 
polyacrylamide gel and electrophoresed as described above. This allows one 
half of the gel to be electroblotted and the other half to be stained for protein. 
Proteins were transferred onto immobllon membranes by electroblotting (Biorad 
Trans-Blot apparatus) for 16 hours at a constant voltage of 30 V in transfer buffer. 
Detection
The blotted membrane is soaked in casein blocking buffer at room 
temperature for 2 hours and then washed several times with low salt buffer and 
water. The membrane is then soaked for 3 hours at room temperature in 100 ml 
of the primary antibody (MAC065, 6 p.g/ml) dissolved in low salt blocking buffer.
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The washing process is then repeated. The washed membrane is placed on a 
glass plate and covered with 10 - 20 ml of the secondary antibody (horse radish 
peroxidase linked anti-mouse fc chain) in high salt blocking buffer and then 
incubated for 1 hour in a humidity chamber. After washing, bands are visualised 
by exposure to autoradiographic film (5 seconds) using the ECL detection system 
(Amersham).
2.4: Pharmacokinetic methods 
2.4:1 Inhibitor extraction
An extraction step is required before measurement of inhibitor levels in 
blood. This is necessary because,
1. Plasma components interfere with UV monitoring
2. Plasma significantly raises the background fluorescence in enzyme assays
3. Plasma contains natural inhibitors of MMPs such as TIMP and a-2 
macroglobulin
Several extraction procedures were developed for use with a range of 
inhibitors according to their individual physicochemical properties and the means 
of detection.
(i) Ethyl acetate extraction
Ethyl acetate extracts lipophilic substances from aqueous solutions. 
Generally, 0.5 ml of whole blood is mixed with 2 ml of ethyl acetate. After 1 - 4 
hours of occasional mixing, 1 ml of the clear supernatant containing extracted 
inhibitor is removed to 2mi eppendorf tubes with perforated lids. The ethyl 
acetate is then removed by vacuum centrifugation (speed vac). The final yield is 
in the range of 80 - 100% depending on the physiochemical properties of the 
inhibitor.
(11) Dichloromethane (DCM)
This reagent was used for the extraction of inhibitors with some degree of 
water solubility. The procedure is essentially similar to that described for ethyl 
acetate but differs in that the DCM phase is not the supernatant but lies below the 
aqueous phase. In order to remove a fraction of the organic phase the pipette 
must be applied through the plasma layer.
60
(iii) Soiid-phase extraction
Sep-pak Gi 8 reverse phase cartridges were used as an alternative to 
organic extraction procedures. Their effectiveness resides in their ability to bind 
to both lipophilic and partially water soluble inhibitors which makes the technique 
available for the extraction of a wide range of inhibitors. Conversely, since they 
bind with equal avidity to various blood constituents the final extract is not as pure 
as that derived from organic extraction procedures. Consequently, it is commonly 
used in combination with ultrafiltration using ultrafree cartridges. Sep-pak 
extraction proceeds in the following steps. Solutions are applied to the end of the 
cartridge using a plastic syringe.
Step 1 Prepare plasma from whole blood by centrifugation at 4,000 rpm
Step 2 Wash the sep-pak cartridge with 10 ml of methanol
Step 3 Wash the cartridge with 2ml of aqueous 70% acetonitrile / 0.1% TFA
(v/v)
Step 4 Wash the cartridge with 10 ml of 0.1 % TFA (v/v)
Step 5 Apply the plasma sample
Step 6 Wash through unbound material with 10 ml of 0.1% TFA
Step 7 Elute bound inhibitor with 2 ml of aqueous 70% acetonitrile/0.1% TFA 
(v/v)
Step 8 Lyophilise the bound fraction by vacuum centrifugation
Step 9 Reconstitute in methanol and then dilute into an appropriate buffer
Yield of inhibitor is characteristically greater than 90%.
(iv) Methanol precipitation
Extraction procedures are optimised to maximise the yield of the parent 
compound which is invariably lipophilic. In order to do this effectively they must 
discriminate against more hydrophilic substances. This limits their capacity to 
isolate drug metabolites which are often more hydrophilic than the parent. 
Plasma proteins may be precipitated by organic solvents such as acetonitrile and 
methanol. These methods leave small molecules that are soluble in organic 
solvent in solution they are relatively non-specific and so an additional 'clean up' 
step may be required. Methanol precipitation is performed as follows overleaf;
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Step 1 Incubate methanol on ice for 30 - 60 minutes
Step 2 Prepare plasma from whole blood by centrifugation at 4,000 rpm
Step 3 Mix 1 ml of ice-cold methanol with 0.25 ml of plasma sample
Step 4 Store sample on ice for 1 - 2 hours with occasional mixing
Step 5 Centrifuge sample in a microfuge for 10 minutes
Step 6 Remove 1 ml of the supernatant
Step 7 Lyophilise supernatant by vacuum centrifugation or analyse directly
Step 8 Reconstitute lyophilised sample in methanol and then dilute into an
appropriate buffer 
Yield of inhibitor is 100% by this method.
2.4:2 Measurement of inhibitor ieveis in biologicai fiuids
(1) Titration against geiatinase-A
This method is based on the observation that one molecule of inhibitor 
binds to one molecule of gelatinase-A. The high specific activity of gelatinase-A 
towards the QF24 substrate makes this assay very sensitive, since low 
concentrations of enzyme and hence inhibitor may be tested. There are, 
however, two major limitations to its use, namely; (1) The Ki of the test compound 
must be low enough such that dissociation of the enzyme-inhibitor complex is 
negligible. In practice this limits the technique to sub-nanomolar inhibitors and
(2) The assay cannot discriminate between parent compound and active 
metabolites.
Construction of the titration curve
The linearity between the reduction in enzymic rate and inhibitor 
concentration may be established from the titration curve which is constructed as 
follows.
Briefly, 50 jL il of active gelatinase-A (20 nM) is mixed with 50 \i\ of inhibitor 
at concentrations of 0, 2.5, 5, 7.5, 10 ,15, 20, 30 and 40 nM in peptide assay 
buffer (inhibitors diluted from methanol). After 2 hours at room temperature 25 pi 
of sample is added to 2.475 ml of peptide assay buffer and the reaction is started 
by adding 10 pi of QF24 (1.4 -1.6 pM). Hydrolysis of QF24 is monitored as 
described previously for the titration of TIMP (section 2.3.5).
By plotting initial rate (FU/min) on the x-axis versus inhibitor concentration 
(nM) on the Y-axis, the value (V) of an unknown inhibitor concentration may be 
determined directly using the enzfitter programme (linear regression).
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This method may be modified according to the extraction procedure. The 
blood concentration of inhibitors extracted into ethyl acetate, for example, is 
calculated from a titration curve of ethyl acetate extracted inhibitor.
Procedure for the determination of inhibitor levels in biood after in vivo  
experiments
Extracted inhibitor from the blood of 5 animals representing a single time- 
point is pooled and then titrated at three concentrations as described above. This 
establishes an approximate concentration for a more detailed study. Extracts 
from the blood of individual animals are then tested at appropriate dilutions. The 
inhibitor concentration can be established from the corresponding rate on the 
titration curve. The concentration of inhibitor in the original blood sample may 
then be calculated by multiplying this figure by the appropriate dilution factor.
(I!) Capillary electrophoresis (CE)
Capillary electrophoresis separates charged compounds in a small 
diameter capillary filled with buffer. The separated peaks may be detected by 
several methods including mass spectrometry but most commonly an integrated 
flow cell is used with UV detection. The technique combines high resolving 
power with a sensitivity that is superior to HPLC. The source of this sensitivity, 
however, is the ability of the technique to measure very small amounts (nl) of 
concentrated sample. This has limited its application In pharmacokinetic studies 
which often involves dilute sample solutions This problem was addressed by 
manipulating the procedure by which sample was loaded (Method 1). For more 
concentrated samples a standard procedure was employed (Method 2).
Method 1 (dilute sample)
Electrokinetic loading effectively concentrates sample ions on the capillary 
by removing them from the solution. It is limited, however, by a comparative lack 
of reproducibility which can be overcome by the inclusion of a range of spiked 
controls. This method is suitable for inhibitors such as CT543 (Fig. 5.1) which 
possess a positively charged group. Since the sample is loaded electrokinetically 
competing charged ions should first be removed. This may be achieved by 
extracting the compound with an organic solvent or sep-pak and then 
reconstituting the lyophilised extract in methanol. The methanolic solution is then
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passed through an ultrafree filtration unit as a final clean up step. The sample is 
analysed by CE using the following conditions.
CAPILLARY
SAMPLE SOLVENT
RUNNING BUFFER
INJECTION
RUN CONDITIONS
TEMPERATURE
DETECTION
Fused silica, 3 mm pathlength, 75 pm I.D., length to
flow cell 80 cm, total length 110 cm
Methanol
100 mM Sodium citrate pH 2.5 
Electrokinetic, 30 seconds, 5 kV 
20 minutes, 20 kV, (+ve)
30°C 
210 nm
Peak areas were integrated using a trivector computer. The response is linear 
between 5 and lOOng loaded on the column.
Method 2 (concentrated sample)
Samples are generally applied to the CE capillary using vacuum loading. 
This method is reproducible since the rate of flow of sample liquid onto the 
column can easily be controlled. The concentration of the sample, however, is 
not altered by this method. It is applicable to the measurement of a range of 
charged Inhibitors. The following conditions were applied to the measurement of 
the inhibitor, CT989 (Fig. 5.1).
CAPILLARY 
SAMPLE SOLVENT 
RUNNING BUFFER
INJECTION 
RUN CONDITIONS 
TEMPERATURE 
DETECTION
As above
50% Aqueous methanol
20 mM TRIS-HCI pH 9.0, 28.8 mM borate,0.68 mM 
EDTA, 30% methanol (v/v)
Vacuum, 30 seconds
20 minutes, 30 kV, (+ve), (current 4 mA)
30°C 
200 nm
Peak areas are integrated as described above. The response is linear between 
1 and 20 pg/ml.
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(iii) HPLC (concentrated sampie)
HPLC was used in this study for testing extraction efficiency, a process 
which may be performed using high concentrations of inhibitor. Samples, which 
typically contained greater than 100 pg of inhibitor, were analysed on a varian 
HPLC using a dynamax cig reverse-phase column with detection at 254 nm.
Aqueous samples (500 pi) can be applied directly to the column although 
plasma cannot be applied without an extraction step. Organic samples are 
lyophilised and then reconstituted in 50 pi of methanol and adjusted to 1 ml with 
0.1% aqueous TFA (v/v). Peaks are resolved using an 10 - 40% gradient of 
acetonitrile, at a flow rate of 1 ml/min, for 20 minutes.
2.4:3 Mouse pleural cavity assay
This assay derives from the rat pleural cavity assay described by Lark et al. 
(1990) in which stromelysin and pH]-transferrin were co-injected into the rat 
pleural cavity. The enzymic activity of stromelysin on this substrate was shown to 
be inhibited by the administration of TIMP-1. The assay described here is 
modified to study the inhibition of gelatinase-A by low molecular mass inhibitors. 
It is essentially a variation on the In vitro gelatin degrading assay reported in 
section 2.2:6
Preliminary experiments were undertaken to ensure that (1) the activity of the 
enzyme control was on the linear part of the concentration-rate curve and (2) that 
there was no significant loss of gelatin or its fragments from the pleural cavity 
during the time-course of the assay.
Method
200 pi of [i4c]-labelled gelatin (1 mg/ml) with a specific activity of 100,000 
cpm/mg is mixed with an equal volume of active gelatinase-A (20 nM) in peptide 
assay buffer. The mixture is cooled on ice before injection into the pleural cavity 
of an anaesthetised mouse. A needle of sufficient length as to prevent damage 
leading to internal bleeding was used for this purpose.
After 30 minutes, the mouse is sacrificed and the cavity is then aspirated 
and lavaged using 1 ml of PBS containing 50 mM EDTA. Intact gelatin is 
precipitated by adding TCA to a final concentration of 15% (v/v). Samples are 
then processed as described in section 2.2:6. Radioactivity in the supernatant is 
proportional to the level of enzymic activity and the presence of inhibitor 
depresses this value in a concentration dependent manner.
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By administering inhibitor at a pre-determined time before the injection of 
substrate and enzyme, the assay can be used to screen for inhibitors with 
superior pharmacokinetic properties. The study can be extended by dosing at a 
range of times prior to assay to produce an inhibition time-course. Variation of 
the route of administration permits the study of bioavailability. The assay cannot, 
however, be used to determine inhibitor concentrations since the dependency of 
inhibition on inhibitor concentration is affected by the tightness of inhibitor- 
enzyme binding. It is, therefore, most effective for the comparison of compounds 
with similar potencies.
2.4:4 Determination of pharmacokinetic parameters 
(i) Systemic haif-iife (ti/2)
Following the rapid intravenous administration of a compound there is an 
early distribution phase, during which the compound is distributed to the tissues 
followed by an interval during which it is eliminated from the body (elimination 
phase). The simplest model to describe this process assumes that the body acts 
as a single compartment throughout which the compound is distributed 
homogeneously.
Many compounds exhibit more complex behaviour which can only be 
described using more than one compartment. Throughout this study data was 
analysed using a 2-compartmental model. In this model, the body is represented 
by two compartments, a central one which comprises the blood and easily 
accessible tissues and a peripheral one into which compound distributes more 
slowly.
The decline in plasma concentration of the drug is biexponential. 
Accordingly, the concentration can be described by the sum of two 
monoexponential terms,
C = + BeP*
where A and B are the intercepts of the respective monoexponential curves on 
the y-axis, A + B = Co (concentration at time 0) and a and p are the hybrid rate 
constants equal to the slopes of the Ln concentration-time curve of the two 
monoexponential terms.
The determination of the p-phase half-life (ti/2 {P}) is particularly useful for 
the study of MMP inhibitors. Experimentally it is determined by measuring the 
plasma levels of inhibitor after intravenous dosing. A plot of Logio concentration
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(y-axis) versus time (x-axis) comprises a relative steep a-phase which is then 
followed by a more shallow p-phase. The slope of this second phase, also 
known as the terminal phase equals -p /2.303 and the corresponding t i /2 =
0.693 /  p . The t i/2 value was determined both manually and by using the Siphar
pharmacokinetic programme.
(II) Oral bioavailability
This is a measure of the relative amounts of drug appearing in the plasma 
after oral (p.o.) and intravenous administration (i.v.). The latter is presumed to be 
100% bioavailable. Oral bioavailability may be calculated from the ratio of the 
area under the plasma concentration-time curves (AUCs) for the two routes of 
administration. AUCs may be determined manually using the trapezoidal method 
as shown in the following hypothetical example.
n Time (mins) Concentration (A) (B) (A) X (B)
(pg/ml) Time ^ . (n-i) Cn + C(n-1)/2 (ugmin/ml)
1 0 0 - -
2 1 40 1 20 20
3 5 20 4 30 120
4 10 15 5 17.5 87.5
5 30 5 20 10 200
6 60 2 30 3.5 105
AUC = 532.5 M,gmin/ml
Plasma concentrations (Cn) are determined at various times (Tn) after 
administration of the compound. The AUC is most accurately extrapolated to 
infinity, however, this was not generally applicable to the analysis of oral data 
since the concentration-time curves were often very flat. Consequently, AUC 
values were generally determined to the last time-point as presented above. 
Values were also calculated by the Siphar pharmacokinetic programme.
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CHAPTER 3
CHARACTERISATION OF HUMAN RECOMBINANT GELATINASE-A
AND GELATINASE-B
3.1 : Introduction
This Chapter describes the biochemical properties of gelatinase-A and 
gelatinase-B. The study focuses on three important features of these enzymes;
1. Activation of the proenzyme
2. The contribution of the C-terminal domain to enzyme action
3. The specific activity of the activated enzyme
For an MMP to become catalytically competent it must first undergo a 
process of activation. As described earlier, (Chapter 1.3:3) the end-point of the 
activation process is the removal of about 80 amino-acids from the N-terminus 
of the proenzyme with a concomitant reduction in molecular mass of 10 kDa as 
visualised by SDS-PAGE under reducing conditions (reviewed in Birkedal- 
Hansen, 1993). The events leading to the eventual activation of an MMP may 
provide an additional level at which to target therapeutic agents but the 
mechanism is still poorly understood.
Progelatinase-A is comparatively resistant to hydrolysis by serine 
proteinases such as trypsin and neutrophil elastase (Okada et al., 1990; 
1989b). The primary sequence of the propeptide shows that it lacks the basic 
amino-acid rich 'bait region' of other MMPs that makes them a substrate for 
trypsin-like proteinases (Chapter 1 (1.3:3). Artificial activation can, however, be 
affected by a variety of agents of which APMA is most commonly used. This 
agent causes the gelatinase to remove its own propeptide in a process which is 
thought to be initiated by an intramolecular cleavage (Okada et al., 1990). At 
what stage intermolecular cleavages may also contribute to this process is still 
unclear. As yet no physiological counterpart to APMA has been identified and 
although activation by a proteinase is strongly suspected there has been little 
progress in discovering a suitable candidate.
Evidence for a cellular involvement has been presented by several 
laboratories (Brown et ai, 1990; Overall and Sodek, 1990; Ward et ai, 1991; 
Emonard et a i, 1992; Monsky et ai, 1993). Progelatinase-A can, for example, 
be activated in the presence of appropriately stimulated intact cells or cell
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membranes (Ward et al., 1991). Moreover, this reaction can be inhibited 
effectively by TIMP-2 and more poorly by TIMP-1. More recently, Strongin et al. 
(1993) identified an intermediate produced by the action of a stimulated human 
fibrosarcoma cell-line (HT1080) on progelatinase-A. By showing that activation 
could be competitively inhibited by a 26 kDa peptide derived from the C- 
termlnus they were also able to demonstrate a possible involvement of the C- 
terminal domain.
The following studies are specifically aimed towards (1) characterising the 
sequence of events leading to APMA activation and (2) identifying a proteinase 
which fulfils the requirements for being considered as a physiological activator 
of progelatinase-A.
The role of the C-terminal domain in activation was studied by using a 0- 
terminally truncated gelatinase (NGL-A). Finally, the specific activity defined by 
the kcat/^m was determined against several substrates In order to determine 
suitable enzyme concentrations for kinetic studies (Chapters 5 and 6).
The activation of progelatinase-B has been studied by a number of 
groups but the data emerging has been somewhat conflicting. Desrivieres et 
al. (1993) reported that tissue kallikrein, a component of the Inflammatory 
response, efficiently activated progelatinase-B making it a candidate for the 
role of In vivo activator. In contrast a closely related enzyme, plasma kallikrein, 
was unable to carry out the activation. Progelatinase-B can, like neutrophil 
procollagenase (Knauper et al., 1993), be activated directly by stromelysin 
(Ogata et al., 1992). Ogata and his co-workers showed that stromelysin 
hydrolyses the bond between - p®® resulting in a drop in molecular mass 
from 92 kDa to 82 kDa. In contrast Okada et al. (1992) observed active species 
of 68 kDa with APMA and 64 kDa with stromelysin treatment. Other groups 
have found that the C-terminal domain is also lost during this process and 
indeed Goldberg et al. (1992) presented evidence that removal of this domain 
Is a prerequisite for the efficient activation of progelatinase-B by stromelysin. In 
other studies, Triebel et al. (1992) reported that APMA produces an enzyme 
which is fully active despite retaining the cysteine involved in maintaining 
latency. All these studies use a gelatin substrate to follow activation but this 
makes a kinetic treatment of the data difficult (Chapter 6).
In this work, activation processes were investigated using SDS-PAGE 
and N-terminal sequencing to identify the products of activation. The kcai/^m
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values of the active forms were then measured against QF24 (Knight et al., 
1992). Additionally, the rates at which recombinant human progelatinase-B 
was activated by several agents were compared and the influence of the C- 
terminal domain on this process was assessed.
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3.2 : Results
3.2:1 Progelatinase-A activation
(i) Time-course of APMA activation
Progelatinase-A can be conveniently activated in the presence of the 
universal MMP activator, APMA. The time-dependent generation of mature 
enzyme was followed using a peptide substrate and the identity of the fully 
activated species was determined by N-terminal sequencing.
Progelatinase-A (IpM) was incubated at 23°C with APMA (1mM). At 
times ranging from 0 - 2 4  hours (hrs). samples were removed for assay against 
QF24 (Fig. 3.1). The rate of enzyme activity was determined by linear 
regression analysis. Progelatinase-A is maximally activated after 8 hrs under 
these conditions. Previous work has indicated that the rate of activation is buffer 
dependent as changes in the level of Brij 35 or ionic strength can have 
significant effects on the time taken to reach maximum activity (data not shown). 
Rates of APMA activation can, therefore, only be compared using identical 
conditions.
In a further experiment, progelatinase-A was incubated for 16 hrs in the 
presence of APMA. The sample was then analysed using SDS-PAGE. APMA 
caused a reduction in molecular mass from 72 kDa to 66 kDa (Fig. 3.2). N- 
terminal sequencing of the 66 kDa activated form identified a single N-terminus 
corresponding to Y®1 •
This activation procedure was subsequently used to generate a single form of 
the enzyme for all kinetic studies of the enzyme and its Inhibitors.
(ii) Effect of TIMP-1 and a synthetic Inhibitor CT989 on the activation of 
progelatinase-A by APMA
APMA induces an autocatalytic activation of progelatinase-A by a 
process which may be either bimolecular or unimolecular. In the following 
study two inhibitors TIMP-1 and a low molecular mass inhibitor,CT989, were 
used to study this mechanism. Both molecules are effective at comparable 
concentrations to those of the enzyme and this tight-binding is reflected in their 
low inhibition constants of <10“1‘* M. The potency of these inhibitors means 
that they can completely block the ability of residual active enzyme (which 
represents 0.1% of the total enzyme in progelatinase preparations) to initiate
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Figure 3.1 Time-course of progeiatinase-A activation by APMA
60
5 0 -
4 0 -
I
g 20-  
§
^  1 0 -
2010 15 255
Time (hours)
Progelatinase-A (1 p,IVI) was Incubated at 23°C in gelatinase activation buffer and 5% 
DMSO in the presence of APMA (1 mM). At various times, ranging from 0 - 24 hrs, 
60 \i\ was removed and diluted appropriately for assay against QF24 as described in 
Chapter 2.
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Figure 3.2 Activation of progelatinase-A by APMA
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(A) Progelatinase-A (2^iM) was incubated with APMA (1mM) in peptide 
assay buffer containing 5% dimethyl sulphoxide (DMSO) for 16 hrs at 23°C. 
The resulting enzyme was analysed by SDS-PAGE (10 - 20%) under reducing 
conditions.
Lane Sample
1 Molecular mass markers
2 Progelatinase-A
3 Progelatinase-A after APMA treatment
(B) The band arising from treatment with APMA (lane 3) was electroblotted
onto a polyvinylidine fluoride membrane and N-terminal sequencing (Chapter 2) 
revealed the amino-terminus ^lyNFF.
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the activation process. The low molecular mass inhibitor, CT989 (600 Da), may 
unlike TIMP, diffuse into the active-site of enzyme which has become 
catalytically competent through the action of APMA but has retained its 
propeptide. A time-course was conducted in order to test the effects of these 
inhibitors on the activation of progelatinase-A by APMA.
Progelatinase-A (IpM) was incubated for 10 minutes with or without 
TIMP-1 (4 )liM) or CT989 (4 |iM) prior to the addition of APMA (ImM) and 5 % 
DMSO. At various times ranging from 0 - 24 hrs samples were analysed by gel 
electrophoresis (Fig. 3.3). In the absence of inhibitor, activation correlates with 
the disappearance of the 72 kDa proenzyme species and the concomitant 
increase in the level of a 66 kDa species (Fig.3.3 {A}). The reaction proceeds 
via a major intermediate of about 67 kDa which disappears after 4 hrs 
incubation. Complete conversion takes place after 8 hrs and this correlates 
with maximal activity against QF24 (see above {i}). Addition of TIMP-1 
significantly reduces the rate of formation of both the 67 kDa intermediate and 
the 66 kDa fully active form (Fig. 3.3 {B}). Also the conversion of the 67 kDa 
species to the 66 kDa form appears to be much reduced or blocked totally 
since its levels increase at a similar rate to the active form. Similarly, CT989 
significantly reduces the rate at which the 72 kDa band is removed (Fig.3.3 {0}) 
but it is slightly less effective in inhibiting the production of the 66 kDa form. 
About 50 % of the proenzyme is converted to the lower molecular mass form 
after 24 hrs incubation in the presence of either inhibitor. The data indicate a 
process which does not involve pre-activated enzyme as this would be bound 
up by inhibitor. APMA may, by breaking the active-site zinc - cysteine bond, 
induce the enzyme to hydrolyse a bond in the vicinity of its own active site in a 
unimolecular process.
(iii) Activation of gelatinase-A by APMA : Effect of heparin
The concentration dependence of a bimolecular reaction can be used to 
differentiate it from a unimolecular process. Progelatinase-A can be effectively 
concentrated by the addition of heparin (Crabbe et a!., 1993). This avoids the 
requirement for extensive dilution which can affect the accuracy of such a 
study.
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Figure 3.3 Inhibition of APMA-induced progelatinase-A activation
Progelatinase-A (1|liM) was incubated at 23°C in gelatinase activation 
buffer with or without TIMP-1 (4 pM) or CT989 (4 |iM). After 10 minutes a 
solution of APMA in DMSO was added to give a final APMA concentration of 
1 mM together with 5% DMSO. At various times ranging from 0 - 2 4  hours, 
60 |llI was removed for SDS-PAGE (A - 0). Samples were analysed under 
reducing conditions on 10 - 20% gradient gels. (A) represents uninhibited 
enzyme, (B) TIMP-1 and (0) CT989. Incubation times are shown above each 
gel and the molecular masses (M) of standard proteins are indicated. The 
corresponding gelatinase activity of uninhibited samples (A) is plotted in Figure 
3.2.
Figure 3.3 Inhibition of APMA induced progelatinase-A activation
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Progelatinase-A (1 pM) was incubated with APMA (1mM) as described 
above in the presence or absence of heparin (50 jig/ml). At times ranging from 
0 - Ghrs samples were removed for SDS-PAGE and for assay of gelatinase 
activity against the QF24 substrate. The maximal activity after 6 hrs 
represented about 80% of that achieved by incubating progelatinase-A with 
APMA (1mM) for 16hrs at 23°C in peptide assay buffer (Fig. 3.4). The rate of 
appearance of activity was slightly faster in the presence of heparin but by 6hrs 
there was negligible difference in the activities of the two samples. SDS-PAGE 
analysis of the products of the activation time-course showed the characteristic 
pattern of APMA activation (Fig. 3.4 {A,B}). The 66 kDa band appeared more 
rapidly in the presence of heparin (Fig. 3.4 {B}). Comparison of the 1hr samples 
emphasises this point. At 6 hrs the 72 kDa band was still evident in both 
samples and this correlates with the activity observed by assay. Heparin 
appears to have little effect on the early steps of gelatinase autoactivation 
which lead to the formation of intermediates but appears to increase the 
subsequent rate of formation of the fully active 66 kDa species. This would 
suggest that the initial reaction is not concentration dependent but further 
cleavages are a result of intermolecular processing .
(iv) Activation of gelatinase-A with human collagenase and matrilysin
Progelatinase-A does not appear to be activated by proteinases (Okada 
et al., 1989;1990). In the following studies matrilysin and collagenase were 
used to test the hypothesis that progelatinase-A possesses a bait region that is 
a recognition sequence for MMPs.
Progelatinase-A (3 |iM) was incubated in peptide assay buffer at 37°C in 
the presence of either active collagenase (1 |iM) or matrilysin (1 |iM). An 
additional sample of progelatinase-A without activator was also included to test 
the stability of the proenzyme. At various times, ranging from 0 - 24hrs, 
samples were removed for SDS-PAGE and for assay of gelatinase activity.
Both collagenase and matrilysin maximally activated progelatinase-A 
after 8hrs at 37°C (Fig. 3.5). The level of activity dropped significantly over the 
subsequent 16 hrs. In both cases activation correlated with the appearance of 
the 66 kDa band and was accompanied by a concomitant decrease in the 72 
kDa proenzyme form (Fig. 3.5 (A,B)). After 16 hrs the 66 kDa species was
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Figure 3.4 Effect of heparin on the activation of progelatinase-A 
by APMA
Progelatinase-A (1fiM) was incubated with APMA (1mM) at 23°C in 
gelatinase activation buffer containing 5% DMSO in the presence or absence 
of heparin (50 |ig/ml). At times ranging from 0 - 6 hours, 50 |il aliquots were 
removed for assay of gelatinase activity against QF24 and for analysis by 
SDS-PAGE (10 - 20%) under reducing conditions.
Lane Sample
1 Molecular mass markers
2 5 mins
3 15 mins
4 30 mins
5 1 hour
6 2 hours
7 3 hours
8 4 hours
9 6 hours
Figure 3.4 Effect of heparin on the activation 
of progelatinase-A by APMA
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Figure 3.5 Activation of progelatinase-A by collagenase and matrilysin
Progelatinase-A (3 jiM) was incubated in peptide assay buffer at 37°C 
in the presence of either trypsin activated collagenase (IpM) or matrilysin 
(1pM). At various times ranging from 0 - 24 hours, 60 pi aliquots were 
removed for assay of gelatinase activity against QF24 (A) and for analysis by 
SDS-PAGE (B, C). The activity assay was performed essentially as described 
in Chapter 2 using an enzyme concentration equivalent to 0.3nM of the 
unactivated proenzyme and a substrate concentration of 1.4 pM.
SDS-PAGE analysis of the corresponding samples was carried out using 10 - 
20% gradient polyacrylamide gels and (B) represents progelatinase 
incubated in the presence of collagenase and (0) in the presence of 
matrilysin. Samples were run under reducing conditions. The molecular 
masses (M) of standard proteins are indicated. Incubation times (hrs) are 
shown above each gel. APMA-activated gelatinase-A (GL) is shown for 
comparison.
Figure 3.5 Activation of progelatinase-A by collagenase
and matrilysin
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significantly lower in intensity than at the 8 hr time-point. This was 
accompanied by the appearance of low molecular mass species, notably a 
band of 32 kDa. The band corresponding to matrilysin was unaffected by the 
reaction. The apparent molecular mass of collagenase was reduced from 43 
kDa to 42 kDa, an observation which will be discussed in Chapter 4. 
Progelatinase-A incubated without activator showed negligible activity after 24 
hrs implying that the proenzyme is stable in peptide assay buffer for prolonged 
periods at 37°C.
Both collagenase and matrilysin activate progelatinase-A at 37°C to an 
active species which is similar in size to that generated by ARMA. Unlike the 
proenzyme, once activated, gelatinase-A is unstable at this temperature 
leading to reduced activity after 16 hrs.
(v) Effect of heparin and type 1 collagen on the activation of progelatinase- 
A by collagenase and matrilysin
Heparin can significantly increase the rate of progelatinase-A 
autoactivation under low salt conditions and in the absence of Brij 35 (Crabbe 
et al., 1993). This presumably occurs by a process in which latent and residual 
active enzyme are concentrated on the charged surface of the proteoglycan. 
Collagenase can also bind to heparin and so may substitute for the active 
gelatinase-A. These enzymes also bind to type 1 collagen and indeed, Azzam 
and Thompson (1992) recently described the ability of this agent to induce 
gelatinase-A activity in human cells. Concentration of the two enzymes on the 
surface of either of these molecules may result in an increased activation rate. 
The following experiments, designed to explore this possibility were carried out 
in gelatinase activation buffer (low ionic strength, low Brij 35) in preference to 
peptide assay buffer since both ionic strength and Brij 35 significantly interfere 
with heparin interactions.
Progelatinase-A (4jiM) was incubated at 37°C with active collagenase 
(IpM) with or without type 1 collagen (rat skin) (50 jig/ml) or heparin (50 pg/ml). 
A similar study was carried out in the absence of collagenase. At times, Ohr 
and 4hr, samples were analysed as described in Figure 3.6.
Collagen had no effect on the activation of progelatinase-A by 
collagenase (Fig. 3.6 {A}). Heparin alone and in combination with collagen 
increased gelatinase-A activity in the presence of collagenase. There was no
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Figure 3.6 Activation of progelatinase-A: Effect of activating agents
Progelatinase-A (4 |iM) was incubated at 37°C with or without rat skin type 1 
collagen (50 |ig/ml) or heparin (50 |Lig/ml). An identical study was also conducted in the 
presence of active collagenase (CL) (1|j,M). At 0 hours and 4 hours, 100|il aliquots 
were removed for analysis of gelatinase activity against QF24 (A) and for SDS-PAGE 
(B). Activities are expressed as a percentage of the total activity of a sample activated 
by APMA for 16 hours at 23°C. The results represent the mean value of two readings. 
SDS-PAGE was carried out on 10 - 20% gradient polyacrylamide gels under reducing 
conditions. The molecular masses (M) of standard proteins (lane 1) are indicated.
(A)
Sample no.
(B)
Lane Sample
1 Progelatinase-A 1 Mol. mass markers
2 + heparin 2 Progelatinase-A (0 hrs)
3 + collagen 3 Progelatinase-A (4 hrs)
4 + heparin/collagen 4 + CL (0 hrs)
5 + CL 5 + CL (4 hrs)
6 + heparin + CL 6 + CL + heparin (0 hrs)
7 + collagen + CL 7 + CL + heparin (4 hrs)
8 + heparin/collagen + CL 8 + CL + collagen (0 hrs)
9 + CL + collagen (4 hrs)
10 + CL + heparin/collagen (0 hrs)
11 + CL + heparin/collagen (4 hrs)
12 Active gelatinase control
Figure 3.6 Activation of progelatinase-A:
Effect of activating agents
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Figure 3.7 Effect of heparin on the activation of progeiatinase-A
by matriiysin
M 1 2 3 4 5  6 7 8 9  10 11
(kDa)
94--------
43—  "
Gelatinase-A
30—  -  
2 1 —  • < ----- Matrilysin
Progelatinase-A (1pM) was incubated with matrilysin (IpM ) at 37“C in 
activation buffer in the presence or absence of heparin (50pg/ml). At times 0, 
1 and 2 hours a 20pl aliquot was removed and analysed by SDS-PAGE (10- 
20%) under reducing conditions. The molecular masses (M) of standard 
proteins (lane 1) are indicated.
Lane Sample
1 Molecular mass markers
2 0 hours
3 1 hour No activator
4 2 hours
5 0 hours
6 1 hour Matrilysin
7 2 hours —
8 0 hours
9 1 hour Matrilysin/Heparin
10 2 hours —
11 APMA activated gelatinase-A control
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synergistic effect of the two reagents. No activity was observed in the absence 
of collagenase. SDS-PAGE of the products (Fig. 3.6 {B}) showed that the 
presence of collagen (lane 4,5) had little effect on the ratio of the 72 kDa 
proenzyme and the 6 6  kDa species. Heparin caused a reduction in the 72 kDa 
band and the production of several low molecular mass species in addition to 
the 6 6  kDa band, alone (lane 7) or in combination with collagen (lane 11).
These results indicate that heparin but not collagen stimulates the 
formation of active progelatinase-A by collagenase. The appearance of 
significant levels of low molecular mass species after 4 hrs implies that the 
reaction has proceeded beyond the point of maximal activity. Under these 
conditions heparin does not induce the activation of progelatinase-A in the 
absence of active enzyme.
In further experiments, heparin was tested for its effect on the activation 
of progelatinase-A by matrilysin. SDS-PAGE of the reaction products (Fig. 3.7) 
revealed that heparin does stimulate the formation of active gelatinase-A by 
matrilysin (lanes 8  -10). The level of progelatinase-A remaining after 2 hrs 
incubation with matrilysin and heparin, indicates that heparin is a less effective 
stimulator of matrilysin than it is of collagenase.
(vi) Time-course of heparin / collagenase activation of progelatinase-A and 
a truncated form, proNGL-A
In section 3.2:1 (v) heparin was shown to increase the rate at which 
progelatinase-A is activated by collagenase. This was a qualitative study that 
was carried out under sub-optimal conditions. The following study examines 
the rate of progelatinase-A activation by an equimolar level of collagenase with 
and without heparin. Additionally, the importance of the gelatinase C-terminal 
domain to heparin activation was studied by conducting a parallel experiment 
using a truncated gelatinase which lacked this domain, progelatinase i - 4 1 7  
(proNGL-A)).
Progelatinase-A (1 pM) or proNGL-A (1|iM) were incubated with active 
collagenase with or without heparin (50 pg/ml). At various times ranging from 0 
- 6 hrs, samples were removed for SDS-PAGE and assay of gelatinase activity. 
In the absence of heparin the activity of progelatinase-A (expressed as a 
percentage of that achieved by APMA) increased with time to reach maximal 
activity at 6  hrs (Fig. 3.8 {A}). Addition of heparin significantly increased the
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Figure 3.8 Activation of progeiatinase-A and proNGL-A by collagenase and 
heparin
Progelatinase-A or proNGL-A (1 |liM) were incubated in gelatinase activation 
buffer at 37°C with active collagenase (1pM) in the presence or absence of heparin 
(50 pg/ml). At times 0 , 1 , 2 ,  3 and 6 hrs, 50^1 aliquots were removed for assay of 
gelatinase activity (A) using QF24 and for SDS-PAGE (B,C). Activities are 
expressed as a percentage of the total activity of a sample activated by APMA for 16 
hours at 23°C. The results represent the mean of two readings. SDS-PAGE was 
carried out on 10 - 20% polyacrylamide gradient gels under reducing conditions. 
Incubation times (hrs) and the presence or absence of heparin are indicated above 
each gel. Controls include GL (gel B) which is APMA-activated gelatinase-A and 
Pro (gel 0) which is unactivated proNGL-A. The molecular masses (M) of protein 
standards are indicated.
Figure 3.8 Activation of progelatinase-A and proNGL-A
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rate of progelatinase-A activation and resulted in maximal activity after 1 hr. 
Activity did not increase further over the subsequent 5 hrs. ProNGL-A was 
activated by collagenase at a rate slightly faster than the parent form but its rate 
of activation was not affected by heparin. SDS-PAGE analysis of the products 
of progelatinase-A activation (Fig. 3.8 {B}) showed that activity correlated with 
the appearance of a species of 66 kDa. In the presence of heparin this 
appeared rapidly before decreasing with the subsequent generation of low 
molecular mass species (lanes 7-11).
SDS-PAGE of the products arising from proNGL-A activation indicated 
that the generation of activity was associated with a reduction in molecular 
mass from 45 kDa to 37 kDa (Fig. 3.8 {0}). Addition of heparin (lanes 7-11) had 
no observable effect on the generation of the 37 kDa species. In summary, 
heparin significantly increases the rate of progelatinase-A activation by 
collagenase in a process which involves the C-terminal domain.
(vii) Effect of heparin concentration on the activation of progelatinase-A and 
proNGL-A
The studies of Crabbe et al. (1993) showed that the rate of autoactivation 
of progelatinase-A was dependent on the heparin concentration and that 
excessive heparin can be detrimental to the reaction. This implies that heparin 
works by localising the enzymes on its surface, a process which would be 
reversed if it were in excess. The following study was conducted to test the 
effect of varying the heparin concentration on collagenase activation of 
progelatinase-A and whether or not the response of proNGL-A to heparin is 
concentration dependent.
The two proenzymes were incubated with collagenase as described in 
section 3.2:1 (v), together with heparin at concentrations ranging from 0 - 
1 mg/ml. After 40 minutes at 37°C, 50 pi aliquots were removed for SDS-PAGE 
and gelatinase assay. The rate at which progelatinase-A was activated by 
collagenase increased rapidly with increasing heparin concentration (Fig. 3.9 
{A}). Maximal activity was observed at a concentration of 200 pg/ml and this 
activity remained relatively constant up to a heparin concentration of 1 mg/ml. 
Heparin had no effect on the activation of proNGL-A by collagenase. 
Furthermore, neither progelatinase-A nor proNGL-A responded to heparin in 
the absence of collagenase.
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Figure 3.9 Effect of heparin concentration on collagenase activation of 
progelatinase-A and proNGL-A
Progelatinase-A (proGL-A) or proNGL-A (1pM) were incubated in
gelatinase activation buffer at 37°C with or without active collagenase (GL)
(1pM) in the presence of heparin at concentrations ranging from 0 - 1 mg/ml.
After 40 minutes, 50pl aliquots were removed for assay of gelatinase activity
(A) using QF24 and representative samples were analysed using SDS-PAGE
(B). Activities are expressed as a percentage of the total activity of a sample 
activated by APMA for 16 hours at 23°C. The results represent the mean of 
two readings. SDS-PAGE was carried out on a 4 - 20% polyacrylamide 
gradient gel under reducing conditions.
(B)
Lane Sample
1 Molecular mass markers
2 ProGL-A + CL
3 ProGL-A + CL + heparin (10 pg/ml)
4 ProGL-A + CL + heparin (100 pg/ml)
5 ProGL-A + CL + heparin (1 mg/ml)
6 ProGL-A control
7 ProNGL-A + CL
8 ProNGL-A + CL + heparin (10 iig/ml)
9 ProNGL-A + CL + heparin (100 |Lig/ml)
10 ProNGL-A + CL + heparin (1 mg/ml)
11 ProNGL-A control
Figure 3.9 Effect of heparin concentration on 
collagenase activation of progelatinase-A and proNGL-A
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Figure 3.10 Effect of inhibitors on the activation of progeiatinase-A
by coliagenase
1 2 3 4 5  6 7 8  9
M
(kDa)
94—
Progelatinase-A
6 7 — 5  Gelatinase-A
4 3 “ * '  —  — ----------  < -----  Collagenase
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Progelatinase-A (IpM) samples were incubated with collagenase (CL) (IpM) 
and inhibitor (4pM) as described in the text (section 3.2 (viii)). Aliquots were 
analysed by SDS-PAGE (4-20%) under reducing conditions.
Lane Sample
1 Molecular mass markers
2 Progelatinase-A (0 hours)
3 Progelatinase-A (24 hours)
4 Progelatinase-A + CL (24 hours)
5 Progelatinase-A + CL + TIMP-1 (24 hours)
6 Progelatinase-A + CL + TIMP-1 (48 hours)
7 Progelatinase-A + CL + CT989 (24 hours)
8 Progelatinase-A + CL + CT989 (48 hours)
9 Progelatinase-A (0 hours)
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SDS-PAGE was carried out on representative samples (Fig. 3.9 {B}). 
Generation of the 66 kDa band correlates with the activity of the full-length 
enzyme. It is evident, however, that there is less conversion of the 72 kDa 
proenzyme at a heparin concentration of 1 mg/ml (lane 5) than at 0.1 mg/ml 
(lane 4) and that this does not correlate with the corresponding levels of activity 
in the assay. This apparent discrepancy can be rationalised by observation of 
the relative levels of low molecular mass breakdown products (27 kDa) in the 
two samples. These bands are increased in the 0.1 mg/ml sample although the 
active 66 kDa band remains constant. Excess heparin can, therefore, inhibit 
the conversion of pro- to active gelatinase-A by collagenase. Gel 
electrophoresis of the proNGL-A activation by collagenase (lanes 7-11) 
confirmed the assay results showing that heparin had no effect at 
concentrations up to 1 mg/ml.
(viii) Effect of inhibitors on collagenase activation of gelatinase-A
TIMP-1 inhibits collagenase and gelatinase-A with a Kiapp of <10-10 M 
and IQ-12 m respectively. The synthetic hydroxamate inhibitor, CT989, 
(Chapter 5) is more specific for gelatinase than collagenase (Kiapp is <10-n M 
and 3.29 x 10'^ M, respectively). By using inhibitors of differing specificity the 
relative contributions of gelatinase and collagenase to the activation process 
can be estimated.
Progelatinase-A (1 pM) was incubated in gelatinase activation buffer 
with collagenase (IpM ) at 37°C. Additional samples were incubated as 
described above but in the presence of TIMP-1 (4 pM) or CT989 at two 
concentrations (O.IpM and IpM). After 24hrs and 48hrs, lOOpI aliquots were 
removed. Samples were analysed by SDS-PAGE under reducing conditions 
(Fig. 3.10). TIMP-1 completely blocked the activation of progelatinase-A by 
collagenase at 24hrs and 48hrs (lanes 5 and 6 respectively). At a 
concentration of 0.1 pM, CT989 had little effect on the processing of the 72 kDa 
form (data not shown) but at IpM it did reduce the rate of conversion seen after 
24 hrs (lane 7). At this point an intermediate can be observed in addition to the 
66 kDa active species. Complete hydrolysis of the 72 kDa band was, however, 
evident after 48 hrs incubation at 37°G (lane 8). CT989 at concentrations up to 
IpM  does not significantly inhibit the hydrolysis of 72 kDa gelatinase by 
collagenase but it does block the subsequent step which generates the 66 kDa
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enzyme form. The results indicate that collagenase is responsible for the initial 
cleavage of progelatinase-A resulting in the generation of an intermediate form. 
This step is not inhibited by the relatively poor collagenase inhibitor CT989 but 
is inhibited by TIMP-1. The conversion of the intermediate to the 66 kDa active 
form is a product of self-cleavage. These results are consistent with the 
findings of Dr. T. Crabbe (personal communication) who showed that 
incubation of collagenase with catalytically inactive progelatinase-A (E^^s^ a ) 
results in the production of an intermediate which is not processed further.
(ix) Sequence of the activation intermediate produced by collagenase
Activation of progelatinase-A by TPA stimulated HT1080 cells proceeds 
via an intermediate with the N-terminal residue (Strongin et a!., 1993). The 
studies above (section viii) suggest that the synthetic inhibitor CT989, may be 
used to isolate an intermediate produced by the action of collagenase on 
progelatinase-A. The N-terminal sequence of this intermediate may then be 
established by analysis of the electroblotted band.
Progelatinase-A (3 pM) was incubated with collagenase (IpM ) and 
heparin (50 pg/ml) in gelatinase activation buffer for 6hrs at 37°C in the 
presence or absence of CT989 (3 pM). Samples were run on an SDS- 
polyacrylamide gel and then bands representing the intermediate (68 kDa) and 
the fully processed gelatinase-A (66 kDa) were then N-terminally sequenced 
following electroblotting as described in Chapter 2. Sequence analysis (Fig. 
3.11) indicates that in the absence of CT989 incubation of progelatinase-A with 
collagenase produces an N-terminus Y^i which is identical to that generated 
by APMA. Activation of progelatinase-A by collagenase, in the presence of 
CT989 to inhibit gelatinase activity, resulted in the generation of an 
intermediate formed by the cleavage of the bond This latter
observation is consistent with the possibility that collagenase initiates the 
membrane mediated activation of progelatinase-A by TPA stimulated HT1080 
cells.
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3.2:2 Kinetic analysis of gelatinase-A activity
N-terminal sequencing and gel electrophoresis show that a single form 
of gelatinase-A (Y^i) can be generated by the action of APMA. This permits the 
analysis of kinetic properties such as /Cca^ /Km to be carried out accurately and 
reproducibly. The specific activity of wild-type gelatinase-A was tested on a 
macromolecular substrate, gelatin and on two fluorescent peptide-like 
substrates, DnpPLGLWAR and QF24 to determine the best substrate for 
inhibitor studies.
(i) Determination of a composite Km and c^at^ Km on gelatin
Labelled [i^C]-gelatin was prepared as described in Chapter 2. This 
was diluted with a range of concentrations of unlabelled gelatin and the 
specific activity of the label in each was calculated.
APMA activated gelatinase A (1nM) was incubated at 25°C in gelatin 
assay buffer with radiolabelled substrate at concentrations ranging from 0.18 
pM - 2.5 pM. At times, 0 and 30 mins, 300 pi of reaction mixture was removed 
and processed using TCA precipitation as described previously (section 2.2:6). 
The hydrolysis rate at each substrate concentration was determined by 
converting radioactivity (cpm) in the TCA supernatant to pg of gelatin 
hydrolysed in unit time (min). The Enzfitter programme (Leatherbarrow) was 
used to calculate the Km from a plot of rate (pg/ml) (y - axis) versus substrate 
concentration (pM) (x - axis). Values for /Cca?and kcai/^m were determined from 
the relationship, kcat= ^max/[E] where Vmax is the maximum rate of substrate 
hydrolysis attainable by a fixed concentration of enzyme [E] (Table 3.1).
Gelatinase-A cleaves gelatin at multiple sites. Values for kcat and Km 
are, therefore, not true constants but are a composite of a number of individual 
microscopic constants. Nonetheless, the experimentally determined kcat^m  
does indicate that gelatinase-A has a high specific activity against gelatin and 
this is useful information for the design of gelatin based screening assays. 
Because gelatin is, in effect, a mixture of substrates it is unsuitable for detailed 
kinetic analysis.
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Table 3.1
Specific activity of gelatinase-A
SUBSTRATE kcat (s-1 ) Km (|xM) kcat/Km
(M -is -1 )
GELATIN 0.55a 1.24a 4.47 X 105a
Dnp-PLGLWAR 6.37 70 9.1 X 104
QF24 NDb NDb 6.11 X 105
a These are not true kinetic constants (see text, section 3.2:2 (i)) 
b Insolubility of substrate prevents direct determination of kcat and Km
Progelatinase-A was activated with APMA (1 mM) for 7 hours at 23°C. 
Dnp-PLGLWAR peptide and gelatin assays were conducted at 26°C and QF24 
assays at 23°C. Values represent the mean of at least 3 readings.
Experimental procedures for determining the above kinetic constants are described 
in the text (3.2:2 (i - iii}).
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(ii) Determination of the kca^Km on DnpPLGLWAR
APMA activated gelatinase-A (0.1 nM) was incubated in peptide assay 
buffer at 26°C in the presence of a variety of substrate concentrations, ranging 
from 8 - 1 0 0  pM. After 3 - 5 hrs assays were terminated and the rates of 
hydrolysis were measured as described in section 2.2:2. Endpoints were 
varied according to the substrate concentration such that the reaction was 
linear with time and < 5% of the substrate was hydrolysed. The Enzfitter 
programme was then used to generate /ccat and kcat^m (Table 3.1).
(iii) Determination of the kcai/^m on QF24
A Km value for QF24 was not determined due to the lack of substrate 
solubility, in addition to the effect of fluorescence quenching at high substrate 
concentrations. The evidence of limited studies would suggest that the value is 
>30pM. The kcat^Km was, therefore, determined directly by using a substrate 
concentration of 1.4 pM which satisfies the condition S «  Km (see below)-
Assays were performed at 23°C in peptide assay buffer at an enzyme 
concentration of 0.05 - 0.1 nM. The rate of substrate hydrolysis was measured 
continuously for 1 - 2 mins over which time there was no indication of substrate 
depletion or quenching by product. The kcat^K^ (Table 3.1) was determined 
using the relationship,
c^at _
K ^ ^ s - s . [ E f  
where the Km + S term approaches Km at values of S «  Km-
Gelatinase-A has a high specific activity against gelatin and the two 
peptides, DnpPLGLWAR and QF24. The /Cca/Km values against the peptides 
compare favourably with those of collagenase, matrilysin and stromelysin 
(Chapter 5 and data not shown). Its high specific activity against these 
substrates permits the analysis of very low concentrations of enzyme. In fact, 
20 pM enzyme hydrolyses QF24 at a rate which can be measured with 
sufficient accuracy to calculate inhibitor Ki's as low as 10 pM. The significance 
of this finding will be discussed in later chapters.
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3.2:3 Progelatinase-B activation
The activation of progelatinase-B has been studied by a number of 
groups, but the data emerging are not consistent. Progelatinase-B may be 
activated by trypsin and APMA and can also be directly activated by 
stromelysin. The studies here were undertaken in order to address the 
following issues;
1. The comparative activation rates of several different activating agents
2. The specific activity of the resulting active species
3. Characterisation of the active species by N-terminal sequencing
4. The role of the C-terminal domain during activation
(i) Comparison of trypsin activation to APMA activation
Progelatinase-B was incubated at 37°C in peptide assay buffer in the 
presence of trypsin (0.13pM) or APMA (2mM), the latter contributing 10% 
DMSO to the reaction mixture. At various times, ranging from 0 - 22 hrs, 20pl 
was removed for SDS-PAGE together with lOpI for the assay of gelatinase 
activity. The rate of gelatinase activation was followed using DnpPLGLWAR.
Optimum activity was achieved after 7 hrs incubation with trypsin (Fig. 
3.12). This was associated with the production of an 82 kDa species on SDS- 
PAGE under non-reducing conditions (Fig. 3.13 {B}) which decreased to 70 
kDa following reduction (Fig. 3.13 {A}). Activation using APMA was somewhat 
slower, taking 22 hrs to reach maximum activity (Fig. 3.12). SDS-PAGE of the 
reaction products revealed a time-dependent increase of a major species 
running at 66 kDa under reducing conditions (Fig. 3.13 {D}). Analysis of these 
samples using non-reducing conditions showed that the appearance of a band 
of 68 kDa correlated with enzyme activity (Fig. 3.13 {0}).
Both these methods caused additional hydrolysis at sites within the 0- 
terminal domain as shown by gel electrophoresis using reducing conditions. 
Gel electrophoresis of APMA treated samples using non-reducing conditions 
revealed the production with time of a 68 kDa species which indicates that the 
entire C-terminal domain is eventually removed.
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Figure 3.12 Activation of progelatinase-B by trypsin and APMA
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Progelatinase-B (2 |iM) was activated using either trypsin or APMA as 
described in the text (3.2:3 {i}). The rate of activation was followed by measuring the 
activity of appropriately diluted samples against DnpPLGLWAR. Corresponding 
samples were also analysed by SDS-PAGE (Fig. 3.13, A - D).
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Figure 3.13 Analysis of progelatinase-B activation by trypsin and APMA
using SDS-PAGE
Progelatinase-B (2 pM) was activated using either trypsin or APMA as 
described in the text (3.2:3 {i}). At times ranging from 0 - 22 hours, aliquots 
were removed for analysis of gelatinase activity (see Fig. 3.12) and for SDS- 
PAGE (A - D). Samples were electrophoresed on 10 - 20% gradient 
polyacrylamide gels under both non-reducing (A,C) and reducing conditions 
(B,D). Trypsin-activated samples are analysed on gels (A) and (B) and APMA 
samples on gels (0) and (D). The molecular masses (M) of standard proteins 
are indicated. Incubation times (hrs) are shown above each gel.
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(ii) Comparison of APMA and stromelysin activation of progelatinase-B and 
A426 - 688 progelatinase-B (proNGL-B) which lacks the C-terminal domain
Progelatinase-B (2 pM) or proNGL-B (2 pM) were incubated with 
stromelysin (0.133 pM) or APMA (2 mM) under conditions essentially as 
outlined above (3.2:5. (i)). Samples were removed at times ranging from 0 - 22 
hrs and then analysed by SDS-PAGE and by assay against DnpPLGLWAR.
Both forms of the enzyme were maximally activated after 6 hrs in the 
presence of stromelysin (Fig. 3.14). The products resulting from stromelysin 
activation of progelatinase-B gave a similar pattern when analysed by SDS- 
PAGE under both reducing (Fig. 3.15 {A}) and non-reducing conditions (Fig. 
3.15 {B}). A species of 86 kDa was generated initially and this was 
subsequently converted to an 82 kDa form. Activation of proNGL-B by 
stromelysin correlated with a reduction in molecular mass from 55 kDa to 40 
kDa via an intermediate of 42 kDa under both reducing (Fig. 3.15 {0}) and non­
reducing conditions (Fig. 3.15 {D}). Activation of progelatinase-B and proNGL- 
B in the presence of APMA was much slower and gave maximal activity at 
about 22 hrs (Fig. 3.14). The active form of proGL-B had a molecular mass of 
66 kDa and was formed via several intermediates (Fig. 3.13 {C,D}) as reported 
in section 3.2:3 (i). Activation of proNGL-B by APMA involved the loss of a 3 
kDa fragment before the generation of a fully processed product migrating at 40 
kDa under both reducing (Fig.3.15 {E}) and non-reducing conditions (Fig. 3.15 
{F}).
N-terminal sequencing of the active species of the gelatinases showed 
that stromelysin activation generates F^i at the N-terminus of both the full- 
length and the truncated enzyme whereas APMA induces the cleavage of the 
bond between A^4 and M^s for both enzyme forms (Table 3.2).
The C-terminal domain of progelatinase-B does not appear to influence 
either the APMA induced autolytic activation of the enzyme or the stromelysin 
catalysed removal of the propeptide region.
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Figure 3.14 Activation of progelatinase-B and proNGL-B
by stromelysin and APMA
ProGL-B + APMA
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Progelatinase-B (proGL-B) or proNGL-B (2 |liM) were incubated at 37°C with 
trypsin-activated stromelysin (SL) (0.17 |iM) or APMA (2 mM) and 10% DMSO. At 
various times, ranging from 0 - 22 hrs an aliquot was removed for assay against 
DnpPLGLWAR. Corresponding samples were also analysed by SDS-PAGE under 
both non-reducing and reducing conditions (Fig. 3.13 (C, D}, Fig. 3.15 (A - F}).
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Figure 3.15 SDS-PAGE analysis of progelatinase-B and proNGL-B
activated by stromelysin and APMA
Progelatinase-B (2|iM) or proNGL-B (2jil\/l) were activated using either 
stromelysin or APMA as described in Figure 3.14. At times ranging from 0 - 
22 hours, aliquots were removed for analysis of gelatinase activity (Fig. 3.14) 
and for SDS-PAGE (A - F). Samples were electrophoresed on 10 - 20% 
gradient polyacrylamide gels under both reducing (A,C,E) and non-reducing 
(B,D,F) conditions. Stromelysin activation of full-length proGL-B and proNGL- 
B is demonstrated on gels (A, B) and (0, D) respectively. APMA activation of 
proNGL-B is demonstrated on gels (E) and (F). APMA activation of full-length 
proGL-B is shown in Figure 3.13 (C,D). The molecular masses (M) of 
standard proteins are indicated. Incubation times (hrs) are shown above each 
gel.
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Figure 3.15B SDS-PAGE analysis of proNGL-B
activated by APMA
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(iii) Determination of ^caf/Km values for gelatinase-B and NGL-B on QF24
The concentrations of the maximally activated species from 3.2:3 (ii) 
were determined by titration against the inhibitor TIMP-2 which unlike TIMP-1 
does not interact with the proenzyme form (Murphy et al., 1991).
Briefly, enzyme samples were preincubated for 2 hrs at 23°C in the 
presence of TIMP-2 in the concentration range of 2.5 nM - 40 nM prior to assay 
against QF24. Rates were determined over the first minute of the reaction over 
which time the linearity of the progress curve showed that no dissociation of 
enzyme - inhibitor complex had occurred. Active enzyme concentrations were 
calculated as described in Chapter 2.
Enzyme samples of known concentration were assayed against QF24 to 
determine values of /Ccaf/Km- All assays were performed at 23°C in a total 
volume of 2.5 ml of assay buffer. The substrate concentration of 1.5 pM fulfilled 
the condition of S «  Km required to allow direct determination of ^caf/Km- 
Values for APMA and stromelysin activated progelatinase-B and proNGL-B 
were calculated as described in section 3.2:5 (iii). There were no significant 
differences between any of the activated species (Table 3.2), a result which is 
in agreement with similar studies performed using DnpPLGLWAR (data not 
shown).
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3.3: Discussion
This chapter has focused on three important biochemical properties of 
the gelatinases, namely, the events leading to enzyme activation, the specific 
activity of activated species and the role of the non-catalytic C-terminal domain. 
In conducting this work the author has endeavoured to define conditions which 
will be suitable for kinetic analysis of enzyme inhibitors and combined this 
with,wherever possible, studies that might indicate how these enzymes would 
function in vivo.
Gelatinase-A
Gelatinase-A is activated in the test-tube by APMA to produce an active 
form of 66 kDa with the aminoacid at the N-terminus. By showing that the 
process was not concentration dependent for stromelysin Okada et al. (1990) 
established that activation was initiated by an intramolecular cleavage. Two 
independent methods were used to examine this proposed mechanism of 
APMA activation with the following results;
(i) TIMP which can bind to stoichiometrically to gelatinase-A was not able to 
halt the conversion of pro- to active enzyme. This shows that the activation is 
not due to contaminating active enzyme and that the active-site is not available 
to bind to high molecular mass inhibitors. As this may be a result of steric 
hindrance a low molecular mass inhibitor (CT989) was also tested, with similar 
results.
(ii) Increasing the local concentration of gelatinase-A using heparin did not 
effect the rate of proenzyme disappearance but it did increase the rate at which 
the mature enzyme was produced.
In agreement with the studies of Okada (see Fig.1.4A), APMA promotes 
an intramolecular cleavage which is followed by a concentration dependent 
step leading to the formation of the mature enzyme.
APMA is unlikely to be the physiological activator of gelatinase-A 
although it is possible that it mimics endothelial cell stimulating angiogenic 
factor (ESAF) (Weiss et al., 1983) or some other as yet undefined low 
molecular mass activator. There has been little progress in discovering a 
proteinase activator of gelatinase-A. In vitro studies indicate that serine 
proteinases such as plasmin and trypsin cannot bring about its activation and
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this can be rationalised on the observation that gelatinase-A lacks a “bait” 
region which matches the specificity of these enzymes (Okada et al., 1990; 
Strongin et al., 1993). The matrix metalloproteinase, stromelysin has also been 
shown to be ineffective (Strongin et al., 1993; Crabbe et al., 1994b) although 
incubation with pre-activated gelatinase-A can result in activation (Crabbe et 
al., 1994b). Several laboratories have reported that certain cells, particularly 
after induction with an agent such as concanavalin-A (Con-A), are capable of 
binding and activating gelatinase-A. Overall and Sodek (1990) reported that 
Con-A stimulated gingival fibroblasts produced increased levels of 
collagenase, matrilysin and gelatinase-A and furthermore the latter was fully 
active. Ward et al. (1991) have since shown that gelatinase-A activation by 
Con-A stimulated fibroblasts requires an intact C-terminal domain and is 
completely inhibited by TIMP-2 and partially by TIMP-1. Recently Strongin et 
al. (1993) identified an activation intermediate from HT1080 fibrosarcoma cells 
which was the product of a cleavage between residues and L38. This is 
not a serine proteinase recognition sequence but MMPs do cleave at such sites 
(sectioni .3:5). Accordingly, a range of MMPs were tested for their ability to 
activate progelatinase-A. Of these, fibroblast collagenase and matrilysin 
removed the propeptide from gelatinase-A and were, therefore, examined 
further.
Matrilysin cleaved progelatinase-A to the active species gelatinase- 
A but a transient intermediate could not be isolated in sufficient quantity to 
enable sequencing. Studies conducted by Crabbe et al. (1994a) using a 
catalytically dead mutant (E ^A ) demonstrated that matrilysin has the specificity 
to cleave progelatinase-A to the fully active form. Collagenase cleaved 
progelatinase-A at the N37 _ \_3Q bond but was unable to complete the 
activation process. Removal of the remainder of the propeptide was completed 
by gelatinase-A itself. The rates of both collagenase and matrilysin induced 
gelatinase-A activation were augmented by the addition of heparin. Matrilysin 
does not, however, possess a recognisable heparin binding motif. Studies 
using gelatinase-A (E-^A) (data not shown) proved that this was a result of 
enhanced gelatinase-A self-processing rather than matrilysin binding. 
Truncated gelatinase-A (i - 4 1 7  ) was activated by collagenase at the same rate 
as its wild-type parent suggesting that activation was not preceded by a 
physical association of the two enzyme's C-terminal domains. Heparin had no
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effect on the rate that collagenase activated the truncated enzyme, however, 
showing that this was a C-terminally mediated process. The action of heparin 
can be explained by its ability to bind to the C-terminal domain of both enzymes 
effectively concentrating them on its surface.
These results from these studies imply that collagenase or a related 
enzyme is responsible for the observations of cell-mediated progelatinase-A 
activation. The recent discovery of a membrane bound MMP which activates 
gelatinase-A suggests the latter (Sato et al., 1994). Nonetheless, this does not 
preclude a role for collagenase in other circumstances. Mast cells, for 
example, are often found at sites of matrix remodelling where they release 
heparin and activators of procollagenase (Bromley and Wooley, 1984; Lees et 
al., 1994).
Gelatinase-B
Progelatinase-B may be activated by a number of methods (Ogata et al., 
1992; Okada et al., 1992) but the mechanisms involved in this activation are 
not fully understood. A comparative study was undertaken to analyse its 
activation by three different methods, APMA, trypsin and stromelysin. The 
contribution of the C-terminal domain to this process was studied using 
recombinant enzyme lacking this domain. Activated species were 
subsequently characterised by a combination of gel electrophoresis and N- 
terminal sequencing.
Both trypsin and APMA produced unproductive cleavages in the C- 
terminal domain of progelatinase-B during the activation process. Maximal 
activation by APMA was accompanied by the complete removal of this domain. 
Trypsin activation was complete after 7 hrs at which stage additional hydrolysis 
caused a time-dependent reduction in activity. The most efficient activator was 
stromelysin (6 hrs) which generated an 82 kDa species in a two stage process. 
In agreement with Ogata et al. (1992) stromelysin processing of wild-type 
progelatinase-B is largely confined to removal of the propeptide. Self­
processing and activation of the wild-type and truncated enzymes occurred 
over a similar time-course in this study. Moreover, after active-site titration 
these were shown to have similar specific activities against peptide substrates 
(section 3.2:3 (iii)) and gelatin (data not shown). It can be concluded, therefore, 
that the C-terminal domain of progelatinase-B does not determine the
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autoprocessing specificity of the catalytic domain nor the final substrate 
specificity. Interestingly, the continuing presence of the conserved cysteine in 
the APMA-activated enzymes did not modify the final specific activity (Table 
3.2), thus, confirming the findings of Triebel et al. (1992). This group proposed 
a complex mechanism by which the thiol becomes involved in an internal 
disulphide rearrangement but there is as yet little evidence to substantiate this. 
Furthermore, binding of APMA to the cysteine may block subsequent reactions 
involving the thiol group.
Specific activity of gelatinases
A high enzyme specific activity {kcat^Km) is an important factor when 
attempting to determine inhibition constants (Ki's) in the range of lO 'i^  - 10-1° 
M because it permits reasonable reaction rates to be attained using a relatively 
low enzyme concentration (see Chapters 5 and 6). This permits the inhibitor 
concentration to be varied around its Ki without significant titration of the 
enzyme, kca t^m  values were determined for both gelatinase-A and 
gelatinase-B using three substrates in order to assess their utility for inhibitor 
studies.
The APMA-activated forms of both gelatinase-A and B were efficient 
against the peptide substrates, DnpPLGLWAR (Stack and Gray, 1989) and 
QF24 (Knight et al., 1992). Both enzymes exhibited higher kcat^m  values 
against QF24, ranging from 10 5 - 10 ^ M-Is-1, and there is some preliminary 
evidence to suggest that this is largely a consequence of an improved turnover 
rate (kcat)- This cannot be established definitively, however, since the lack of 
solubility of the QF24 substrate limits Km measurements. Collagenase 
(Chapter 4) as well as stromelysin and matrilysin which are discussed later 
(Chapter 5) all exhibit comparatively low specific activities for these substrates 
(Murphy et al., 1992b and data not shown).
Gelatinase-A also cleaves gelatin efficiently. The Km for this substrate (1 
|iM) was considerably lower than that of either DnpPLGLWAR (70 |iM) or QF24 
(approximately 30 pM; Dr. F. Willenbrock, personal communication). Since 
gelatin is hydrolysed at a number of positions this value is, however, likely to 
reflect the contribution of many different cleavage sites. Consequently, gelatin 
is not a suitable substrate for kinetic analyses but its likeness to the
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physiological substrate may provide a more rigorous test for inhibitors than the 
peptide substrates. The results of such analyses are described in Chapter 6.
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CHAPTER 4
CHARACTERISATION OF HUMAN RECOMBINANT INTERSTITIAL
COLLAGENASE
4.1 : Introduction
Interstitial collagenase is secreted as a 55 kDa non glycosylated and a 57 
kDA glycosylated proenzyme (Stricklin et al., 1977). The mature enzyme has a 
molecular mass of between 42 kDa and 45 kDa depending on the mode of 
activation. These different activated species are known to exhibit varying 
degrees of activity against fibrillar collagen (Suzuki et a!., 1990). Moreover, 
collagenolytic activity is completely abolished upon removal of the C-terminal 
domain (Birkedal-Hansen et a!., 1988; Clark and Cawston, 1989; Murphy et al., 
1992b). In the following study, different forms of activated collagenase were 
generated by varying the activation protocol. These were then compared by 
measuring their specific activities against collagen and peptide substrates, with 
particular attention to the phenomenon of 'superactivation' which results from the 
inclusion of stromelysin in the reaction medium (Murphy et al., 1987). This work 
was completed by assessing the contribution of the C-terminal domain to 
collagenase activity.
In common with most other members of this family, collagenase may be 
activated by AMPA or trypsin in the test-tube (Grant et al., 1987; Nagase et al., 
1990; Suzuki et a l ., 1990). Activation by trypsin starts with a cleavage at a K-R-R 
sequence in the propeptide. The identity of the final active form then appears to 
depend on the relative contributions of trypsin and collagenase to the 
progression of activation. APMA activation is characterised by an initial self­
cleavage between valine (V67) and methionine (M^S) five residues upstream 
from C73 (section 1.3:3). Prolonged incubation may lead to a further cleavage 
between phenylalanine (P81 ) and valine (V^Z) eight residues downstream of C^s. 
A number of groups have shown that the presence of stromelysin during the 
activation of collagenase by APMA or trypsin significantly augments its activity on 
its natural substrate, fibrillar collagen (Murphy et al., 1987; Suzuki et al., 1990). 
Activated collagenase which has retained 0^8 exhibits between 15 and 25 % of 
the collagenolytic activity of the stromelysin generated species. Prolonged 
exposure to APMA removes this cysteine to produce a species with 40 % of the
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full activity. This shows that the formation of an enzyme with full collagenolytic 
activity requires more than just the removal of the cysteine.
In this study trypsin and stromelysin were used to produce different forms 
of collagenase that varied in the identity of their N-terminal amino acids. These 
were then investigated with respect to their activity on type 1 collagen and on 
peptide substrates. By analysing the properties of these enzymes it may be 
possible to establish if the stromelysin catalysed cleavage of the Q80 _p8i bond 
is crucial for the full expression of collagenase activity or, if there is some, as yet, ' 
unidentified mechanism by which stromelysin superactivates collagenase.
In Chapter 3, collagenase was shown to activate progelatinase-A. These 
studies indicated that the process may be reciprocated because trypsin-activated 
collagenase was observed to decrease in molecular mass during the reaction. 
This possibility was explored in a series of experiments leading to the 
characterisation of the activated collagenase by N-terminal sequencing.
The presence of an intact collagenase C-terminal domain has now been 
shown to be an absolute requirement for maintaining collagenolytic activity 
(Birkedal-Hansen et al., 1988; Clark and Cawston, 1989; and Murphy et al., 
1992b). In order to characterise the contribution of the C-terminus to the 
biological activity of the enzyme a truncated version, CL^ 243 - 450 was studied. 
The role of the C-terminus and its potential as a target for the generation of 
specific inhibitors of collagenolysis was also tested by using a collagenolytic 
assay to identify C-terminal specific monoclonal antibodies which possessed 
neutralising activity.
108
4.2: Results
4.2:1 Collagenase activation
The following studies were designed to probe the so-called 
‘superactivation’ of collagenase induced by stromelysin. This process has now 
been described by many groups (Murphy et al., 1987; Suzuki et al., 1990; 
Nagase et al., 1990) but a detailed characterisation of the activated collagenase 
that includes its activity against peptide substrates has not been undertaken. The 
ability of gelatinase-A to superactivate collagenase is also examined.
(I) The collagenolytic activity of human procollagenase activated by trypsin In 
the presence or absence of stromelysin
Procollagenase (2 pM) was incubated with a range of trypsin 
concentrations with or without stromelysin. The trypsin activity was terminated by 
adding excess soya bean trypsin inhibitor (SBTI) and then aliquots were tested 
for collagenolytic activity using the solution phase collagen assay described in 
Chapter 2. Fig. 4.1 shows the effect of stromelysin on trypsin activated samples. 
Stromelysin increased collagenase activity (expressed as percentage hydrolysis 
compared with a bacterial collagenase control) by between 4 and 20 fold over 
corresponding stromelysin negative samples. Gel electrophoresis of the products 
of this reaction showed that stromelysin was not acting synergistically with the 
collagenase to break down the collagen (data not shown). Increased 
collagenolytic activity is a result, therefore, of the action of stromelysin on 
collagenase.
(ii) SDS-PAGE anaiysis and N-terminal sequencing of coilagenase activated 
by trypsin, TPCK-treated trypsin and TPCK-treated trypsin in the presence of 
stromeiysin
Trypsin is reported to cleave procollagenase at a number of sites 
(reviewed in Birkedal-Hansen et al., 1993). The following experiment examines 
the enzyme species produced by trypsin in the absence and presence of an 
inhibitor, N-tosyl-L-phenylalanine chlormethyl ketone (TPCK), which blocks 
contaminating chymotryptic activity. These enzymes are compared to the active 
form of collagenase produced by a combination of trypsin and stromelysin.
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Figure 4.2 SDS-PAGE analysis of procollagenase activation
M  1 2 3 4 5 6
(kDa)
30 WM
Procollagenase (4|iM) was incubated with trypsin or TPCK-treated 
trypsin in the presence and absence of stromelysin for 40 mins at 37°C as 
described in section 4.2:1 (ii)). Samples were then analysed by SDS-PAGE (10 
- 20 %) under reducing conditions.
Lane Sample
1 Molecular mass markers
2 procollagenase
3 + trypsin (10 pg/ml)
4 + trypsin (TPCK) (10 pg/ml)
5 As above + prostromelysin (4 pg/ml)
6 Molecular mass markers
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Human procollagenase was incubated in the presence of trypsin (10 
pg/ml)), or TPCK-treated trypsin with or without stromelysin (4 pg/ml) for 40 
minutes at 37°C. Trypsin activity was terminated using a 10 fold excess of SBTI 
and the products were analysed by SDS-PAGE under reducing conditions 
essentially as described in Chapter 2 (Fig. 4.2).
Trypsin treated with TPCK produced a major species which migrated at a 
position corresponding to a molecular weight of 43 kDa (lane 4). The addition of 
stromelysin to this activation mixture resulted in a further reduction in molecular 
mass to 42 kDa (lane 5). A 43 kDa band was also produced by the action of 
untreated trypsin on procollagenase (lane 3).
N-terminal analysis of the activated collagenase was performed as 
described in Chapter 2 after electroblotting the appropriate band onto a 
polyvinylidine difluoride membrane. Table 4.1 shows the cleavage sites of the 
above activators together with the cleavages resulting from APMA activation of 
collagenase. Under the incubation conditions described above, TPCK-treated 
trypsin hydrolyses procollagenase at the bond between and C^^ The 
r e s id u e , C ^ 8 ^  which contributes to the latency of the proenzyme by interacting with 
the catalytic zinc, is not removed by this method. Incubation of procollagenase 
with untreated trypsin resulted in an active enzyme form with V82 at the N- 
terminus. Inclusion of stromelysin in the TPCK-treated trypsin activation mixture 
resulted in the generation of an enzyme species with P81 at the N-terminus.
(iii) Characterisation of collagenase activation using the synthetic inhibitor 
CT435
Activation of procollagenase by any of the above methods may include 
self-cleavages like those produced by the inclusion of APMA in the reaction 
mixture. APMA is known to induce the hydrolysis of the p8i - bond which, as 
shown above, can also be generated by incubating procollagenase with 
untreated trypsin. The ability of collagenase to self-activate was determined by 
including a synthetic collagenase inhibitor, CT435 (Fig. 5.1), in the reaction 
mixture. The products were analysed by SDS-PAGE (Fig. 4.3) and the results 
shown in Table 4.1. As would be predicted, CT435 blocked the activation of 
procollagenase by APMA showing that this is due to self-cleavage (lanes 7 and 
8). CT435 did not affect the mobility of the active species generated by either
112
c
g*3
(0>
O
(0
o(0
(0co
G)
iS
ôo
c
g
%g
z0)
o(0
(0.cü
0)
n
(0
I -
iiii
ifi
I
I,
0 O fS
O  r r  O  T1-H s© V©1—( m r %
Q0 O S
m o\ oc
M 2 m^ 1-H ^ T-l
H HK'W
«m
O O
< < < <
> >
Q O O
p. eu eu eu
m : > >
O O
U u U
—> 
1% ee ee ee
eu eu eu a,
^ O' o O' O
i4 üd
S S S S
> > > >
üd
hJ >G >G
H H H H
M (S rn Tf
0)
Cg
’"Bcoo
cg
co>
'iGo
<
ü
N
co
(0
v>c
o
'5'
8Cd>o>jO
oo
o
_c
'(5)a.
3:
oTf O >
-  êc (0 
w (0Q. (0 
? C
■Oo
eo(U
üû.
I -
(0Q.>»
T3
B
(0
Sc
D
ü
N00
«
(0c
o
?
w
ou>
&
(D
E
2
w
+
?
W
§
(0Q.>.
■a
I
ü
S5
co
</>c
o(O
üû. û.<
T3
i
>•3
a
-G
c/ü<ü
gGCT
15G
fz
.G
H
CN
Tl"
G
.G
1T3
D T3
t3 aV)
I s73 W)
-S i-  G
1- CM CO ^
I  ^Ë <u
II
113
Figure 4.3 Inhibition of the activation of procollagenase using 
CT435
M
(kDa) 1 2 3 4 5 6 7 8 9
94______ _
67
30_
21
Procollagenase (4 pM) was incubated for 40 mins at 37°C in the presence 
of activating agent ± the synthetic inhibitor CT435. Details of each reaction are 
given below. Samples were then analysed by SDS-PAGE (10 - 20%) under 
reducing conditions.
Lane Sample
1 Molecular mass markers
2 Procollagenase (ProCL)
3 ProCL + TPCK-treated trypsin (10 pg/ml)
4 As (3) + CT435 (15 pM)
5 ProCL + trypsin (10 pg/ml)
6 As (5) + CT435 (15 pM)
7 ProCL + APMA (0.5 mM)
8 As (7) + CT435 (15 pM)
9 ProCL + trypsin (10 pg/ml) + stromelysin (4 pg/ml) control
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TPCK-treated (lanes 3 and 4) or untreated trypsin (lanes 5  and 6 ) suggesting that 
autocatalysis is not involved in these processes. Moreover, the generation of the 
N-terminal residue V82 by untreated trypsin must be due to a component of the 
trypsin mixture itself such as chymotrypsin rather than the action of collagenase 
which would be inhibited by CT435. The - V82 bond does not appear, 
therefore, to be a collagenase self-cleavage site in the absence of a structural 
perturbant such as APMA.
(iv) Characterisation of collagenase activation using specific activity 
measurements
The specific activity of trypsin and trypsin / stromelysin activated 
collagenase was measured against collagen and two synthetic substrates, 
DnpPLGLWAR and QF24. Concentrations of active enzyme were determined by 
active site titration against TIMP-1 as described in section 2.2:5.
Collagenolytic activity was measured using semi-fibrillar collagen in a 
diffuse fibril assay as described in section 2.2:6. Table 4.1 shows the activity of 
each form (together with published data for the APMA activated enzyme (Nagase 
et al., 1990)) expressed as a percentage of that produced by trypsin/stromelysin 
(p 8 i-collagenase). Values for /Ccar/Km were generated for the two peptide 
substrates as described in Chapter 2  under conditions of S «  Km required to 
allow the direct determination of this property (Table 4.1).
Collagenase with the C^3 N-terminus produced by the action of TPCK- 
treated trypsin possessed only a fraction of the collagenolytic activity associated 
with stromelysin "superactivation". This level of activity was comparable to that 
obtained by Nagase et al. (1990) for APMA activated collagenase (13%). (C?3)- 
Collagenase also expressed comparatively low activity against DnpPLGLWAR 
and QF24 (Table 3.2).
(V82).collagenase produced by the action of untreated trypsin, possessed 
only 17% of the collagenolytic activity expressed by (F8i)-collagenase. Specific 
activity against the peptide substrates as indicated by the /Ccaf/Km value was 
equivalent or improved for the (V82)-collagenase compared to the (p8 i) form of 
the enzyme (Table 4.1).
The data suggest that removal of C^s is a requirement for the expression 
of full activity against both the physiological substrate and small synthetic 
peptides. Removal of P81 from the N-terminus of the active enzyme significantly
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reduces its ability to hydrolyse collagen whilst activity against peptide substrates 
appears to be maintained or improved. This suggests that may be involved in 
collagen recognition. Its presence does not appear to be necessary for the 
hydrolysis of small peptides.
(vi) Activation of procollagenase by gelatinase-A
Stromelysin-1, stromelysin-2 and matrilysin have been reported to 
superactivate collagenase (Murphy et al., 1987; He et al., 1989; Nicholson et al., 
1989; Quantin et al., 1989). There is no evidence to date to suggest that 
gelatinase-A possesses this capability even though it is often found at sites of 
tumour invasion together with collagenase. The following experiment examines 
the effect of gelatinase-A on collagenase activation. A related series of 
experiments describing the action of collagenase on gelatinase-A activation 
were presented in section 3.2:1.
Progelatinase-A was added to trypsin-activated collagenase in gelatinase 
activation buffer. The reaction mixture was incubated at 37°C and at times 
ranging from 0 - 6  hours an aliquot was removed and examined by SDS-PAGE 
under reducing conditions (Fig. 4.4). At time 0 hrs the trypsin activated 
collagenase can be seen as a band migrating with an apparent molecular mass 
of 43 kDa. After 2 hours a single band of 42 kDa can be observed. The 
production of this band is accompanied by the concomitant increase of a 6 6  kDa 
species which, as shown earlier, corresponds to activated gelatinase-A. Bands 
representing the 43 kDa form (0 hours) and the 42 kDa form ( 2  hours) of 
collagenase were N-terminally sequenced following electroblotting onto 
polyvinylidine difluoride membranes as described in section 2.3:2. Collagenase 
activated by trypsin alone was comprised largely of a form with its N-
terminus. Incubation of the trypsin-activated collagenase with progelatinase-A 
resulted in the production of a band of lower molecular mass with an N-terminus 
corresponding to F^i. This is the same N-terminal residue that is produced by the 
action of stromelysin, which was shown previously to correlate with 
'superactivation' of collagenase.
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Figure 4.4 Activation of procollagenase by
gelatlnase-A
M
(kDa) 1 2  3 4 ^
94----------
67________________  A (progelatinase-A)
(43kDa collagenase) C 43__________ B (active gelatinase-A)
( 42 kDa collagenase)
30______
Procollagenase (2|iM) was activated with TPCK-treated trypsin (0.4|liM) 
for 45 minutes at 37°C. Trypsin activity was terminated by the addition of a 10 
fold excess of SBTI. This solution was then incubated at 37°C with 
progelatinase-A in a total assay volume giving enzyme concentrations of IpM 
and 4pM for collagenase and gelatinase, respectively. Aliquots were removed 
from each sample for analysis on a 1 0  - 2 0 % polyacrylamide gel under reducing 
conditions.
Lane Sample
1 Molecular mass markers
2 0 hours
3 1 hour
4 2 hours
Band C (0 hrs) and band D ( 2  hrs) were electroblotted onto a polyvinylidine 
fluoride membrane and then N-terminal sequenced as described in Chapter 2.
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Figure 4.5 Time-course of gelatlnase-A activation of
procollagenase: The effect of heparin
M
(kDa) (L l_  JL!L 19
94__
67 . . .  ^  ^ ^
43_
30.
21
(- ) heparin (+) heparin
Procollagenase (0.75 pM) was incubated with an equimolar solution of 
gelatinase-A at 37°C in the presence or absence of heparin (100 pg/ml). At 
0, 1,5, 10 and 20 minutes, 20 pi was removed and then analysed by SDS- 
PAGE (10 - 20%) under reducing conditions (incubation times are shown 
above each lane). Molecular masses (M) of standard proteins are indicated.
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(vii) The rate of superactivation of collagenase by gelatinase-A: the effect of 
heparin
Previous studies have shown that gelatinase-A is capable of 
superactivating collagenase. The efficiency of this process may be tested by 
following the conversion using SDS-PAGE. Moreover, heparin may increase the 
efficiency of the reaction in a comparable process to that described earlier for the 
activation of progelatinase-A by collagenase (Chapter 3).
Trypsin-activated collagenase was incubated at 37°C with an equimolar 
concentration of gelatinase-A in the presence or absence of heparin. At various 
times an aliquot was removed and then analysed by SDS-PAGE under reducing 
conditions (Fig. 4.5). Superactivation is associated with a reduction in molecular 
mass of about 1 kDa. Figure 4.5 shows that in the absence of heparin the 
conversion is nearly complete after 20 minutes (lane 6 ). In the presence of 
heparin the reaction is completed by between 1 (lane 8 ) and 5 minutes (lane 9).
Stromelysin, at a stromelysin:collagenase ratio of 1:100 (M:M) completes 
the superactivation process within 10 minutes (unpublished data). This study 
indicates, that in the absence of heparin, superactivation by gelatinase-A is of the 
order of 200 fold less efficient. Addition of heparin,however, increases this 
efficiency by 1 0  fold whereas it does not affect the stromelysin catalysed reaction 
(data not shown).
3.2:2 The role of the C-terminal domain of collagenase
The C-terminal domain of collagenase does not possess any inherent 
catalytic activity but may, by binding to the collagen molecule, expose a site for 
cleavage by the catalytic domain.
The importance of this domain was established by two methods. Firstly, a 
monoclonal antibody (MAC065) was shown by western blotting to bind to a 
region within the collagenase C-terminal domain. Its effect on collagenolysis and 
collagenase activity against a peptide substrate were then studied. Secondly, a 
genetically engineered collagenase (A243-450 collagenase) which lacked the 
entire C-terminal domain was compared to full-length enzyme with respect to 
TIMP-1 binding, collagenolysis and specific activity against a peptide substrate. 
Results arising from studies on the truncated collagenase are summarised in 
Table 4.2.
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(i) Screening monoclonal antibodies using the collagen diffuse fibril assay
A selection of murine monoclonal antibodies (MAbs), that had been raised 
against both recombinant human and dog collagenase, were assayed for their 
ability to inhibit collagenolysis using the diffuse fibril assay (Chapter 2 ).
Antibodies were first screened at concentrations of 0.1 pM and IpM and 
the extent of inhibition was determined as a percentage of the activity of a 
collagenase alone control. Three MAbs MAC064, MAC065 and MAC066, 
showed 40%, 100% and 50% inhibition respectively, at a concentration of O.IpM. 
Mac065 was re-tested at a range of concentrations. An IC5 0  value of 3nM was 
determined from a plot of percentage inhibition (y - axis) against Logi 0 
[MAC065] (x - axis) (section 2.2:6).
(ii) Western blotting of MAC065 to determine its domain specificity
The C-terminal domain of collagenase (A 1-261) was generated by 
incubating collagenase with stromelysin and trypsin as described above, in the 
presence of 0.8 mg/ml 1,10-phenanthroline. This method produces a single band 
of 30 kDa which has been identified by N-terminal sequencing as the C-terminal 
domain beginning at residue I^ G2 The sample was concentrated two fold using 
an ultrafree concentration unit with a molecular mass cut-off of 10 kDa and then 
analysed by gel electrophoresis under both reducing and non-reducing 
conditions. Identical samples were run on both halves of the gel. One half of the 
gel was stained with Coomassie-Blue whilst the other half was western blotted 
using an HRP-linked second antibody as described in Chapter 2. Enhanced 
chemiluminescence (ECL) was used to visualise HRP containing bands (Fig. 
4.6.), which were compared with equivalent Coomassie-Blue stained samples. 
Intense staining was associated with bands corresponding to reduced full-length 
active collagenase and both the reduced and non-reduced C-terminal domain of 
collagenase. Other studies have shown that MAC065 does not recognise the 
catalytic domain of collagenase (data not shown). This indicates that the epitope 
for MAC065 resides in the C-terminal domain of collagenase. The observation 
that the antibody recognised reduced C-terminal domain would suggest that this 
epitope is a linear sequence of amino acids.
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Figure 4.6 Characterisation of the specificity of MAC065 
using western blotting
A  B C M
(kD a)
  43
30
21
Lane Sample
A Non-reduced C-terminal domain
B Active collagenase
0 Reduced C-terminal domain
Collagenase C-terminal domain (A i-2 i i)C L  was generated by 
incubating procollagenase (2|liM) with TPCK-treated trypsin (lOpg/ml) and 
stromelysin (4pg/ml) for 45 minutes at 37°C in the presence of the zinc 
binding agent 1, 10 - phenanthroline (0.8mg/ml). The identity of the C- 
terminal domain was determined by N-terminal sequencing. Samples were 
electrophoresed on a 10-20% polyacrylamide gel and then transferred to an 
immobilon membrane by electroblotting (30 volts) for 16 hours. The samples 
were western blotted using MAC065 as the first layer as described in the 
text (4.2:2 (ii)). Proteins that were recognised by MAC065 were visualised 
by ECL detection (Chapter 2). The molecular masses (M) of standard 
proteins are indicated.
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(iii) MAC065 inhibition of collagenase activity on DnpPLGLWAR
The presence of an intact C-terminal domain on collagenase is not 
required for cleavage of DnpPLGLWAR (section 3.2:4{v}). Consequently, an 
antibody directed against this region would not be expected to neutralise the 
enzymic activity of collagenase on such a substrate. The assay may, therefore, 
be used to discriminate between those agents which interfere with the catalytic 
activity of the enzyme and those that bind to enzyme but do not directly effect 
catalysis.
Collagenase (200 pg/ml) was activated by incubating it with trypsin (4 
pg/ml) and stromelysin (4 pg/ml) at 37°C for 40 minutes. The collagenase 
mixture was diluted to a final concentration of 10 pg/ml for assay. MAC065 was 
tested at a concentration of IpM for its ability to inhibit the activity of collagenase 
against DnpPLGLWAR. The reactants were mixed in peptide assay buffer to a 
final volume of 135 pi at 23°C. The reaction was initiated by the addition of 15pl 
of DnpPLGLWAR (ImM) resulting in a final substrate concentration of lOOpM. At 
times between 0 mins and 30 mins an aliquot (20 pi) was removed for 
fluorescence measurement. Duplicate samples containing MAC065 gave rates 
of 14.5 and 11.1 FU/min. These rates are not significantly different from the 
enzyme alone controls (12.9 and 13.4 FU/min). These results show that MAC065 
does not neutralise the catalytic properties of collagenase and that the antibody 
probably inhibits collagenolysis by masking the enzyme's collagen binding site.
(iv) Characterisation of A243-450 collagenase : Inhibition by TIMP-1
An apparent Ki (Kiapp) for the inhibition of full-length and A243-450 
collagenase by TIMP-1 was determined by assaying against DnpPLGLWAR. 
The assay was performed using a substrate concentration of 20pM, an enzyme 
concentration of 2 - 5 nM and TIMP-1 concentrations in the range of 0.4 - 22 nM. 
Overnight assays were performed at 37°G with timepoints of 0 and 16 hrs. 
Results were analysed using Enzfitter (Leatherbarrow, 1987) by a nonlinear 
regression analysis of the equation for tight-binding inhibition described by 
Morrison and Walsh (1988) (Chapter 2).
The results for full-length collagenase were of limited accuracy, since 
enzyme activity was titrated by TIMP-1 even at the lowest enzyme concentration 
of 2nM. The Kiapp is, therefore, less than 0.2nM and could not be analysed
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Table 4.2
Characterisation of collagenase and A243-450 collagenase
Collagen DnpPLGLWAR TIMP-1
Enzyme (pg/ml) kcat/Km (M""ls"1) Ki (nM)
Collagenase 97.9 827 <0.2
A243-450
Collagenase 0 653 1.2
The recombinant human enzymes were activated by incubation with trypsin 
(10 pg/ml) and stromelysin (4 pg/ml) for 45 minutes at 37°C. Under these conditions 
the contribution of stromelysin to the rate of substrate hydrolysis or to the association 
of collagenase with TIMP-1 is not significant. Collagenase concentrations were 
determined by titration against TIMP-1 as described in Chapter 2. Assays were 
conducted as described in the text (4.2:2 {iv - vi}).
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further owing to limitations in the sensitivity of the assay. A Kiapp value of 1.2 nM 
was obtained for the truncated enzyme and this figure was reproducible over the 
course of several experiments (Table 4.2). The results indicate that the C- 
terminal domain of collagenase is involved in the interaction of the enzyme with 
TIMP-1.
(v) ^catfKm determinations
Collagenase and A243-450 collagenase were assayed against 
DnpPLGLWAR. The Km was determined to be greater than 300pM which means 
that the substrate concentration of 20 pM fulfilled the condition of S « Km 
required to allow the direct determination of kca^m- Assays were performed at 
37°G in peptide assay buffer using 30 - 60 nM enzyme. At time intervals up to 
1hr, 20 pi aliquots were withdrawn and added to 500 pi of stopping buffer. 
Reaction rates were determined as described in Chapter 2. The kcai/^m values 
for the two enzymes were not significantly different (Table 4.2) suggesting that 
the C-terminal domain of collagenase does not influence the catalytic activity of 
the enzyme..
(vi) Collagenolytic activity
Collagenolytic activity was assayed using the [i^Cl - collagen diffuse-fibril 
assay as described in section 2.2:6. The truncated enzyme showed no 
collagenolytic activity at the test concentration whilst full-length collagenase 
cleaved collagen at a rate of 97.9 pg/min/ml. The specific activity of full-length 
collagenase has been observed to be variable and it rises as the solubility of the 
collagen used in the assay is increased. The results (Table 4.2) show that the C- 
terminal domain of collagenase is an essential requirement for the hydrolysis of 
type 1 collagen.
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4.3: Discussion
Human interstitial collagenase can be activated by both APMA and trypsin. 
Murphy etal. (1987) showed that addition of stromelysin to activated collagenase 
produced a form of collagenase with a higher specific activity against collagen. A 
comparative study of these different forms of collagenase has not, however, been 
performed using peptide substrates. Moreover, there is still some debate over 
the explanation for the improved collagenolytic activity of the 'superactivated' 
collagenase.
In this study, collagenases which differed In their amino-terminal 
sequences were tested against collagen and two peptide substrates. The ability 
of gelatinase-A to superactivate collagenase was also examined and the 
contribution of the C-termlnal domain to collagenase activity and inhibition was 
studied using a genetically engineered enzyme.
The superactivation of coiiagenase by stromeiysin
Incubation of procollagenase with TPCK-treated trypsin produces an 
active 43 kDa form of collagenase with the amino-terminus Addition of 
stromelysin removes a further eight residues generating a form which starts at 
residue . This species is several fold more active on collagen and twice as 
active against peptide substrates. These results are consistent with those of 
Knauper et aL (1993) who showed that the specific activity of trypsin-treated 
neutrophil collagenase against a peptide substrate was improved after the 
addition of stromelysin. Removal of the peptide containing 0^3, therefore, 
enhances the catalytic activity of collagenase. (V82)-Collagenase can be formed 
by the action of trypsin which has not been treated to remove chymotryptic 
activity. That this species was not a product of self-cleavage was demonstrated 
by its lack of sensitivity to CT435, a collagenase inhibitor. Surprisingly, this form 
of collagenase is also less active than superactivated collagenase against 
collagen but Its activity on peptide substrates is at least comparable (Table 4.1). 
There has been some debate on the nature of superactivation since stromelysin 
generated collagenase differs by only one residue from that produced by APMA. 
One explanation is that it is merely an artifact of the assay system. The collagen
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assay is dependent upon differential precipitation to separate the hydrolysed 
fragments from Intact collagen. Additional cleavages within these fragments may 
produce an apparent increase in the level of soluble material which can be 
wrongly attributed to the action of collagenase. The prospect that synergism 
between the two enzymes was responsible for increased collagen degradation 
was investigated by studying the collagen cleavage products using SDS-PAGE 
(data not shown). These results indicated that 'superactivation' leads to a genuine 
increase in the collagenolytic potential of collagenase.
The crystal structure of the superactivated form of the catalytic domain of 
neutrophil collagenase has recently been solved by Reinemer etal. (1994). 
They concluded that by making a salt link with a C-terminal aspartic acid (D232j  ^
the amino-terminal phenylalanine promotes a more ordered structure of the N- 
terminal fragment. It is argued that the reduction in mobility of this fragment might 
then prevent it from entering the substrate binding cleft of another molecule thus 
blocking its activity. This study, however, provided no evidence that the catalytic 
activity of fibroblast collagenase is modified. An alternative proposal is that the 
salt bridge involving 0^32 helps provide the correct juxtaposition of the catalytic 
domain and the C-terminal collagen binding domain. In this way only 
collagenolytic activity would be affected.
The superactivation of collagenase by gelatinase-A
Superactivation may explain the accelerated degradation of collagens 
observed under certain physiological and pathological conditions (Unemorl et a!., 
1991) but stromelysin, having a low pH optimum (Harrison et a!., 1992 ), would 
be expected to retain only a fraction of its activity outside the acidic environment 
of the joint matrix. It is evident from reports of matrilysin's capacity to carry out the 
Q80 - p8i cleavage (Quantin et a!., 1989) that alternative means of 
superactivation exist. During studies on the activation of progelatinase-A by 
collagenase (Chapter 3) a reduction in the molecular mass of the collagenase 
was noted. The newly formed collagenase was subsequently identified as the 
p3i form by N-terminal sequencing. This establishes that like stromelysin and 
matrilysin, gelatinase-A Is also capable of superactivating collagenase. The 
process was, however, about 200 fold less efficient than that due to stromelysin 
although the difference was less substantial (20 fold) in the presence of heparin.
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The role of the C-terminal domain
The activity of a genetically engineered mutant which lacks the C-terminal 
domain was tested against collagen and a peptide substrate. In agreement with 
Birkedal-Hansen etal. (1988) and Clark and Cawston, (1989) the collagenolytic 
activity of the truncated collagenase was totally abolished. In contrast, activity 
against a fluorescent peptide substrate was not significantly modified. This 
shows that collagen is only recognised as a substrate by collagenase after 
binding of the enzyme C-terminal domain modifies its structure. Indeed, collagen 
modelling experiments indicate that only one chain of the triple-helical collagen 
molecule can be accommodated in the active-site cleft at any one time (Bode et 
a/., 1994). This suggests that the role of the C-terminal domain is to promote the 
unravelling of the triple helix at the cleavage site, thus exposing it for cleavage.
The C-terminal domain also increases the strength of binding of TIMP-1 to 
collagenase. In its absence the Ki for this interaction is of the order of 10'^ M 
which is similar to that for the naturally truncated MMP, matrilysin (unpublished 
data). Assays lacked the sensitivity to determine an accurate Ki for the full-length 
form of collagenase but it is likely to be lower than lO'^o M.
The proposal that the C-terminal binding interaction might be a target for 
inhibitors was tested using specific monoclonal antibodies (MAbs). MAC065, 
which did not neutralise the activity of collagenase against a peptide substrate, 
proved to be highly efficient in blocking collagenolysis. Clearly, inhibition of 
collagen binding presents an opportunity to discover highly selective inhibitors of 
collagenase.
In summary, both stromelysin and gelatinase-A can process collagenase 
to a form which is fully active against collagen. The increased collagenolytic 
activity correlates with the appearance of F^ 'i at the N-terminus. Interestingly, the 
effect is collagen specific since a form of collagenase with the phenylalanine 
removed, retains activity against peptide substrates. In Chapter 3 gelatinase-A 
was shown to be processed by collagenase. The reciprocated activation of these 
two enzymes which is enhanced in the presence of heparin may be 
physiologically relevant to mast cell action.
Collagenase lacking a C-terminal domain does not cleave collagen, but 
this domain is not required for peptidase activity. Inhibition of the binding of this 
domain to collagen would selectively block collagenolysis without affecting other
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activities of collagenase. Moreover, the site responsible for collagen binding is 
presumably absent in other MMPs making it a potentially selective target for 
intervening in pathological collagen breakdown.
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CHAPTER 5
THE DESIGN OF POTENT SYNTHETIC MMP INHIBITORS 
5.1 : Introduction
In Chapters 3 and 4 the biochemical characterisation of gelatinase-A, 
gelatinase-B and collagenase was described. These enzymes together with 
stromelysin and matrilysin were then used to test the efficiency of inhibitors 
synthesised by the Celltech Chemistry Department. The focus of the chemistry 
effort towards the design of first generation compounds has been targeted at 
synthesising competitive, reversible inhibitors, which prevent substrate hydrolysis 
by binding to the active site of gelatinase-A. In this chapter, data will be 
presented describing our use of structure activity relationships (SARs) for rational 
drug design.
The first orally active drug against a zinc metalloproteinase was the ACE 
inhibitor, captopril (Fig. 1.8). This was designed on the basis of the structure of 
the active site of the zinc exopeptidase, carboxypeptidase A (Ondetti et al. 1977; 
Cushman et al. 1977). Its strength of binding (Ki = 1.7 nM) derives largely from a 
sulphydryl group (-SH) which mimics the carbonyl oxygen of the scissile bond 
and binds to the zinc atom at the active site. Additional binding and specificity is 
provided by a pseudo-peptide structure which has features of bradykinin, an ACE 
substrate. Subsequently, a variety of zinc binding ligands have been 
incorporated into molecules of this basic design. This work has resulted in the 
synthesis of carboxylic acid (-COOH) (Patchett ef a/., 1980), phosphonic acid (eg. 
-P0(0H )2) (Holmquist and Vallee, 1979; Galardy, 1980) and hydroxamic acid (- 
CONHOH) (Subissi etal., 1992) inhibitors with nanomolar or sub-nanomolar Ki's.
The design of MMP inhibitors has not been based on crystal structures 
since until recently these have not been available. The first rational design of 
collagenase inhibitors was reported by Gray et a i (1981) who used a similar 
approach to that used successfully for the ACE inhibitors. This right hand side 
(RHS) inhibitor had an IC50 of 10 fiM against tadpole collagenase. By 1986 a 
range of zinc-binding ligands had been designed (See Chapter 1) the best of 
which was a Searle hydroxamic acid (Dickens et ai, 1986) (Fig. 1.9) with an IC50
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of 20 nM against human interstitial collagenase. Two other important 
requirements for efficient inhibition had also been established,
1. Collagenase is stereoselective with a preference for R,S,S stereochemistry at 
the Pi', Pg' and P3' binding sites, respectively.
2. Inhibitors based on the left hand side (LHS) of the cleavage site are 
significantly less active than their RHS counterparts.
The compound Z-Pro-Leu-Gly-NHOH, for example, had an IC50 of 40 pM against 
collagenase despite the presence of a hydroxamate ligand.
Celltech compounds are classified as RHS inhibitors and are structurally 
related to the Searle inhibitor described above. The relationship of the structure 
to efficiency and selectivity was examined with the aid of structurally related 
compounds. In this way the consequence of a single modification could be 
analysed. Structure-activity relationships (SARs) were constructed for 
gelatinase-A, stromelysin and collagenase and selected compounds were also 
tested against gelatinase-B and matrilysin. Selectivity data were also obtained for 
representatives of other zinc metalloproteinase families, ACE and 
aminopeptidase-N (AP-N). In early studies results were expressed as ICso's 
(section 1.4:5). The introduction of peptide based assays allows Ki's to be 
calculated in later studies. SAR results will be presented in the form of Ki's where 
the experimental design permits. The following studies were designed to identify 
the optimum zinc binding ligand together with the side-chains on the pseudo­
peptide backbone (Pi ' - P3'/P4') which are important for gelatinase binding and 
discriminate against other enzymes. Finally this information is summarised in the 
form of an inhibitor model based on crystal structure data.
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5.2 : Results
5.2:1 The Design of Selective Gelatinase inhibitors from experimental SARs
A series of compounds were chemically synthesised of the form Z - Pi ' - 
P2‘ - P3' in which Z represents a zinc binding ligand and Pi ', P2' and P3 ' align 
with the corresponding S i', S2' and S3' substrate binding sites of the enzyme. 
SARs were then constructed to allow the contribution of each inhibitor side-chain 
to be examined. Inhibitor efficiency, expressed as Ki's, was determined using 
DnpPLGLWAR. Particularly active gelatinase-A inhibitors (Ki < 0.05 nM) were 
also analysed using the more sensitive substrate, QF24.
Mechanistic studies have revealed that many of the compounds exhibit 
time-dependent inhibition at concentrations used for Ki determination. An 
example of this will be presented later (section 6.2:2 {c}). In order to minimise the 
effects of time-dependent Inhibition, enzymes were routinely pre-incubated for up 
to 4 hours in the presence of inhibitor, prior to the addition of substrate. Apparent 
Ki's (K iapp) were determined from steady-state rates as described in Chapter 2 . 
Ki's were determined using the relationship, Kiapp = Ki(1 + ^/Km) (competitive 
inhibition). Since, collagenase and stromelysin assays were performed under 
conditions of 8 «  Km, Kiapp is equivalent to the true Ki. A Km value of 70 pM was 
determined for the hydrolysis of DnpPLGLWAR by gelatinase-A (Chapter 3) and 
substitution of this value in the above equation permits Kiapp values to be 
converted to Ki's. Hydrolysis of QF24 by gelatinase-A was monitored 
continuously using a substrate concentration significantly lower than the Km- 
Data was then analysed as described in Chapter 2 .
(i) Analysis of the zinc binding group (Table 5.1)
A variety of compounds with modifications of the zinc binding ligand were 
synthesised by the Celltech Chemistry Department. Ki values were established 
as described above and Table 5.1 shows the results for a representative 
selection of these inhibitors.
Compounds with a hydroxamic acid (-CONHOH) ligand (CT572, CT921, 
CT471 and CT989) proved to be far more effective against all test enzymes than 
inhibitors with alternative ligands. The rank order potency for gelatinase-A and 
stromelysin is in the order of -CONHOH »  -COOH > -P0(0H)2 »  -SH. Only
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the presence of hydroxamic acid produced sub-micromolar inhibition of 
collagenase. In some cases substitution of -CONHOH with -COOH did appear to 
improve selectivity for gelatinase-A over coiiagenase (compare CT921 {11,500} 
and CT876 (22,322)) but this relationship was not consistent for ail series 
studied. Similarly, phosphonic acid ligands had no consistent effect on the SARs 
for each enzyme. In all cases activity against gelatinase-A was substantially 
reduced in comparison to the corresponding hydroxamic acid inhibitor. 
Replacement of the hydroxamic acid with a thiol group (CT572 , CT730, 
respectively) caused a dramatic loss in potency against gelatinase-A in 
particular. Selectivity was also abolished suggesting that the thiol was not 
interacting with the zinc either as a consequence of poor positioning or of 
oxidation. This is substantiated by the observation of a reduced Ki after complete 
removal of the zinc binding ligand (CT1466). Removal of the zinc-binding ligand 
reduced activity by the order of 10^ to 10® over the corresponding hydroxamate 
(CT989). Nonetheless, the Ki value of 2.67 pM for CT1466 is much lower than 
the Km of any published peptide substrate indicating a reasonable fit of the 
peptide side-chains into the binding pockets of the enzyme.
The significant increase in efficiency caused by the presence of the 
hydroxamate ligand is consistent with the observations of other investigators 
(reviewed in Johnson et a/., 1987). In contrast to the results presented above, 
highly efficient thiol inhibitors of collagenase have also been described but these 
invariably have an isobutylsuccinyi group at the position.
(ii) Modifications of the Pi' position (Table 5.2)
The structures of most current MMP inhibitors have evolved from 
compounds which were based on amino acid residues bordering the site on 
collagen which is cleaved by coiiagenase. The Pi ' position of collagen is 
occupied by leucine or isoleucine and there is evidence that the preference of 
collagenase for these residues extends to substrate based inhibitors (reviewed in 
Johnson et al., 1987). Collagen is, however, resistant to cleavage at this position 
by any other member of this family and indeed coiiagenase only hydrolyses this 
bond with the aid of a non-cataiytic element provided by its C-terminal domain. 
Preliminary studies identified this position as a target for building gelatinase-A 
selectivity over collagenase. Early SAR data was generated by using stromelysin 
rather than gelatinase-A but the two enzymes are predicted to possess similar
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Table 5.2
Modifications of the P i’ Position of Hydroxamate inhibitors
Activity /  Ki [nM ] 
GL-A SL CL
7.80.3 25.3435
15.10.54 19.1539
6182.24 77466
2030.06 8.3471
200 15,000 30,000574
o. o 415338743
O H
44 94,000 60,000763
9210.08 8.2921
1,5300.06 4.21043
5,1200.1 5.41044
2,4400.03 7.31071
F
,F
5,0000.31291
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binding pockets based on their substrate specificity. Compounds with a range of 
modifications at the Pi ‘ were analysed by measuring their ICso's for stromelysin 
using a [14c]-casein assay (section 2.2:6). These studies identified the 
hydroxamic acid inhibitor, CT435 (Table 5.2), as a lead compound. CT435 
possesses a cyclohexylalanine at the Pg' position, phenethyl amide at the P3' 
position and a residue based on leucine (isobutyl) at its Pi" site. Analysis of this 
inhibitor using peptide assays showed it to be highly effective against gelatinase- 
A (Ki = 0.18 - 0.3 nM), 25 fold less potent on collagenase (7.8 nM) and 75 fold 
less potent on stromelysin (25.3 nM). Extension of the P f  hydrocarbon chain to 
C5 (CT539) had little effect on either affinity or selectivity for gelatinase-A 
although some activity against collagenase was lost.
A phenethyl group was introduced (CT466) into the P i' position, based on 
the observation that the gelatinases and stromelysin hydrolyse peptide bonds on 
the amino side of aromatic amino acids during auto-catalysis. Surprisingly, 
affinity for all the enzymes was reduced, although there was a significant 
increase in selectivity for both gelatinase-A and stromelysin over collagenase. 
This latter observation is consistent with the substrate data. Shortening the 
hydrocarbon chain by a single carbon further accentuated this finding (data not 
shown). Extension of the hydrocarbon chain to produce a phenylpropyl group 
(CT471) highlighted differences between collagenase and the other enzymes at 
this position. The affinity for gelatinase-A was significantly improved (0.06 nM) as 
was that for stromelysin (8,3 nM) but inhibition of collagenase remained relatively 
poor (203 nM). Interestingly, replacement of phenylpropyl with a phenylbutyl 
reduced activity on gelatinase-A, thereby, defining the length of the S f  channel 
(data not shown).
In order to probe the nature of this interaction additional modifications 
were evaluated. Substitution of the phenyl group with naphthalene (CT574) 
resulted in a reduction in activity of greater than 1000 fold for all the enzymes 
which indicates an upper size limit for the width of this pocket. Incorporation of 
carboxylate functions based on glutamic acid (CT743 and CT763) was clearly 
detrimental to inhibitor activity against all test enzymes although the resulting loss 
in activity was less marked for gelatinase-A which is known to cleave gelatin 
peptides at glutamic acid (Seltzer et a/.,1990).
The aryl group is a potential substrate for enzymes of the cytochrome P450 
family and therefore a range of substitutions on the aryl ring was tested. In
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general, substitutions at sites other than the para position were detrimental to 
activity on gelatinase-A (data not shown). Inclusion of a toluyl group (CT921) at 
this position improved selectivity over collagenase. In later inhibitor series this 
modification also resulted in a minor improvement in activity against gelatinase-A 
(data not shown). Selectivity against collagenase was further enhanced by 
increasing the size of the group at the para position (CT1043, CT1044 and 
CT1071). Substitution with chlorine (CT1071) or methoxy (CT1043) groups 
consistently produced the most highly active inhibitors in each series whereas no 
pattern emerged for other groups such as fluorine (CT1291). Modifications along 
the hydrocarbon chain were examined using the CT1746 series. Interruption of 
the chain with oxygen was tolerated to some extent by gelatinase-A, whereas, the 
introduction of branching lead to a reduction in activity dependent on the number 
and position of the additional methyl groups (data not shown).
The intolerance of collagenase to extensions of the P i' chain and in 
particular to the addition of an aryl group is evidence that the pocket is closed off. 
The gelatinases and stromelysin on the other hand facilitate such a group and, 
moreover, the improved activity of these inhibitors indicates the presence of 
additional interactions of the aryl group with the enzyme's binding pocket. These 
enzymes may be visualised as possessing a large hydrophobic space beyond 
the S i' channel which may be present in collagenase but is inaccessible to 
inhibitors. Activity against gelatinase-A is consistently 50 - 100 fold higher than 
against stromelysin although the SAR for the two enzymes is similar suggesting 
that they possess similarly shaped substrate binding pockets.
(iii) Modifications of the Pg' position (Tabie 5.3)
The Pg' position was first explored by measuring Ki's for a range of 
compounds which were based on CT420 which has the (8)- stereoisomer of 
isobutyl at this site. Replacement of this group by the leucine mimic, 
cyclohexylalanine (CT435) did not effect activity on collagenase but resulted in a 
10 fold increase in affinity for gelatinase-A and a 2 fold increase for stromelysin. 
The presence of this group conferred both improved activity and selectivity for 
gelatinase-A and formed the basis for the design of highly active, selective
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Table 5.3
Modifications of the P2* Position of Hydroxamate Inhibitors
Activity /  Ki [nM ] 
GL-A SL CL GL-B
420 2.85 46 7.6
435 0.33 25.3 7.8
455
0.73 20.2 5.5493
1408
CH3 0.02 9.91 84.4 0.141622
CH3 <0.01 2.17 35.8 0.071670
1694
a
CH3 <0.01 5.3 26.3 0.051711
CH3 <0.01 5.92 20.7 0.051713
o—s=o
1727
H
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inhibitors of this enzyme. A variety of alternative groups were tested. 
Incorporation of a tryptophan at this position has been shown by several groups 
to be potency enhancing for collagenase (Kortylewicz etal., 1990) but this did not 
prove to be the case in the CT420 series (CT455). Affinity for collagenase was 
slightly reduced whereas affinities for gelatinase-A and stromelysin were similar 
to those produced by cyclohexylalanine. Inclusion of a naphthalene group at this 
position (CT493) reversed this process by restoring activity against collagenase 
and reducing activity on gelatinase-A and stromelysin. The effect of 
cyclohexylalanine replacement was also examined in the CT14Q8 and 1694 
series. Replacement by a tertiary-butylglycine (BUG) caused a slight reduction in 
gelatinase-A, gelatinase-B and stromelysin potency whilst activity against 
collagenase was significantly enhanced (CT1622). In this series tryptophan 
(CT1670) improved affinity for gelatinase-A, stromelysin and also collagenase. 
The introduction of penicillamine based analogues of tertiary butylglycine to the 
CT1694 series produced a slight improvement in affinity for both gelatinases, 
reduced affinity for stromelysin and little effect on collagenase (CT1711, 
CT1713). Addition of a large Pg' side-chain to produce CT1727 was well 
tolerated by all the enzymes except for collagenase.
A broad range of groups is tolerated at the Pg' position. Both the size and 
variety of side-chains accepted at this site indicate that the corresponding 
enzyme pocket is orientated away from the body of the enzyme and towards the 
solvent.
(iv) Modifications of the P3' position (Table 5.4 )
Early work on the P3' site focused primarily on modifications of CT383, 
which had an isobutyl group occupying the P i' position. Removal of the C- 
terminal amide from CT383 produced compound CT420. This modification, 
which removes a chiral centre, resulted in a significant improvement in inhibitory 
activity against collagenase and gelatinase-A and a more modest enhancement 
of stromelysin inhibition. The phenethylamide group was then incorporated into 
the active CT435 series which have cyclohexylalanine at the P2' site. Complete 
removal of the P3 ' group (CT478) was detrimental to activity against all the 
enzymes in particular stromelysin and collagenase. The phenethylamide group 
could, however, be replaced with a pyridyl moiety attached to an equivalent 
hydrocarbon chain (CT480), without affecting the affinity for any of the enzymes.
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Table 5.4
Modifications of the P3’ Position of Hydroxamate inhibitors
383 V
420 V
435
478 / -
480 S o
505 V )
471
S o
543
962 S o
546
550 r ^ O S o
570
S o
572
S o
715 ‘X )
733 r j - O
Activity /  Ki [nM ] 
GL-A SL CL
'NHg
w
H
OH
VV
. 0
r '
/
CH3
\
33 129 303
2.8 45 7.6
0.33 25.3 7.8
6.32 902 600
0.33 27 11
327 15.000 7,400
0.06 8.3 203
0.1 24.8 210
0.04 9.4 535
0.06 17.7 225
0.11 38 393
0.59 81.5 942
0.02 5.92 150
0.08 34.5 231
2.82 1,020 16,700
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Substitution of this group by a hydroxyl (CT505), produced a 50 - 100 fold loss in 
activity against all the enzymes. The reduction in activity was significantly greater 
than that resulting from complete removal of this group (CT478) and may indicate 
that the presence of the hydroxyl distorts the inhibitor structure. The intolerance 
of the enzymes to P3' hydroxyl groups is confirmed by studies conducted on later 
series of compounds (data not shown). A broad selection of P3' modifications 
was tested in the CT471 series of compounds which all possess a phenylpropyl 
group at the P i' position. It is evident from these studies that a range of side- 
chains of varying charge and size are tolerated at this position by all the 
enzymes. Examples include CT543 (morpholino), CT546 (ester), CT550 
(dimethylamino), CT572 (arylsulphonamide) and CT715 (N-methylamide). An 
exception to this is provided by the arylsulphonic acid of CT570 which causes 
some reduction in activity against all the enzymes. Comparison of CT962 with 
CT543 shows that extension of the hydrocarbon chain by a single carbon can 
improve activity against gelatinase-A and stromelysin and also improve 
selectivity over collagenase.
The large variety of groups tolerated at this position, by gelatinase-A in 
particular, is exemplified by CT733 which has a biotin label attached to an 
extended hydrocarbon chain. Despite the large size of this group the Ki value for 
gelatinase-A was relatively low (2.8 nM). Indeed further extension of the chain 
produces an inhibitor with a Ki of 0.08nM against gelatinase-A (data not shown).
The results indicate that, like the S2* subsite the S3' is orientated towards 
the solvent. For this reason a range of large charged and uncharged groups are 
tolerated by the enzymes.
(v) Inhibitor selectivity for a range of zinc metalloproteinases (Tabie 5.5)
A wide variety of zinc metalloproteinases are present in the body in 
addition to the MMP family. Many of these enzymes are membrane-bound 
peptidases such as aminopeptidase N (AP-N) and the carboxypeptidase, 
endopeptidase-dipeptidyl A (ACE). Their location on exposed surfaces such as 
the microvilli of the gut and kidney, endothelial cells and the plasma membrane 
of lymphocytes make them easily accessible to orally ingested and circulating 
xenobiotics. Representative compounds (Fig. 5.1) were tested against a range of 
zinc metalloproteinases which included gelatinase-A, gelatinase-B, stromelysin, 
collagenase, matrilysin, ACE and AP-N. MMP assays were performed
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using DnpPLGLWAR. ACE activity was monitored continuously using the 
furylacryloyl - F -F- G substrate (X328) and AP-N activity was monitored using the 
substrate L-Leucine-p-nitroanillde (X405). The results of these studies are 
presented in Table 5.5
None of the inhibitors exhibited any significant activity against the 
carboxypeptidase, ACE. This result is consistent with the requirement of 
carboxypeptidases for a free C-terminal carboxylate on their substrates.
Compounds with isobutyl occupying the P f  site (CT435, CT1847, Ro31- 
9790) were more potent inhibitors of AP-N than those with arylpropyl groups at 
this position. CT435 exhibited an IC50 of less than 1pM for AP-N which was 
comparable to that of actinonin, a natural inhibitor isolated from actinomycetes 
(data not shown). This result is compatible with the observation that the two 
inhibitors possess common structural features (Fig. 1.8). CT1847 and Ro31-9790 
do not inhibit AP-N as efficiently as CT435 despite the presence of a conserved 
P1 ' group. This may reflect a preference of AP-N for a bulky P3' residue.
Matrilysin does not tolerate an aryl group at the P i' position. The most 
active matrilysin inhibitors CT435, CT1847, Ro31-9790 and BB94 all have an 
isobutyl group at this site. A range of Pi ' arylpropyl inhibitors represented by 
CT1166 all possess micromolar Ki's against matrilysin. An exception to this 
finding is provided by CT1746 which has a Ki of 136 nM. This indicates that 
features in addition to the Pi ' site are also responsible for determining activity on 
matrilysin.
The Ki values for these inhibitors against collagenase, stromelysin, 
gelatinase-B and gelatinase-A confirm and extend earlier observations. A 
leucine-like Pi ' site is an essential requirement for efficient inhibition (low 
nanomolar) of collagenase (CT435, CT1847, Ro31-9790 and BB94). A range of 
substituents is tolerated at the P2' position although groups larger in size than the 
amino acid valine are generally preferred (data not shown). Collagenase prefers 
small groups such as N-methylamide at the P3' which distinguishes it from the 
gelatinases and stromelysin. The most active collagenase inhibitors, CT1847, 
Ro31-9790 and BB94 all possess such a group. CT435 on the other hand 
possesses a phenethylamide in this position. This causes a reduction in activity 
compared to CT1847 but the flexibility of this group and the absence of a chiral 
centre may contribute to a significantly better interaction with the enzyme than
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that provided by the phenylalanine amide of the parent compound, CT383 (Table 
5.4).
As a general rule affinity for stromelysin follows a similar SAR to that 
observed for gelatinase-A and gelatinase-B. The inhibitors, CT1746 and CT962 
for example, differ at all positions but exhibit very similar SARs for all the test 
enzymes. Whilst selectivity data indicates that these three enzymes have very 
similar Si', S2' and S3' binding pockets, absolute inhibitor potency varies in the 
order; gelatinase-A ( 5 - 10  fold) > gelatinase-B (20 fold) > stromelysin.
The British Biotechnology inhibitor BB94 is interesting in that it possesses 
a thioether linked group at the a-carbon position. The a-carbon substituent 
appears to promote a significant enhancement of potency against all the MMPs 
tested. Despite the absence of a Pi ' arylpropyl group, it is highly active against 
the gelatinases and stromelysin and the compound is unusual in that the relative 
activities against gelatinase-A and gelatinase-B are reversed. Additionally, the 
thioether moiety significantly improves activity against collagenase and matrilysin 
relative to structurally similar inhibitors lacking this group.
The structure-activity relationship for inhibition of MMPs by hydroxamates 
is summarised in Fig. 5.2 (A). The model is based on the crystal structure of a 
related MMP inhibitor and, therefore, the orientation of the side-chains is 
probably accurate. The corresponding CPK model is presented in Fig. 5.2 (B).
In summary, the presence of phenylpropyl at the Pi ' confers selectivity and 
potency for gelatinases-A and B and stromelysin and is not tolerated either by 
collagenase and matrilysin or by other zinc metalloproteinases, including AP-N. 
The S2' sub-site of the enzyme appears to be orientated towards the solvent and 
can tolerate a large variety of inhibitor side-chains. A range of substituents is 
tolerated at the P3' site although the increased activity observed on extension of 
the alkyl chain may be a result of interactions away from the S3' pocket. Whilst 
the most potent gelatinase-A inhibitors such as CT989 and CT1166 possess very 
large groups at this position, collagenase appears to prefer a much smaller 
substituent such as N-methylamide. This class of inhibitors is not recognised by 
the carboxypeptidase, ACE.
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5.3: Discussion
Inhibition constants (Ki's) were determined against gelatinase-A, 
stromelysin and interstitial collagenase for a range of inhibitors of the general 
structure Z -P i'-P g '-P s ' where Z represents a zinc binding ligand (generally 
hydroxamic acid) and Pi ' - P3 ' align the inhibitor with corresponding substrate 
binding sites (S i‘ - S3 ') on the enzyme. Additional data was also presented for 
the inhibition of gelatinase-B, matrilysin, aminopeptidase-N and peptidyl- 
dipeptidase A. SARs were used to define the optimum chemical groups 
responsible for activity and selectivity for gelatinase-A.
The results of these studies will be discussed in the light of new data 
provided by the 3-D structures of several MMPs which have been determined by 
crystallography (Lovejoy et al., 1994a; 1994b; Bode at al., 1994; Borkakoti at al., 
1994; Stams at al., 1994) and NMR studies (Gooley at a!., 1994).
Zinc binding ligand
This study shows that inhibitors with zinc binding ligands (hydroxamic acid 
and carboxylic acid) capable of bidentate binding were considerably more active 
against gelatinase-A than inhibitors with monodentate ligands (sulphydryl). 
Furthermore, hydroxamates were at least 100 fold more active than the 
corresponding carboxylate for all the test enzymes. This indicates that 
hydroxamic acid forms an additional bond with the enzyme and from our 
knowledge of the consequences of modifying the NH group (data not shown) this 
was presumed to be the point of interaction. This has recently been confirmed by 
Borkakoti at al. (1994) who, having co-crystallised interstitial collagenase with a 
hydroxamate inhibitor, found that the NH had the potential to hydrogen bond to 
the carbonyl of an alanine eleven residues downstream of the zinc box. This 
interaction may be responsible for the well documented potency of hydroxamic 
inhibitors against MMPs.
P1 ' modifications
Requirements for effective S i' binding were identified by using SAR data 
provided by a series of inhibitors with invariant P2 ' and P3 ' side-chains (Table 
4.2). Leucine-like groups were tolerated by all the test enzymes but replacement 
by an aryl group produced a significant improvement in the selectivity and
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efficiency of hydroxamate inhibitors for the gelatinases and stromelysin over 
collagenase and matrilysin. This result is consistent with the ability of the 
gelatinases and stromelysin to cleave both peptides and macromolecules on the 
N-terminal side of phenylalanine. Interstitial collagenase, on the other hand, 
cleaves only at leucine or isoleucine on collagen. Surprisingly, introduction of a 
side-chain which resembled phenylalanine (phenethyl) reduced activity (CT466) 
against gelatinase-A and stromelysin but the substrate data was borne out when 
the chain was extended. Propyl was the optimal hydrocarbon chain for both the 
gelatinases and stromelysin. The results of SAR analysis indicate that the 
enzymes possess a narrow hydrophobic channel at this site. The pocket 
broadens to accept an aryl group in the gelatinases and stromelysin but is 
blocked in collagenase and matrilysin. This conclusion can be rationalised by 
comparing the primary amino acid sequence of each enzyme with the published 
3-D structures. In all the enzymes, apart from interstitial collagenase and 
matrilysin, a leucine four residues down-stream of the zinc box enters the S i ' 
pocket but is directed away from the zinc. In interstitial collagenase this residue 
is replaced by the larger arginine residue which effectively closes off the pocket. 
Matrilysin has a tyrosine in this position which may partially block the pocket (see 
Fig.1.11).
P2' modifications
The P2 ' position may be occupied by a variety of groups of differing size 
and charge. The first significant progress was made when leucine (CT420) was 
replaced by cyclohexylalanine, a leucine mimic used extensively in the renin 
inhibitor area. As a result of this modification, activity against gelatinase-A was 
increased by an order of magnitude, there was a more modest improvement 
against stromelysin and collagenase was unaffected. This group, therefore, 
satisfied the criteria of activity and selectivity for gelatinase-A and became a 
consistent element in the structure of future potent in vitro inhibitors. As a rule 
groups smaller than leucine were less effective but no upper size limit was 
apparent. In later studies the tolerance of gelatinase-A to modifications at this 
subsite provided scope for altering the physiochemical properties of the molecule 
(eg. CT1694). These studies show that the P2 ' side-chain is orientated away 
from the bulk of the enzyme towards the solvent. A limited degree of potency and 
selectivity was achieved at this position but beneficial modifications were difficult
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to predict from SARs alone. SAR data from other groups substantiates these 
results (Chapman et al., 1993). Fig. 1 . 1 1  shows that a shallow subsite is formed 
by the side-chain of a single non-conserved residue, thereby confirming the SAR 
results.
P3' modifications
The first significant improvement in inhibitory activity against all the test 
enzymes was discovered upon removal of the C-terminal amide from P3 ' 
phenylalanine (CT383). The resulting phenethylamide (CT420) enhanced 
inhibitor efficiency by an order of magnitude for gelatinase-A and collagenase 
with a more modest improvement for stromelysin. This position was identified as 
a potential site for modifying the water solubility of the inhibitors. Accordingly, an 
extensive range of substituents were synthesised including, amides, N- 
methyamides, carboxylic acids, morpholino's, hydroxyls, amines, sulphamylureas 
and arylsulphonamides. Amongst these only hydroxyls were not tolerated 
(CT505). Sulphamylurea (CT1166) and arylsulphonamide (CT989) are the most 
active inhibitors of gelatinase-A described to date. Both possess Ki's significantly 
below 10 "11 M and indeed the Ki of CT1166 has been estimated to be 10"12 M. 
The observation that biotinylated molecules were recognised by the biotin 
specific agent streptavidin indicates that the P3 ' resides at or near the surface of 
gelatinase-A.
Although collagenase can accept large extended groups at this position 
most active inhibitors have a small substituent such as methylamide. This is not 
unexpected as the corresponding residue in collagen is glycine.
There are two possible explanations for the results described above.
1 / The S3 ' subsite is similar to the 8 2 ' pocket in being orientated towards the 
solvent. The wide variety of side-chains tolerated by the enzyme at this position 
provide some evidence for this.
2/ The S3 ' pocket is small and hydrophobic as indicated by SARs for 
collagenase. Extension of the hydrocarbon chain which was a feature of highly 
active inhibitors may effectively by-pass the S3 ' subsite.
NMR studies on the catalytic domain of neutrophil collagenase confirm that the 
first hypothesis is correct (Stams ef a/.,1994).
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Selectivity for MMPs
Lack of selectivity may result in toxicity and there are a range of reiated 
zinc-dependent metaiioproteinases in the body. Accordingly, a selection of 
hydroxamic acid inhibitors were tested against an aminopeptidase (AP-N) and a 
carboxpeptidase (ACE) in addition to five MMPs. None of the test compounds 
showed any inhibitory activity against ACE. This is not unexpected as the 
specificity of this enzyme for the C-terminus of peptides is determined by its 
interaction with the free carboxyiate group of the substrate. It does not hydrolyse 
C-terminally blocked peptides for instance. Surprisingly, compounds with P f  aryl 
showed relatively poor activity against AP-N aithough the enzyme hydroiyses 
substrates with a corresponding phenylaianine. Potent inhibitors of such 
peptidases do have a phenylalanine at this position which indicates that the lack 
of inhibitory activity is a consequence of extending the hydrocarbon chain. In this 
study compounds with a Pi ' aliphatic group (CT435) inhibited AP-N with ICso's 
in the nanomoiar range. Comparison of the resuits for CT435, CT1847 and 
Ro31-9790 indicate the presence of a significant P3 ' interaction. A simiiar 
inhibitor profiie has been reported for neprilysin and mouse meprin, a non-MMP 
member of the metzincin famiiy (Dr. A. Kenny, personai communication).
BB94 is unique amongst these inhibitors in possessing an a-carbon 
substituent. Its presence in the (S)- form augmented the activity of corresponding 
isobutyl inhibitors against a range of MMPs. This might arise from it extending 
into the ST space which is occupied by an aryi ring in geiatinase inhibitors. This 
idea is not consistent, however, with moiecuiar modeliing studies based on 
collagen (Johnson et a/., 1987) which indicate that groups at this position point 
away from the ST pocket. This class of inhibitor is yet to be co-crystaiiised with 
an MMP and so the role of the a-carbon side-chain remains unciear.
In summary, selective, picomoiar inhibitors of geiatinase-A have been 
deveioped with the aid of SAR data. The hydroxamic acid zinc binding iigand 
and the alignment of the pseudo-peptide side-chains with the substrate 
recognition sites on the enzyme both contribute to the high strength of binding. 
On the enzymes, the ST pocket is the major site of substrate / inhibitor 
recognition and therefore is the primary target for obtaining potency and 
selectivity. Other prime-side pockets are shallow which aliows scope for 
manipuiating the physicochemicai nature of inhibitors to provide improved in vivo 
characteristics.
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The construction of SARs on isoiated enzymes are only one aspect of 
inhibitor design. In Chapter 7 the relationship of structure to in vivo activity wili be 
investigated.
152
§
■ 8
CHAPTER 6
KINETIC ANALYSIS OF INHIBITOR BINDING 
6.1 : Introduction
Chapter 5 described how SARs can be used to discover potent, selective 
inhibitors. The data was presented iargely in the form of Ki's which presumes 
reversibility. Information derived from Ki's may be extended by analysing the 
components of this term, nameiy the rates of association and dissociation of the 
enzyme-inhibitor complex. The following study examines mechanisms of MMP 
inhibition and the nature of the enzyme-inhibitor interaction.
The reiationship between the experimentaily determined apparent Ki of a 
reversible inhibitor and the true Ki varies according to whether the inhibitor is 
competitive with substrate, uncompetitive or non competitive. The use of robust 
soluble peptide assays allows these properties to be determined. Conversely, 
information on the behaviour of inhibitors on soiubie substrates in vitro may not 
necessarily extrapolate to the in vivo situation. Selected inhibitors were, 
therefore, aiso tested for their abiiity to inhibit gelatinase-A in a more natural 
environment provided by geiatin, a physioiogical substrate.
Inhibitors of MMPs possess many of the characteristics of the ACE and 
neprilysin inhibitors including Ki's in the range of 10-8 - 10-12 m. As a 
consequence of this high affinity these inhibitors exhibit tight-binding inhibition 
rather than ciassical reversibie inhibition (section 1.4:5). Since the inhibitor 
concentration must be varied around its Ki during any inhibition experiment it is 
likely that inhibitor concentrations will be equivalent to that of the enzyme. 
Accordingly, the assumption that the free inhibitor concentration is equal to the 
total inhibitor concentration is not vaiid and therefore a steady-state treatment of 
the results is inadequate. A general steady-state rate equation that ai lows for the 
mutual depletion of inhibitor and enzyme was derived by Morrison (1969). The 
theory was further extended by Cha (1975, 1976) who considered the situation 
where the rate of establishment of equiiibrium between free enzyme, inhibitor 
and enzyme-inhibitor compiex is siow relative to the rate of substrate conversion.
Apparent Ki’s (Kiapp) may be determined for such inhibitors using 
equilibrium methods by preincubating the inhibitor and enzyme soiution untii 
equilibrium has been established. The reaction may then be started by the
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addition of substrate. The Kiapp can be determined by a non-iinear regression of 
the equation for tight-binding inhibition described by Morrison and Walsh (1988) 
(section 2.2:4). If the substrate concentration is significantly lower than the Km 
then competition for the enzyme is negligible and the Kiapp approximates to the 
true Ki.
Additional information can be obtained from studies of the pre-steady-state 
kinetics. The slow establishment of equilibria between enzyme, inhibitor and 
enzyme-inhibitor complexes leads to time-dependent inhibition. Such ‘slow- 
binding inhibition’ commonly arises from a slow off-rate (koff) whilst the on-rate 
{kon) may be fast or slow. This form of inhibition is a common property of 
inhibitors with low Ki’s In these circumstances when the inhibitor concentration [I] 
is varied in the region of its Ki, values for the pseudo first order rate constant for 
the formation of the enzyme-inhibitor complex (ki\) (see page 36) and the rate 
constant for the dissociation of the compiex (kg) would be low. The low 
association and dissociation rates would result in slow-binding inhibition even 
though the former is of a magnitude expected for a diffusion limited reaction.
Mechanisms to account for slow-binding inhibition were discussed in 
Chapter 1 (section 1.4:5). Essentially, the two simplest mechanisms to account 
for any complex formation are mechanism (A) simple bimolecular collision or (B) 
a pathway that includes intermediates. They may be distinguished by the 
dependence in mechanism B of the initial steady-state velocity (Vq) on [I]. 
Additionally, ko^s (a pseudo-first order rate constant, equation {4}) exhibits 
saturation at high Inhibitor concentration, in practice, the two mechanisms may 
be difficult to distinguish. Firstly, large errors may be introduced into the 
measurement of by excessive reactant mixing times. This is particularly 
evident at the comparatively high inhibitor concentrations required to determine 
the Ki relating to the initial ‘collision’ complex. Conversely, it is apparent from the 
general equation for ciassical linear competitive inhibition (page 35) that the term 
[H/Ki becomes insignificant when [I] «  Ki in which case Vq is invariant and 
mechanism B degenerates to mechanism A.
The following pre-steady-state analyses were performed under the 
limitations described above which favour mechanism A although preliminary 
studies on the hydroxamate inhibitor CT435 showed that Vq was not significantly 
reduced in the presence of increasing concentrations of inhibitor. Analyses of the 
pre-steady-state kinetics of several inhibitors were performed on the progress
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curves obtained by incubating a range of inhibitor concentrations with a fixed 
concentration of enzyme. These resuits are then discussed with reference to the 
contribution of the inhibitor side-chains to the rates of association and 
dissociation with gelatinase-A.
The studies described above do not provide information on how 
gelatinase-A binds to a hydroxamic acid inhibitor. It is possible, for example, that 
the nitrogen atom of hydroxamic acid binds to the oxygen of the glutamic acid 
(E375) and that this is responsible for the greater potency of such inhibitors over 
corresponding carboxylate inhibitors. Recent crystal log raphic data, however, 
supports an alternative hypothesis in which the NH forms an interaction with a 
peptide backbone carbonyl group (Borkakoti ef a/., 1994; Stams ef a/., 1994) (see 
Fig. 1.11). Moreover, the absence of such an interaction has been described for 
the zinc endopeptidase, neprilysin (Devauit ef a/., 1988). In this study, a 
cataiytically compromised mutant geiatinase-A (geiatinase-A{E375_>D})  ^ was 
used to examine the contribution of this amino acid to the high affinity of 
hydroxamate inhibitors.
TIMPs are unable to bind to the catalytic domain of MMPs which have an 
intact propeptide. Low moiecuiar mass synthetic inhibitors may, however, diffuse 
into the catalytic site as a consequence of their small size. This would not be a 
desirable property, since it would lead to removal of inhibitor from the circulation 
by already inactive proenzyme. Two independent methods were used to analyse 
this property.
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6.2: Results
6.2:1 The kinetics of geiatinase inhibition
(I) Inhibitor Mechanism
Methods for the evaluation of inhibition constants (Ki's) are dependent on 
the mode of inhibition. Because the compounds are structurally related to the 
substrate early data were analysed on the assumption that the enzyme-inhibitor 
interaction was both reversible and competitive. The design of more robust 
peptide assays has subsequently permitted these parameters to be easily 
investigated. A knowledge of the basic mechanism of the inhibitor-enzyme 
interaction is also essential for examining the kinetics of association and 
dissociation and these studies will be described later.
(a) Reversibility
The reversibility of gelatinase-A inhibition by CT1746 was tested as 
follows. Enzyme-inhibitor solution (0.05 nM) was tested either (A) following a 3 
hour preincubation at full assay volume to permit the attainment of equiiibrium or 
(B) following a 3 hour preincubation of a concentrated (5 nM) solution of enzyme 
and inhibitor. After 3 hours, the QF24 substrate was added to the mixtures to 
initiate the reaction. Equivalent assays, performed in the absence of inhibitor 
showed that the attainment of a steady-state rate was distinct and measurable 
and not due to loss of linearity resulting from substrate depletion, product 
quenching or enzyme instability.
CT1746 preincubated with geiatinase-A in a full volume of buffer (A) elicited a 
steady-state rate of 8.3 FU/min (Fig. 6.1). Sample B produced rates of 0.4 FU/mln 
and 8.2 FU/min at 1 minute and 25 minutes, respectively. These results indicate 
that the interaction between geiatinase-A and CT1746 is fully reversible.
(b) Competitive Inhibition of matrix metailoproteinase inhibitors
Competitive inhibition is characterised by an increase in Kiapp with
increasing substrate concentration. From the relationship for competitive
Kiinhibition Ki^ pp = Ki + s. w e  can see that there is a linear dependence of Kiapp 
and substrate concentration with intercepts of Ki and Km- Geiatinase-B
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Figure 6.1 Reversible inhibition of geiatinase-A
by CT1746
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CT1746 and gelatinase-A were mixed in peptide assay buffer to a final 
concentration of each of 5 nM. An aliquot (25 pi) was then removed to 2.465 ml 
of the same buffer, either immediately (A) or after a 3 hr incubation at room 
temperature (B). Sample A was incubated for 3 hrs to allow the enzyme and 
inhibitor to attain equilibrium. Following incubation, 10 pi of QF24 (final 
concentration, 1.4 pM) was then added to each sample to start the reaction. 
The rate of substrate hydrolysis was measured as described in Chapter 2.
157
Figure 6.2 Mode of Inhibition of CT1847
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Gelatinase-B (0.03 nM) was Incubated with a range of Dnp-PLGLWAR
concentrations in the presence of 0 -100 nM of CT1847. Apparent Ki's (Kiapp)
were determined for each substrate concentration using the equation for tight-
binding inhibition (Morrison and Walsh, 1988) (Chapter 2). From the relationship
Kifor competitive inhibition Ki^p =Ki + s - ^  a plot of Kiapp versus inhibitor
concentration will intercept the y-axis at the Ki (0.83 nM) and the x-axis at - Km 
(3.9 pM).
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was used in preference to gelatinase-A for this purpose since the Km of the latter 
for DnpPLGLWAR approaches the limit of solubility of the substrate.
Kiapp s were determined for GT1847 (Fig. 5.1) against gelatinase-B at a 
range of DnpPLGLWAR concentrations (6.25 - 100 |iM). Results were analysed 
by the tight-binding method of Morrison and Walsh (1988). The resulting plot of 
Kiapp versus substrate concentration is presented in Fig. 6.2 It is characteristic of 
competitive inhibition with intercepts on the y-axis and x-axis, giving values of 
0.83 nM and 3.9 |xM for the Ki and Km, respectively.
(II) Inhibition of gelatinase-A (Table 6.1)
A kinetic study was carried out on selected compounds which represent 
lead molecules at different stages of the geiatinase inhibitor programme. The 
structures of these inhibitors are presented in Fig. 5.1. Inhibition of gelatinase-A 
was studied using several substrates and data were collected from both steady- 
state analyses and pre-steady-state analyses. IC50 values were calculated using 
gelatin in order to establish that inhibitors would be effective in a more 
physiological environment. These assays are described in detail in Chapter 2. 
Approximate Ki values (Kiapp) were determined using DnpPLGLWAR at a 
concentration of 20 fiM. Kiapp values were converted to Ki's using the 
relationship for competitive inhibition, = K/^1+ ^  j  where the Km for
gelatinase-A has been shown to be 70 p,M (Chapter 3). All detailed kinetic 
studies were undertaken using QF24 at a concentration of 1.4 p,M, which is 
significantly below the estimated Km.
(a) IC50 determination
IC50 studies using gelatin were limited by the sensitivity of the assay which 
required a gelatinase-A concentration of 0.5 nM. Under conditions where 
inhibitor concentration [I] ~ enzyme concentration [E] the following equations 
describe the influence of the enzyme and substrate concentration on the IC50 
value for a competitive inhibitor (Morrison and Stone, 1985). Rearrangement of 
the general equation for tight-binding inhibition (Henderson, 1972) gives.
1-"!
S+/C,= [E]+Ki V  (1)
Kr
where Vj and Vq are the respective rates in the presence and absence of inhibitor.
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Figure 6.3 inhibition of geiatinase-A action on gelatin by CT976: 
iC50 Determination
Gelatinase-A (0.5 nM) was incubated with [i4C]-gelatin (1 pM) for 100 
minutes at 26°C together with CT976 at concentrations ranging from 0 - 1000 
nM. Radioactivity remaining in the TCA supernatants (expressed as % 
inhibition of an enzyme alone control) was then plotted against Logio CT976 
concentration. The IC50 value was then determined using Enzfitter 
(Leatherbarrow, 1987). Each point represents the mean of three 
determinations.
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At an inhibitor concentration equivalent to the IC50, vi = vo/2, and this reduces to
Kn,
(2)
The concentration of gelatin In this assay approximates to the Km (1.2 p.M) (Table 
3.1) and thus,
IC» = f^ j^  + 2K-/ (3)
and in the majority of cases as Ki «  [E] the IC50 becomes equivalent to half the 
enzyme concentration i.e. titrates the enzyme. Accordingly, inhibitors that 
exhibited Ki's significantly below [E] using peptide substrates, (eg. CT962, 
CT989, CT1166 and CT1746) had IC50 values of < 1 nM. A typical IC50 curve for 
a less active inhibitor, the carboxylate CT976 (IC50 = 13 nM), is presented in Fig. 
6.2. From the above equation this corresponds to a Ki of 5.7 nM. This value is 
higher than the Ki determined using peptide substrates (0.45 - 0.9 nM) which 
suggests that the activity of MMP inhibitors is decreased in the presence of 
gelatin. Corresponding values for other Inhibitors (data not shown) confirm that 
the Ki is elevated about 10 fold in this assay. The most likely explanation for this 
finding is that, since geiatinase cleaves gelatin at multiple sites, the true substrate 
concentration is much higher than the gelatin concentration. Under these 
circumstances equation (3) becomes invalid.
(b) Steady-state analysis on peptide substrates
Ki values were calculated as described in section 2.2:4 by assaying for 
residual activity after a 3 - 4 hour preincubation of inhibitor and enzyme at 23°C 
in a full assay volume. The attainment of a steady-state rate was verified for 
CT435, which has a comparatively slow association rate, by also preincubating 
enzyme and inhibitor for 16 hours prior to substrate (QF24) addition and 
comparing the resulting Ki's determined under both sets of conditions. The Ki 
curve for CT435 after 4 hours preincubation is presented in Fig. 6.4. The KI value 
(0.18 nM) calculated from this curve is comparable to that produced after a 16 
hour preincubation period (0.25 nM ) indicating that 4 hours is sufficient time to 
attain equilibrium. This study also demonstrates that the enzyme is relatively 
stable for prolonged periods at low concentration, a property which is a 
prerequisite for accurate analysis of pre-steady-state kinetics. Table 6.1 shows Ki 
data for the DnpPLGLWAR substrate and for the QF24 substrate. Comparison of 
the Ki values generated from the two assays shows the former to be consistently 
higher which underlines the difficulty in analysing data from assays where
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Figure 6.4 The Determination of Kiapp for CT435 against gelatinase-A
Gelatinase-A (0.06 nM) was incubated at 23°C in peptide assay buffer 
(2.49 ml) together with GT435 at concentrations ranging from 0 - 1 0  nM. After 4 
hours, 10 pi of the substrate (QF24) was added to give a final concentration of 
1.4 p,M. Rates of hydrolysis were determined over the first two minutes. The 
apparent Ki (Kiapp) was determined using Enzfitter (Leatherbarrow, 1987) by a 
non-linear regression of the following equation;
2Eo.
Vo and Vs are the steady state rates of the reaction in the absence and 
presence of inhibitor, respectively. Et and It are the total concentrations of 
enzyme and inhibitor, respectively. Under conditions of S «  Km the Kiapp value 
approximates to the KI.
Figure 6.4 The Determination of Kigpp for CT435 Against Geiatinase-A
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[E] >Ki. The rank order potency, however, is similar for the two substrates. 
Comparison of these values with the corresponding ICso's emphasises the 
importance of determining Ki's to establish SARs for highly potent compounds.
(c) Pre-steady-state kinetics
Progress curves of the response of gelatinase-A to CT989 confirm that 
inhibition is time-dependent (see Fig. 6.6) and occurs at concentrations which are 
comparable to those of the enzyme. Progress curves were analysed by two 
procedures according to the inhibitor concentration range tested.
Method 1
CT435 (Ki ~ 0.2 nM) was studied under conditions in which inhibitor 
concentration was at least 10 fold higher than that of gelatinase-A. CT435 
concentrations were varied in the range of 0.5 nM - 10 nM in the presence of 
0.05 nM enzyme. Under these conditions < 10% of the inhibitor can be bound to 
enzyme at any time and so free [inhibitor] approximates to total [inhibitor] and the 
pseudo-first order rate constant kobs can be determined from equation (4)
P = (4)
where P is the concentration of product, Vq and Vs are the initial and final steady- 
state velocities, respectively for enzyme catalysis in the presence of inhibitor 
(Morrison and Walsh, 1988).
The second order rate constant for association, kon (equivalent to ki in 
mechanism A), was determined from a plot of kobs (y - axis) against [ I ] (x - axis ) 
according to the equation,
+ (5)
The unimolecular rate constant koff (dissociation rate constant) (equivalent to ka 
in mechanism A) was determined from the vertical intercept. Kiapp can be 
determined from the intercept on the horizontal axis. As there can be a high 
margin of error associated with the calculation of koff by this procedure 
(particularly for inhibitors exhibiting slow dissociation rates) this value was 
verified by using the relationships.
Ki = '^ %  (6) and k ^ = k ^o^n (7)
Results from the CT435 study are shown in Fig. 6.5 The linearity of the 
dependence of kobs on CT435 concentration provides no evidence for a situation 
other than a simple bimolecular interaction (mechanism A). A Ki value of 0.188
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nM was determined from the intercept on the horizontal axis and this result is 
consistent with that obtained from steady-state analysis (0.18 nM).
Method 2
Many of the inhibitors have substantially lower Ki values than CT435. For 
such compounds the rate of inhibition at concentrations greater than 10 fold 
higher than the enzyme concentration was too rapid to permit the use of method 
1 for data analysis. In order to permit the use of lower inhibitor concentrations the 
equation must include terms which allow for the depletion of free inhibitor. 
Appropriate equations, have been described for mechanism A by Williams et ai 
(1979) in a study of the binding of folate analogues to dihydrofolate reductase.
l-re x p (-A f)  
which on integration becomes,
(9)p ^ l-y e x p (-A f)''
Af 1- /
where the terms P, Vq and v^are as described above and the parameters y and X 
are described by the equations,
( (10)
A = ---------- , .... — __________  (11)
(/c„ + S).J[(K/,^ + E ,+ l,f-4 E ,l,'
in which Et and It are total enzyme and inhibitor respectively and S is the 
concentration of substrate. The terms Kiapp and kon have been described 
previously. Since 8 «  Km equation (11) reduces to,
A = /f„„^[(K/^ + E, + l,) -4E.I.J (12)
This form of the equation was used for analysing data from inhibitors with Ki's of 
the same order of magnitude as the enzyme concentration such as CT1746. 
Where Ki «  Et and It (CT989) this reduces further to,
A=#r^[(E, + l,f-4 E ,l,]  (13)
from which a value for kon can be determined directly. A value for koff for CT989 
was determined by using either equation (6) together with a Kiapp determined 
under steady-state conditions or (7) at inhibitor concentrations suitable for the 
determination of the rate constant, kots-
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Figure 6.5 Analysis of pre-steady-state kinetics of CT435 against 
gelatinase-A
CT435, at concentrations ranging from 0 . 5 -10  nM, was added to QF24
(1.4 |xM) in peptide assay buffer (2.49 ml). The reaction was initiated by the
addition of gelatinase-A (0.05 nM) and then hydrolysis of the substrate was
monitored continuously until a steady-state velocity was attained. Progress
curves were analysed using the Enzfitter programme and kobs an apparent first
order rate constant describing the establishment of equilibrium between
enzyme-inhibitor complexes was determined from the integrated rate equation- 
P = + (v„ -  V ,)(l-exp[-^^f])/#f_^ (4)
where P is the concentration of product, and vq and vg are the initial and final 
steady-state velocities, respectively for enzyme catalysis in the presence of 
inhibitor (Morrison and Walsh, 1988).
Figure 6.5
Analysis of pre-steady-state 
kinetics of CT435 against gelatinase-A
0.010
0 . 0 0 8  -
0 . 0 0 6 -
I
0 . 0 0 4  -
0.002 -
0.000
1 21 084 620
[I] (nM)
- Intercept on y-axis = 1.44e-04/sec (koff)
- Slope = 7.67e+05/M/sec (kon)
- Intercept on x-axis = 0.188 nM (Kiapp)
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Table 6.2 shows the result of such an analysis for the Inhibitor CT989 and 
the corresponding progress curves are presented in Fig. 6 .6 . The progress 
curves for CT989 were generated essentially as described in method 1 using 
inhibitor concentrations ranging from 0.075 - 1 nM together with 0.032 nM 
gelatinase-A. A mean value for /fonwas determined from the x values generated
by Enzfitter analysis of the progress curves using equation (9). A mean value for 
koff y^ as determined from the progress curves at 3 inhibitor concentrations 0.3, 
0.5 and 1 nM which satisfy the criteria [ I ] > 10 times [E] that permits analysis by 
method 1.
The results of pre-steady-state analysis on a selection of inhibitors are 
presented in Table 6.1. The high affinity of inhibitors such as CT962, CT989 
and CT1166 appears to be a function of their exceptionally slow rates of 
dissociation. Replacement of the hydroxamic acid zinc binding group (CT989) 
with a carboxylic acid (CT976) had little effect on the kon but increased the koff 
by 30 fold and this is reflected in the comparative Ki's of the two compounds. 
Comparison of the dissociation rates of CT543 (3.02 x lO'^s""*) and CT962 
(3.56 X 10"5 s’ i) indicates scope for manipulating this property by modifying the 
P3 ' position. CT962 differs from CT543 only by the presence of an additional 
carbon in the P3 ' hydrocarbon chain. Extension of the chain at this position did 
not affect the rates of association. Association rates were generally in the range 
of 2 - 7 X 10® M"is"i (Table 6.1 and data not shown). These values are within 
the range of diffusion controlled association rates. Consequently, by the criteria 
of Bartlett and Marlowe (1987) these inhibitors cannot be described as slow- 
binding. Inhibitors which are outside this range include CT435 and CT1746 
which exhibited slower binding and faster binding rates, respectively. In the 
case of the former compound this may be due to an unfavourable fit of the P3 ' 
phenethyl group into the S3 ' binding pocket, since there is no reason to 
presume that it should have any more difficulty than other hydroxamates in 
displacing water from the active-site. The improved association rate of CT1746 
may simply be a function of its reduced size and the absence of an extended 
P3 '/P4 ' interaction. The lack of this side-chain also produces a significantly 
faster dissociation rate than those inhibitors with bulky P3 ', resulting in a higher 
Ki value.
In summary, the very low Ki of this series of inhibitors is a property of their 
slow rates of dissociation and fast rates of association but differences due to koff
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Figure 6.6 Slow-blndlng Inhibition of Geiatinase-A by CT989
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A range of CT989 concentrations 
were mixed with 0.032 nM of 
geiatinase-A. Hydroiysis of QF24 
was monitored continuousiy using 
an LS 5B fluorescence spectrometer 
(Fiusys Programme, Chapter 2).
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may be achieved by modifications at the P3' position. Extending the hydrocarbon 
chain and increasing the size of the group at this position appears to increase 
either the strength or number of contacts made with the enzyme. Binding of the 
hydroxamic acid also appears to play a key role in preventing dissociation of the 
inhibitor-enzyme complex. These studies provided no evidence to suggest a 
mechanism of slow-binding Involving significant intermediate states (mechanism 
B) although the experimental difficulty in establishing the relationship of v/to Vo at 
high inhibitor concentrations means that such a mechanism cannot be 
discounted.
6.2:2 Requirements for inhibitor binding
(i) Binding of CT435 to geiatinase-A (E3^^->D)
Zinc metalloproteinases with mutations of the catalytic glutamic acid 
residue exhibit significantly reduced activity (Devault et a i 1988; Sanchez-Lopez 
et ai 1988). This has been demonstrated using gelatinase-A by Crabbe et ai, 
(1994a) and its importance in the catalytic process makes it a potential target for 
inhibitors. In order to study the role of the glutamic acid in inhibitor binding, the 
Kiapp for CT435 was determined against gelatinase-A(E375_>D), using QF24. 
This was possible because this form of gelatinase retains 10% of the catalytic 
activity (kcai/^m = 5.7 x 10  ^ IVI-is-\ Crabbe et ai, 1994a) of the parent. If E^^s 
does have a significant interaction with CT435, the Kiapp would be expected to 
be higher than that for the parent.
Gelatinase-A(E375_^D) or gelatinase-A (0.2 nIVI). were incubated in 
peptide assay buffer (2.49 ml) for 2 hours at 23®C in the presence of CT435 at 
concentrations ranging from 0 - 4 nM. A similar study was conducted in parallel 
using gelatinase-A at a concentration of 0.02 nM (standard Ki assay conditions). 
Reactions were initiated by the addition of QF24 (1.4p,M). Kiapp values were 
determined using the Enzfitter programme (tight-binding inhibition). GT435 had 
Kiapp values of 0.155 nM against g e la t in a s e - A ( E 3 7 5 _ _ ^ o) and 0.218 nM and 
0.195 nM against 0.2 nM and 0.02 nM gelatinase-A, respectively.
These results indicate that the catalytic glutamic acid residue E^^s does 
not interact with the inhibitor.
170
Figure 6.7 CE analysis of CT543 binding to progeiatinase-A and 
geiatinase-A
A solution of CT543 was added to either activated gelatinase-A, 
progelatinase-A (20pM) or assay buffer to give a final inhibitor concentration of 
40 |xM. Solutions were then incubated at 23®C for 2 hours. Free enzyme and 
complexed enzyme were subsequently removed by ultrafiltration (ultrafree 10 
kDa molecular mass cut-off filter) and then residual inhibitor was bound to a 
sep-pak C i8 reverse-phase cartridge and eluted as described in Chapter 2. 
Bound fractions were lyophilised prior to reconstitution in methanol. Samples 
were loaded electrokinetically for 30 secs at 30°C. Electrophoresis was carried 
out using a citrate buffer (pH 2.5) and peaks were detected at X210.
Figure 6.7 A n alys is  o f C T543 B ind ing  to  Progelatinase~A a n d  
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(ii) CT543 binding to progelatinase-A
Low molecular mass inhibitors may be able to diffuse into the presumably 
masked active site of latent proenzyme. If this were to occur In vivo it might result 
in removal of inhibitor from the circulation before it can interact with active 
enzyme. The ability of a typical hydroxamic acid inhibitor, CT543 (see Table 5.5), 
to bind to progelatinase-A was investigated by ultrafiltration.
Progelatinase-A (20 p-M) was activated using APMA (1 mM) for 7 hours at 
23°C. A solution of CT543 was then added to either activated gelatinase-A, 
progelatinase-A or assay buffer. Following incubation free inhibitor was 
separated from bound using a combination of ultrafiltration and reverse-phase 
chromatography. Residual inhibitor was detected using capillary electrophoresis 
(CE). CT543 incubated with gelatinase-A, progelatinase-A or buffer produced 
relative peak areas of 21.75, 40.05 and 40.25, respectively (Fig. 6.7). Activated 
gelatinase-A, therefore, removed about 50% of the total inhibitor present which, 
assuming an initial enzyme:inhibitor ratio of 1:2 indicates stoichiometric binding. 
There was no difference in the peak areas of CT543 in the presence or absence 
of progelatinase-A which shows that the inhibitor does not bind to the proenzyme 
form of gelatinase-A. This result indicates that CT543 requires a freely accessible 
active-site for binding. This is corroborated by further studies in which addition of 
a 10 fold excess of progelatinase-A to a mixture of CT435 and gelatinase-A did 
not modify the ability of the inhibitor to titrate the active enzyme (data not shown).
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6.3: Discussion
The interaction of Celltech MMP inhibitors with gelatinase was examined 
by kinetic analyses. The mechanism of the inhibitor-enzyme interaction was 
studied using both steady-state and pre-steady-state conditions. Ki's were 
determined using different substrates and subsequent analyses, using conditions 
designed to follow time-dependent inhibition, permitted the Ki to be broken down 
to its component terms, kon and koff. Finally, features of gelatinase-A required for 
inhibitor binding were established by testing the proenzyme and mutated enzyme 
which lacked the catalytic glutamic acid.
Throughout this work the assumption that inhibitors were both reversible 
and competitive inhibitors of MMPs has dictated the treatment of kinetic data. If 
this were not the case Ki's used for the construction of SARs would be invalid. 
Results in this chapter have, however, established that the inhibitors do have 
finite dissociation rates and the elevation of Kiapp in the presence of increasing 
concentrations of substrate effectively demonstrates the competitive nature of the 
interaction. The validity of these compounds as therapeutic inhibitors of 
gelatinases was tested using a physiological substrate, gelatin. Such assays 
were limited, however, by the high affinity of the inhibitors for gelatinase-A. The 
enzyme was titrated by inhibitor even at sub-nanomolar concentrations which is 
indicative of tight-binding. Additionally, the response of the enzyme to the 
presence of inhibitor occurred over many minutes which means that enzyme and 
inhibitor must be pre-incubated prior to assay. Steady-state analysis of the 
binding of CT435 to gelatinase-A demonstrated that under assay conditions 
equilibrium was established within four hours. The association kinetics of other 
inhibitors revealed that CT435 had a comparatively slow /fon value, thereby 
justifying the suitability of a four hour preincubation period for determining Ki's.
Tight-binding with time-dependent inhibition has also been reported in the 
neprilysin and ACE literature. The hydroxamate, idapril for example, has a Ki of 
0.47 nM, kon of 3 xIO® M'is‘i and koffoi 1.4 x 10'3 S"1. The typical range for the 
second order rate constant (kon) of zinc metalloproteinase inhibitors is 10  ^ - 1Q7 
M'is-1 which is comparable to those presented in this chapter. Several studies 
were conducted to confirm the 'slow', tight-binding kinetics of these inhibitors 
described above. In one example (CT989), the time-course of the enzymic 
reaction was examined with or without preincubation of gelatinase-A and
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inhibitor. Initiation of the reaction by the addition of enzyme resulted in a high 
initial velocity which gradually decreased to a lower steady-state velocity thereby 
producing a downward concave curve (Fig. 6.6). In another example, a high 
concentration of enzyme and inhibitor (CT1746) was incubated for four hours 
prior to initiation of the enzymic reaction by the addition of substrate. This 
produced an upward concave curve with a final steady-state velocity equivalent 
to that achieved under steady-state conditions (Fig. 6.1). This clearly indicates 
that equilibrium between gelatinase-A and inhibitor is not rapidly established 
under these assay conditions. It may be argued that time-dependent inhibition is 
not necessarily a consequence of slow-binding kinetics although the two have 
now become synonymous. These inhibitors clearly fulfil the criteria for slow- 
binding suggested by Schloss etal. (1988) i.e. potency increases on a time-scale 
that is readily followed by conventional assays. Indeed these authors include 
inhibitors with kon values of the order of 10  ^M-Is-1 as slow-binding inhibitors. 
This classification leads to the inclusion of inhibitors with slow off rates (and 
which therefore take a long time to reach a steady-state velocity) and those that 
exhibit time-dependent inhibition as a consequence of the reaction conditions. 
Recognising the complexity of the process, Bartlett and Marlowe (1987) 
suggested a lower limit of 10  ^M'^s'i for diffusion limited reactions and, indeed, 
there are many examples of inhibitors with /con's considerably lower than this. On 
these criteria many of the MMP inhibitors described in this study cannot be 
described as slow-binding, although CT435 does possess a kon which is lower 
than this limit. The mechanism by which CT435 interacts with gelatinase-A was 
examined assuming a true slow-binding interaction. Whilst it is generally 
accepted that slow binding kinetics are a consequence of the fast formation of a 
collision complex followed by a slow isomérisation to a 'so-called' tightened 
complex (mechanism B) this proved to be difficult to prove experimentally. It was 
necessary to use inhibitor concentrations substantially lower than the Ki for the 
dissociation of the collision complex (where Ki* is the overall inhibition constant) 
and under these conditions this complex becomes kinetically insignificant. 
Accordingly, the linear dependence of the pseudo-first order rate constant kobs 
on inhibitor concentration (Fig. 6.5) indicated that a single slow step leading to 
complex formation provided a satisfactory description of the kinetics.
Dissociation rate constants (koff) were also established on the basis of a 
single enzyme-inhibitor complex. Examples were presented in which (1) koff
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could be determined from the y-axis intercept of a plot of kots against [I] (CT435) 
and (2) koff was calculated from its relationship to kobs and the initial and final 
steady-state velocities at several inhibitor concentrations (CT989). The former 
method could not be applied to CT989 because of its very slow rate of 
dissociation (dissociation half-life = 315 minutes). As the rate decreases the y- 
axis intercept approaches the origin at which point the reaction becomes 
essentially irreversible.
In this study, low Ki's were mainly a consequence of slow dissociation 
rates. CT1746 was an exception to this rule in that an increased association rate 
also contributed to its low Ki. This may be attributed to the absence of a large P3' 
side-chain and its comparatively low molecular mass compared to inhibitors such 
as CT989 and CT1166.
Other studies were performed in order to discover which features of 
gelatinase-A might be important for inhibitor binding. Crystal log raphic studies 
have shown that inhibitors possessing a Pi' nitrogen form a hydrogen bond via 
this atom to the catalytic glutamic acid (Lovejoy etal., 1994b). It may be argued 
that the nitrogen atom of hydroxamic acid may fulfil a similar role. This possibility 
was explored by studying the binding of a hydroxamic acid inhibitor to 
gelatinase-A, lacking the glutamic acid. Since the absence of the glutamic acid 
did not decrease the affinity of the inhibitor for gelatinase we can conclude that 
the hydroxamic acid does not interact with this residue. This has now been 
confirmed by co-crystallisation studies (Borkakoti etal., 1994; Stams etal., 1994).
Evidence for the requirement of a freely accessible active-site for inhibitor 
binding has been obtained by two independent methods. In one study, 
ultrafiltration was used to show that the addition of a concentrated solution of 
progelatinase-A to CT543 had negligible effect on the concentration of free 
inhibitor. Other studies examined the effect of progelatinase-A on the ability of 
inhibitor to titrate active enzyme as well as the effect of its presence on apparent 
Ki's (data not shown). Data from these studies are consistent with the 
ultrafiltration results and suggest that low molecular mass inhibitors cannot 
diffuse into the active-site.
In summary, the inhibitors interact with gelatinases in a reversible and 
competitive fashion. Additionally, they fulfil the criteria of Morrison et al., (1982) 
for being classified as tight-binding. By using concentrations of enzyme and 
inhibitor of the same order of magnitude as the Ki's, the inhibitors may be
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analysed using slow-binding kinetics. The high affinity of the hydroxamate 
inhibitors results from their slow rate of dissociation (long residency time) and a 
high rate of association with the enzyme. Finally, the catalytic glutamic acid at the 
active site of gelatinase-A is not involved in inhibitor binding but a freely 
accessible active site is required.
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CHAPTER 7
IN  V IVO  PROPERTIES OF SYNTHETIC MMP INHIBITORS 
7.1: Introduction
Chapter 5 showed how classical structure-activity relationships (SARs) 
can be used to discover potent gelatinase inhibitors with a broad spectrum of 
properties against other MMPs. The structure of a compound also governs its 
behaviour in the body. Without information to the contrary we may assume that 
gelatinase inhibitors must provide continuous cover. For such drugs, an orally 
active formulation is the preferred route of administration. The level and 
frequency of dosing is determined largely by pharmacokinetic properties such as 
the systemic half-life. Since the relationship between the structure of a drug and 
its pharmacokinetic properties is different from that which determines inhibitory 
activity, the clinical candidate will probably result from a structural trade-off 
between the two. Studies described in this chapter, therefore, expand the 
inhibitor screening cascade to include pharmacological SARs.
Peptides or peptide-like substances exhibit notoriously poor 
pharmacokinetics (reviewed in Humphrey and Ringrose, 1986). Consequently, 
despite the fact that potent hydroxamic acid MMP inhibitors were discovered ten 
years ago there are few published reports describing their biological stability. 
Investigators at Sterling Winthrop (Singh etal., 1993) reported SARs for a series 
of isobutyl (P i‘), tryptophan (P2') inhibitors with a range of modifications at the P3' 
position. Systemic half-lives in the rat were in the range of 6,9 minutes ((CH2)4 - 
COOH) to 43.7 minutes ((CH2)2 - S-(CH2)2 - N -(CH3 )2) and percentage oral 
bioavailability was reported to range from 0 - 1 0  %. Biliary excretion was the 
major route of elimination either of the hydroxamate parent compound or of the 
corresponding carboxylic acid metabolite. Metabolic studies on BB94 (see Fig. 
5.1) gave similar results (Yachetti et aL, 1993) but no pharmacokinetic details 
were presented. More recently Roche UK demonstrated that incorporation of a t- 
butylglycine at the P2' position (eg. Ro31-9790) can lead to improved oral 
bioavailability in the isobutyl (PV) class of inhibitors (Lewis etal., 1993).
Research in the renin area has been particularly influential in the design of 
MMP inhibitors. A common theme arising from this work is the need for the 
correct balance of lipophilicity and hydrophilicity for oral bioavailability. To this
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end, morpholines and other slightly basic groups are frequently used to provide a 
degree of water solubility to compounds.
Attention has been drawn to the rapid metabolism of hydroxamic acids in 
the 5-lipoxygenase area. Inhibitors of this enzyme are being developed as anti­
inflammatory agents. Underivatised hydroxamates attached by methylene 
spacers to non-peptide structures were observed to convert rapidly to the 
corresponding carboxylic acid in rats (Summers etal., 1987; Tateson etal., 
1988).
The ability of rats to metabolise hydroxamates is presumably the result of 
blood esterase action. This means that whole blood or plasma may be used, 
therefore, as an early screen for susceptible inhibitors. Moreover, it dissociates 
the effects of blood metabolism from that attributed to other organs. 
Consequently, in this study the metabolic activity of the blood from several animal 
species was tested using a range of extraction and detection techniques to 
measure inhibitors with diverse physiochemical properties. By comparing the 
activity of human blood to that of other species we can predict the extent of 
systemic metabolism at a stage well before the drug can be tested in humans.
Lark et al. (1990) described a rat pleural cavity assay which was used to 
allow synthetic inhibitors of gelatinase-A to be tested (section 2.4:3). It provides a 
primary in vivo screen to identify compounds with improved pharmacokinetic 
properties. Potential lead molecules can then be studied in more detail by 
measuring their blood levels in mice after intravenous administration. Since the 
resulting plots of Logio concentration against time are essentially bi-exponential, 
pharmacokinetic treatment of the data employs a two-compartmental model 
(section 2.4:4) throughout this study.
The pharmacokinetic profile of an animal species may not be predictive of 
what may occur in other species, including humans. The ketomethylene 
tripeptide inhibitors described by Almquist etal. (1985), for example, exhibit half- 
lives of 10 minutes in the rat and 9 minutes in the rabbit, which shows that 
systemic half-life does not necessarily increase with the size of the species. A 
similar situation has been observed with non-peptide hydroxamic acids. The 5- 
lipoxygenase inhibitor zileuton, for instance, exhibits half-lives of 2.4 hrs, 4 hrs, 
7.5 hrs and 0.3 hrs in rat, sheep, dog and monkey, respectively. Consequently, 
the following pharmacokinetic studies have been performed in mice, rats and 
rabbits.
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Few orally active MPIs have been described and none with the Pi' aryl 
group which confers gelatinase potency and selectivity. It is nonetheless an 
important requirement for MMP inhibitors. It is commonly presented as the term 
"percentage oral bioavailability" which relates the amount of drug entering the 
systemic circulation via the oral route to that present after intravenous 
administration. Methods for calculating this value are presented in section 2.4:4. 
The pleural cavity identified a number of orally active compounds for 
pharmacokinetic analysis in mice and rats. Ro31-9790 was used as a control for 
these studies since its bioavailability in the rat has been reported.
The bioavailability studies described above were performed using non­
radiolabelled samples. Concentration-time plots were, therefore, generated by 
titrating extracted activity against gelatinase-A. This technique is very sensitive 
but may not discriminate between parent drug and active metabolites. The 
results of these studies will, therefore, be discussed in the light of recent data 
obtained from [“l^cj-labelled CT1746.
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7.2 : Results
7.2:1 The blood stability of MMP inhibitors
Studies of hydroxamic acid inhibitors of 5-lipoxygenase (Tateson et al., 
1988) have suggested that rodents may possess plasma esterases capable of 
converting the hydroxamic acid to the corresponding carboxylic acid. The 
comparative lack of inhibitory activity of the latter was shown to produce a rapid 
loss in biological activity which is reflected in the poor systemic half-lives of these 
compounds. Peptide hydroxamates may also act as substrates for these 
enzymes and their susceptibility may be tested ex vivo using whole blood or 
plasma. A range of methods have been developed to measure the presence of 
parent drug in biological fluids, examples of which will be presented in the 
following ex vivo studies.
(i) The stability of CT543 and CT550 in mouse blood
CT550 and CT543 were incubated at 37°C in mouse blood containing an 
anti-coagulant. Samples were removed after 0, 2 and 5 hours for the preparation 
of plasma fractions. Inhibitors were isolated using solid-phase extraction prior to 
analysis by CE. Table 7.1 shows that after 5 hours, 44% and 46% of CT543 and 
CT550 remained, respectively. The decrease in levels of parent compound was 
not accompanied by a corresponding increase in any other peak. Since 
electrokinetic loading discriminates against negatively charged species it is 
possible that carboxylic acid metabolites, for example, would not be detected. 
This study suggests CT550 and CT543 are unstable in mouse blood although the 
rate of removal of parent compound is comparatively slow.
(II) The stability of CT420 in human plasma
The stability of the Pi' isobutyl inhibitor CT420 was tested using human 
plasma. Parent compound was detected using reverse phase HPLC after ethyl 
acetate extraction. Results were compared to those for a corresponding sample 
incubated In water (Table 7.2).
Table 7.2 shows that CT420 is stable at 37°G in human blood for at least 4 
hours. Additional HPLC data indicates that the parent compound remains in the 
blood after 24 hours incubation (data not shown). This study indicates that
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Table 7.1 The stability of CT543 and CT550 in mouse blood
0 2636 100
CT543 2 1729 66
5 1171 44
0 3601 100
CT550 2 1849 51
5 1677 46
CT543
HONH
CT550
NH
NHHONH
CT543 and CT550 (100 |ig/ml) were added to 3.3 ml of citrated whole 
mouse blood. At 0, 2 and 5 hours plasma was prepared and passed over a C i8 
sep-pak reverse-phase cartridge. Bound inhibitor was eluted with 70% 
acetonitrile/0.1% TFA and then dried by vacuum centrifugation. Reconstituted 
(0.5 ml methanol) material was filtered prior to electrokinetic application (5Kv, 
30 secs) to an ABI 270A CE. Samples were electrophoresed in citrate buffer, 
pH 2.5 at 39°C. Peaks were detected at A.210 nm.
181
j - i , ;  -■ ..T  ir^,"ATOI»C- :
Table 7.2 The stability of CT420 in human plasma
0 536188 652901 122
0.25 591251 712568 121
4 587629 701157 119
CT420
N H
N HH O N H
CT420 (250 ng/ml) was added to 1 ml of human plasma. At 0, 15 mins 
and 4 hrs Inhibitor was extracted into ethyl acetate and dried by vacuum 
centrifugation. Reconstituted sample (0.5 mis of 5% methanol/0.1% TFA) was 
applied to a Dynamex Cis reverse-phase column. CT420 was separated from 
contaminating species using a 10 - 40% acetonitrile gradient with detection at 
% 2 5 7  nm. Peak areas represent the mean of 3 determinations.
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Table 7.3 The stability of CT1746 in mouse and rabbit biood
Mouse Ethylacetate 1.09 ± 0.09 0.88 ± 0.02 81
Mouse Methanol 1.21 ±0.1 0.934 ±  0.07 77
Rabbit Ethylacetate 0.86 ±0.12 0.845 ± 0.02 99
Rabbit Methanol 1.13 ±0.03 0.742 ±  0.04 66
CT1746 (1pM) was added to duplicate samples of whole mouse or rabbit 
blood (heparinised) previously warmed to 37°C. At 0 hrs and 1 hr samples (0.5ml) 
were removed either directly into ethyl acetate (2ml) or centrifuged to produce the 
plasma fraction. Plasma samples (0.25ml) were precipitated on ice with 4 volumes 
of methanol. Ethylacetate samples (1ml) were lyophilised by speedvac and 
reconstituted in assay buffer + 5% methanol. Plasma proteins were precipitated 
from the methanol samples by centrifugation and then 1 ml of the methanol was 
removed, lyophilised by speed vac and then reconstituted in assay buffer/methanol 
as above. Samples were diluted appropriately for titration against gelatinase-A 
using the QF24 assay. Fluorescence recordings were read off an appropriate 
standard titration curve.
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human blood does not metabolise hydroxamate inhibitors as efficiently as rodent 
blood.
(ill) The stability of CT1746 in mouse and rabbit biood
The hydroxamate inhibitor CT1746 has shown some interesting in vivo 
characteristics which will be described in section 7.2:3 but there is evidence of 
instability in rodent blood (Dr. G. Curtiss, personal communication). Stability was 
examined in the blood of two species, mouse and rabbit, after ethyl acetate 
extraction or methanol precipitation. The former should discriminate against 
hydrophilic metabolites. This study was performed using an inhibitor 
concentration of 1 pM which is comparable with concentrations observed in vivo. 
Inhibitor levels were estimated by titration against gelatinase-A for maximal 
sensitivity.
CT1746 was added to heparinised blood which had been pre-warmed to 
37°C. Samples were removed either immediately or after 1 hour and then 
inhibitor was extracted and quantified as described above.
Table 7.3 shows that the recovery of activity was similar for both methods 
of extraction. This result suggests that the compound is not extensively modified. 
Approximately 80% of CT1746 related activity was recovered after 1 hour in the 
blood of both species.
CT1746 exhibits some instability in both mouse and rabbit blood which 
shows that the ability to modify these inhibitors is not confined to rat blood.
7.2:2 The pharmacokinetics of MMP inhibitors
(i) The pharmacokinetic properties of aryisuiphonamide inhibitors in mice
A long systemic half-life may be particularly important if a drug is to 
maintain 24 hour cover in humans. This parameter can be calculated by 
measuring the levels of inhibitor in the blood at various times after intravenous 
(i.v.) administration of a bolus dose. In the following study systemic 
concentrations of the CT989 series of arylsulphonamides (CT989, CT1398 and 
CT1418) were compared to those obtained from three non-arylsulphonamide 
inhibitors (CT1166, CT1507 and CT1509).
Compounds were administered intravenously at a dose of 4 mg/kg to 
groups of 5 animals (25g). At various times the animals were sacrificed and the
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Figure 7.1 Inhibitor levels in mouse biood following intravenous administration
CT1509 
CT1166 
CT1507 
CT989 
CT1418 
CT1398
Arylsulphonamides
Non>arylsuIphonamides
100 200
Time (mins)
40 0
Compounds were administered intravenously at a dose of 4 mg/kg to groups of 5 
animals. At times ranging from 10 secs to 6 hrs the animals were sacrificed and inhibitor 
was extracted from 0.5 ml of blood using ethyl acetate (2 ml). The concentration of 
inhibitor-related activity was determined by titration against gelatinase-A. Logio 
concentration was then plotted as a function of time for each inhibitor. The plots 
represent the mean of 5 indivdual determinations.
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Figure 7.2 The role of hydroxamic acid in the clearance of arylsulphonamides 
in mice
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CT1466 was administered intravenously at a dose of 4 mg/kg to groups of 5 
animals. At times ranging from 10 secs to 4 hrs the animals were sacrificed and 
inhibitor was extracted from 0.5 ml of blood using ethyl acetate (2 ml). The 
concentration of inhibitor-related activity was determined by CE analysis using 
vacuum application. Samples were electrophoresed in a buffer of 20 mM Tris / 
28.8mM borate / 0.68 mM EDTA / 30% methanol, pH 9.0. The resulting plot was 
then overlaid on the blood profiles for CT989, CT1398 and CT1418 (Fig. 7.1).
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concentrations of inhibitory activity were determined In ethyl acetate extracts of 
whole blood.
Fig. 7.1 shows that all the inhibitors possess a vary rapid a-phase distribution 
with half-lives (ti/2) typically shorter than 1 minute. Analysis of the raw data 
reveals this to be particularly evident for the aryisuiphonamide, CT989 which has 
an t i /2 (a) of only 0.39 minutes. Only 1.4% of the CT989 activity present 10 
seconds post-administration could be detected after 5 minutes. The 
corresponding percentages for CT1509, CT1507, CT1418 and CT1398 are in the 
range of 6.4% - 9.4%. It is apparent from the blood profiles that much higher 
levels of the arylsulphonamides are retained in the blood from 15 minutes 
onwards. After 1 hour, for example, only 0,4% of the initial concentration 
(measured at 10 secs) of CT1509 and CT1507 is still detectable, whereas, the 
corresponding figures for CT989 and CT1398 are 3% and 4%, respectively. An 
additional distinguishing feature of CT989 and CT1418 is the presence of a 
significant increase in inhibitor concentration between 30 minutes and 1 hour.
The p-phase half-lives were estimated to be in the range of 15 - 20 
minutes for the non-arylsulphonamides. The concentration-time plots show that 
the ti/2(P) is significantly higher for the aryisuiphonamide series. A half-life of 
120 minutes was calculated for CT989 but this figure is likely to be inaccurate 
since the kinetics of its elimination appears to be far more complex than can be 
described by a simple two-compartmental model.
The prolonged ti/2(P) of the arylsulphonamides is not consistent with 
pleural cavity assay data (data not shown). This assay could not distinguish 
between CT989 and CT1166 although concentrations of the former appear to be 
considerably higher in the blood. This indicates that the pleural cavity is 
inaccessible to a fraction of the ethyl acetate extracted CT989.
The t i/2(P) values are comparable to those described by Singh et aL 
(1993) for a structurally related series of collagenase inhibitors tested in rats 
(range, 6.9 - 43.7 minutes). This study provides further evidence that peptide- 
hydroxamate inhibitors of MMPs exhibit relatively poor pharmacokinetics in 
rodents.
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(ii) The role of hydroxamic acid In the blood clearance of arylsulphonamldes 
In mice
The hydroxamic acid provides a major contribution to the inhibitory activity 
of MMP inhibitors. For this reason its presence is ubiquitous in the design of most 
active compounds. The hydroxamate may also play a major role in promoting the 
rapid clearance of these compounds since an extensive programme of side- 
chain modifications has not produced a compound with markedly altered 
pharmacokinetics.
Its role In the pharmacokinetics of the arylsulphonamldes was examined 
by removing the entire zinc-binding ligand to produce CT1466. If the hydroxamic 
acid dictates the elimination rate of the arylsulphonamldes, one would expect 
considerably higher concentrations of CT1466 to be retained in the blood at later 
times.
CT1466 was administered at 4 mg/kg (i.v.) to groups of 5 mice. At various 
times the animals were sacrificed and inhibitor was extracted from the blood. The 
concentration of CT1466 was determined in individual samples using CE 
analysis. The data were plotted as described above and the resulting plot was 
overlaid on the blood profiles of CT989, CT1398 and CT1418 (Fig. 7.2).
CT1466 displayed a rapid a  distribution phase which was reflected in only 
2.1% of the initial inhibitor concentration being detectable in the blood after 5 
minutes. Like the other arylsulphonamldes blood concentrations appeared to 
increase after 30 minutes. At no point were the blood concentrations of CT1466 
significantly higher than those of other members of this series. The overall shape 
of the concentration curve was similar to that produced by other 
arylsulphonamide inhibitors. These results indicate that the arylsulphonamide 
rather than the hydroxamic acid is the major determinant of the pharmacokinetics 
of this series of inhibitors.
(iii) The properties of hydroxamic inhibitors in the rabbit
Pharmacokinetic data obtained from mice is of limited accuracy because 
the low blood volume makes sequential blood sampling from a single animal, 
impractical. Additionally, the pharmacokinetics of this class of molecule has only 
been described in mouse and rat (see above) which are both rodents. 
Consequently, the pharmacokinetics of a broad spectrum hydroxamate (CT435) 
and a selective gelatinase inhibitor (CT989) was studied in the rabbit.
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Figure 7.3 Concentration-time plots of CT435 and CT989 in rabbit blood 
following i.v. administration
CT435 (2mg/kg) and CT989 (10mg/kg) were administered via the 
femoral vein to two rabbits. Blood samples (1ml) were then removed directly 
into ethyl acetate at times ranging from 0 - 6  hrs. The concentration of 
extracted Inhibitor was then determined by activity assay (3 determinations) 
against gelatinase-A and the results verified by CE (CT989 only).
Figure 7.3 Concentration-time piots of CT435 and CT989 
in rabbit blood
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Table 7.4
Levels of CT989 in rabbit blood following i.v. administration of a 
dose of lOmg/kg
0.45 48.0 29.0
0.75 21.6 13.0
1.08 15.0 9.0
1.5 10.6 6.3
2 6.1 3.7
3 4.3 2.6
4 3.2 1.9
5 2.4 ' 1.4
10 1.9 1.1
15 1.5 0.9
30 1.0 0.6
60 0.37 0.22
120 0.07 0.04
240 0.01 0.006
360 0.0 0.0
Levels of CT989 in tissues /  other fluids
Urine 4.5 6 - 198.0
Urine 6 9 - 46.8
Bile 6 1 - 61.3
Kidney 6 - 21.85 210.0
Lung 6 - 23.75 178.0
Liver 6 - - negligible
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Rabbits were cannulated via the femoral vein before the administration of 
CT435 (2mg/kg) and CT989 (10 mg/kg). Blood samples were then removed 
directly into ethyl acetate at times ranging from 0 - 6 hrs. The concentration of 
inhibitor in the blood was then determined by activity assay.
The resulting concentration-time profiles are presented in Fig. 7.4. The 
elimination kinetics can be described by a 2-compartmental model. Both 
Inhibitors were removed rapidly from the circulation with a ti/2 (a) of the order of 1 
minute. The t i /2 (P) for CT435 was estimated to be 15 minutes and that for 
CT989 to be 21.6 minutes. After 5 minutes the concentration of CT989 had 
decreased to 5% of that measured at the first time-point (0.45 mins) (Fig. 7.3). 
CT435 was also significantly cleared from the blood compartment after 5 minutes. 
No CT989 was detectable In the blood after 6 hours.
The results indicate that the Pi' isobutyl derivative, CT435, and the Pi' 
toluylpropyl derivative, CT989, both undergo rapid clearance in the rabbit. The 
half-lives of both compounds were similar to those of CT1166 and CT1509 in the 
mouse. CT989 displayed a typical bi-exponential profile in the rabbit In contrast 
to its behaviour in the mouse (section 7.2:2 {i}).
The CT989 study was expanded to include the measurement of inhibitor 
concentrations in urine, bile, liver, lung and kidney. The compound was 
extracted using ethyl acetate directly from the fluids and from homogenised 
tissues. CT989 activity was quantitated by titration against gelatlnase-A. The 
results of this study are presented In Table 7.4 together with the corresponding 
blood levels. CT989 activity was detected in all extracts except for liver. The 
unexpected presence of CT989 In the lungs may arise from the precipitation of 
this very hydrophobic compound within their network of small blood vessels. The 
total amount of inhibitor recovered, however, represented only 3% of the 
administered dose. CE analysis of selected samples Identified only intact 
compound, but this may be due to the extraction procedure which would 
discriminate against hydrophilic metabolites. Acidification of the urine followed 
by p-glucuronldase treatment to extract hydrophilic glucuronides failed to account 
for any more inhibitor.
Subsequent studies using radiolabelled CT1746 have Indicated that a 
high percentage of the inhibitor may have re-entered the gastrointestinal tract in 
the form of a glucuronldated metabolite (Dr. O. Epemolu, personal 
communication).
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7.2:3 The oral bloavaiiablity of MMP inhibitors 
(i) Screening by pleurai cavity assay
The pleural cavity assay is used to screen for orally active inhibitors. 
Preliminary experiments showed a positive correlation between water solubility 
and the oral bioavailability of inhibitors in mice. This is Illustrated In Table 7.5 
which shows the BAR data for a series of P2' cyclohexylalanine inhibitors with 
modifications at the P3' position (Dr. S. Chander, personal communication). 
Hence, CT1509 which has an extended hydrophilic morpholino group at the P3', 
produced far higher levels of Inhibition in this assay after oral dosing than the 
much more hydrophobic inhibitors, CT1166 and CT989. In order to correlate 
results in the pleural cavity assay with blood levels (and subsequently 
bioavailability), the blood concentration of CT1166 and its percentage inhibition 
(pleural cavity) were determined simultaneously at several time-polnts. The 
results of this study demonstrated that inhibition was effectively stoichiometric 
and that an inhibitor concentration of 20 nM could completely block enzyme 
action (Fig. 7.4). This narrow concentration range severely limits the Information 
that this assay can provide. Consequently, even though CT1509 appears to be 
very effective (55% inhibition) one hour after oral administration (Table 7.5), its 
bloavailabllity is probably well below 1%.
Despite Its limitations, BAR data provided by this assay lead to the 
important discovery that replacement of the P2' cyclohexylalanine with tertiary 
butylglycine could significantly increase oral bioavailability. As a result, the 
bioavailabllitles of three hydroxamic acid inhibitors from the tertiary butylglycine 
series were determined in mice and rats.
(il) Oral bioavailability of MPis in mice
Inhibitor efficacy is routinely tested in mouse models of tumour growth and 
metastasis. In order to aid in interpreting the efficacy data, blood levels were 
measured in mice after i.v. and p.o. dosing. CT1847 and CT1746 were 
compared to Ro31-9790. The structures of these compounds are presented in 
Chapter 5 (Fig. 5.1).
Ro31-9790, CT1847 and CT1746 were administered either intravenously 
or orally at 10 mg/kg to groups of 5 mice. At various times after administration the 
animals were sacrificed and samples of blood were removed. Inhibitor was
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Table 7.5
Pleural cavity assay of orally administered gelatinase inhibitors
P3* group Compound % Inhibition
Carboxylic acid CT1508 0
Sulphamyl urea CT1166 5
Arylsulphonamide CT989 13
CT1398 19
Imidazole CT1400 23
Morpholine amide . CT1575 26
Dimethyl amine CT1514 40
Morpholine CT1509 55
Extended chain CT1495 58
Compounds (80 mg/kg) were administered by oral gavage to groups of 7 
mice. After 1 hour assays were initiated by the co-injection of gelatinase-A and 
["•^Cj-gelatin into the pleural cavity (Dr. S.K.Chander). Samples were then processed 
as described in Chapter 2. Results are expressed as a percentage of the gelatinase- 
A activity obtained in the absence of inhibitor.
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extracted from the blood using methanol precipitation and then inhibitor 
concentrations were determined by titration against gelatinase-A. Concentration­
time plots are presented In Fig. 7.5. and pharmacokinetic parameters are shown 
in Table 7.6.
The systemic half-lives were established from the i.v. traces using a two- 
compartmental model of drug kinetics (section 2.4:4). In all cases, drug was 
distributed less rapidly than has been previously described for P2' 
cyclohexylalanine inhibitors (section 7.2:2). This is reflected in ti/2's (a) of the 
order of 3 minutes. After 5 minutes the concentrations of CT1746, CT1847 and 
Ro31-9790 represented 32%, 19.5% and 17% respectively, of the corresponding 
10 second concentrations.
In each case, inhibitor could be detected in the blood 4 hours after administration. 
The ti/2 (p) values were 38, 34 and 36 minutes for CT1746, CT1847 and Ro31- 
9790, respectively. This value represents a two-fold increase over comparable 
cyclohexylalanine inhibitors.
The most striking changes were observed after oral dosing. An oral dose 
of 80 mg/kg of cyclohexylalanine inhibitors such as CT989, CT1166 and CT1509 
produced negligible activity in the blood (data not shown). Ro31-9790, CT 1847 
and CT1746, however, all remained in the blood for as long as eight hours after a 
single dose of 10 mg/kg. Activity peaked between 30 minutes (CT1847) and two 
hours (CT1746) and this was followed by a gradual decrease in inhibitor levels 
over the following 6 - 8 hours. Areas under the curves were calculated using the 
trapezoidal method to the last measurable time-point since the flat curve shape 
does not permit extrapolation to infinity. Oral bioavailability ranged from 35% to 
45%. Not surprisingly, the intravenous and oral AUCs were similar for the two 
most closely related inhibitors CT1847 and Ro31-9790. CT1746, however, 
produced a larger area under the curve and a higher Co concentration which 
indicates a lower volume of distribution (Vd ). This was confirmed using the 
Siphar pharmacokinetic programme. The Vd for CT1746, in particular, indicates 
the absence of any extensive tissue / protein binding.
In summary, the replacement of the P2' cycohexylalanine with tertiary 
butylglycine significantly increases both plasma half-life and oral bioavailability in 
mice.
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Figure 7.5 Concentration-time piots of 3 MPIs in the mouse
Ro31-9790, CT1847 and CT1746 (lOmg/kg) were administered either 
intravenously (tail vein) or by oral gavage to groups of 5 mice. At times ranging 
from 10 secs to 4 hrs (intravenous) and 5 mins to 8 hrs (oral) animals were 
sacrificed and samples of blood were removed. Inhibitor was extracted from 
the plasma fraction using methanol precipitation. Blood concentrations were 
determined by titration of appropriately diluted extract against gelatinase-A. 
Each point represents the mean of the determinations from 5 animals. (The 
corresponding pharmacokinetic parameters are presented in Table7.6).
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Table 7.6
The pharmacokinetics of 3 MPis in the mouse
Compound
Terminal
half-life
(mins)
% Oral 
availability v d (P)(ml/kg)
Total
Clearance
(ml/kg/min)
MRT
(mins)
Ro31-9790 36 36 3244 62.6 16.2
CT1847 34 34.7 4814 98.8 14
CT1746 38 44.9 1207.5 21.9 19.3
Pharmacokinetic parameters were calculated by the Siphar programme 
using a structurally independent model. Percentage oral availability was 
calculated from the oral and intravenous AUCs (determined using the trapezoidal 
rule). The AUC after oral administration was calculated to the final time-point. 
Abbreviations :
Vd : volume of distribution 
MRT : mean residence time
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(iii) Bioavailability and systemic half-lives of CT1746 and Ro31-9790 in rats
The pharmacokinetics of CT1746 and Ro31-9790 were investigated in the 
rat for 2  main reasons,
1/ This species is used for toxicological studies.
2/ All published data for comparable compounds relates to rat studies.
Dosing regimens and experimental procedures were essentially as described for 
mice (see above). The resulting plasma concentration-time profiles are shown in 
Fig. 7.6.
After intravenous administration the activity of both compounds decreased 
rapidly over the first 1 5 - 3 0  minutes and this was followed by a comparably 
shallow secondary phase which is presumed to represent p-phase elimination. 
In contrast to the mouse data, the area under the i.v. curve was similar for both 
compounds producing Vd values intermediate to those calculated for these 
compounds in the mouse (data not shown). In both cases, inhibitor related 
activity was detected in the blood 8  hours after administration. Half-lives of 55 
minutes and 81 minutes were determined for Ro31-9790 and CT1746, 
respectively. These values are somewhat higher than those observed in the 
mouse.
The oral profiles are characteristic of drugs that are either poorly absorbed 
or suffer extensive first pass metabolism. At no point does the concentration of 
inhibitor in the plasma overlap the intravenous profile. The maximal blood 
concentration (Cmax) occurs 15 minutes after administration and this is followed 
by a gradual reduction in inhibitor levels that parallels the p-phase elimination 
observed after i.v. dosing. This indicates that compounds are more rapidly 
absorbed in the rat than the mouse which exhibits a prolonged absorption phase. 
The oral bioavailabilities of Ro31-9790 and CT1746 were 5.4% and 7.2%, 
respectively. The Ro31-9790 result, confirms the low oral bioavailability figure 
(7%) previously reported by Roche.
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Figure 7.6 Concentration-tim e plots of Ro31-9790 and 
CT1746 in the rat
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Ro31-9790 and CT1746 ( 1 0 mg/kg) were adm inistered e ither 
intravenously (i.v.) or by oral gavage (p.o.) to groups of 5 rats. At 
times ranging from 10 secs to 8  hrs, 0.5 ml of blood was removed. 
Inhibitor concentrations were determined as described in Fig. 7.5.
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7.3: Discussion
The stabilities of hydroxamic inhibitors were examined in the blood of 
mouse, rabbit and human. Rat studies were also conducted in collaboration with 
Dr. G. Curtiss. These ex vivo studies provided stability data to augment 
subsequent in vivo investigations. Additionally, this work allowed analytical 
methods to be tested prior to their use in pharmacokinetic studies.
Pharmacokinetic studies were performed in mice, rats and rabbits to 
determine the systemic properties of hydroxamic acid inhibitors after intravenous 
(i.v.) and oral (p.o.) administration. The results of these studies will be discussed 
in the light of recent data provided by radiolabelled CT1746.
Stability in blood
Blood stability was tested either indirectly by titration against gelatinase-A 
or directly by chromatographic and electrophoretic methods. The advantage of 
the former method resides in its sensitivity but the potential for interference by 
active metabolites is a major disadvantage. Although the low absorbance of 
these compounds limited the application of techniques which rely on UV 
detection, such techniques were employed wherever possible so that parent 
compound could be measured unequivocally.
Prior to analysis, compounds were isolated from contaminating 
substances using either organic extraction, solid phase extraction or methanol 
precipitation. Extractions produced more homogenous sample making them 
more amenable to CE or HPLC. Methanol precipitation, on the other hand is 
non-selective, which is a major advantage for detecting metabolites.
Hydroxamic acid inhibitors representing the two major classes of 
compound (P i' isobutyl or arylpropyl) were tested in the whole blood of several 
species namely;
(1) Mouse (Tumour growth and metastasis model, pleural cavity model)
(2) Rabbit ( Sequential blood samples can be collected from a single animal)
(3) Human (Target species)
In addition, rat studies (Toxicokinetic species) were undertaken in collaboration 
with an external metabolism group. (Dr. G. Gurtiss, Biodynamics, Cardiff 
Medicentre).
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Results presented in sections 7.2:1 (i) - (iii) and data not shown, 
demonstrate that the blood stability of these inhibitors follows the general pattern 
of human > mouse = rabbit > rat. It should be emphasised, however, that no 
single structure was tested in all the species although the hydroxamic acid was 
common to all. There was evidence of inhibitor loss in both mouse and rabbit 
blood after 1 hour. The stability of CT1746 in the plasma of this species (Dr. O. 
Epemolu, personal communication) suggests that this activity is cell associated. 
The disappearance of hydroxamates in rat blood is presumably a consequence 
of high levels of C l esterase activity. The esterase converts hydroxamate to the 
corresponding carboxylic acid, a process which has been described for 5- 
lipoxygenase inhibitors (Summers et a i, 1987; Tateson et a i, 1988). In fact, 
degradation is considerably reduced by the addition of an esterase inhibitor (data 
not shown). From these studies we can predict that MMP inhibitors would 
undergo extensive metabolism in rats but would be more stable in mice, rabbits 
and humans. The stability of such compounds in human blood (7.2.1 {ii}) is 
encouraging for future clinical applications.
In vivo studies
The in vivo properties of these drugs have been tested in two ways. 
Firstly, an in vivo gelatinase screen was established. In effect, the in vitro V^C]- 
labelled gelatin assay was transferred in vivo by using the mouse pleural cavity 
to compartmentalise the reagents within the body. Variation of the route, time or 
concentration of the dose permitted the construction of inhibitor SARs. As an 
enzyme based assay, however, it can not easily isolate pharmacokinetic and 
enzymic effects and moreover, its narrow concentration range limits its 
usefulness. The blood levels of active compounds were, therefore, measured by 
more quantitative techniques. In one example the contribution of Pg' 
arylsulphonamide to the pharmacokinetics of the CT989 series was tested after 
intravenous administration. The results show that arylsulphonamldes exhibit 
distinctive pharmacokinetics in the mouse. After an initial rapid distribution phase 
compounds appeared to re-enter the circulation with subsequent levels 
remaining constant for a further several hours. Other inhibitors exhibited a more 
classical bi-exponential elimination with relatively short (3 half-lives (~ 20 
minutes). These latter results are comparable to those reported by Singh et al. 
(1993) for a range of collagenase inhibitors. The retention of CT989 in the blood
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was not detected by the pleural cavity assay which requires freely diffusable 
inhibitor. This suggests that ethyl acetate may extract the compound from a non- 
bioavailable pool. A precedent has, indeed, been set by other sulphonamide 
drugs which are retained in erythrocytes as a result of their interaction with 
carbonic anhydrase (Gupta, 1987). Comparison of CT989 with CT435 in the 
rabbit indicated that the unusual mouse profile may be an isolated case. The 
compounds exhibited similar pharmacokinetics after intravenous dosing.
The development of a CE assay permitted inactive compounds to be 
tested. Such studies can increase our understanding of how individual chemical 
features might contribute to the biological profile of a compound by isolating its 
pharmacokinetic and inhibitory activity. The hydroxamic acid was predicted to be 
the most pharmacologically active group. Unexpectedly, CT1466 which lacks 
this group was shown to exhibit similar pharmacokinetics to its parent compound, 
CT989. Thus a combination of the arylsulphonamide and the overall 
hydrophobicity of these compounds may overide the influence of the hydroxamic 
acid. That the arylsulphonamide series may be anomalous in this respect has 
subsequently been shown using ['•^C] - radiolabelled CT1746. Metabolism was 
limited exclusively to the hydroxamic acid which was converted to the carboxylic 
acid, amide and conjugated glucuronide in both mouse and rat (Dr. Epemolu, 
personal communication).
The rapid clearance of CT989 from rabbit blood after intravenous 
administration prompted a limited biodistribution study. Inhibitory activity, 
presumably due the parent drug, was identified in urine, bile, lung and kidney but 
not the liver. The presence of both intact drug and metabolites in the bile of rats 
has previously been described (Singh et al., 1993 Yachetti et al. 1993). This 
would not appear, therefore, to be an uncommon route of excretion for this class 
of compound. The appearance of CT989 in the kidney and urine indicates an 
additional excretory pathway although its appearance at this site may be a 
consequence of kidney damage by precipitated drug. This may also account for 
the presence of compound in the lung which is the first organ encountered after 
administration of a drug via the femoral vein. The total recovery of drug was 
estimated to represent only 3% of the administered dose. This indicates that the 
drug is deposited in tissues other than those described above. Recent studies, 
using radiolabelled CT1746 have shown that the majority of i.v. administered
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compound may be glucuronldated before being emptied into the gastro-intestinal 
tract (Dr. Epelomu, personal communication).
Oral bioavailability was first tested using the pleural cavity assay. SARs 
generated by this method identified a requirement for some hydrophilicity, whilst 
a nitrogen atom was preferred at the Pg' (Table 7.5). The most significant 
modification, however, proved to be the replacement of Pg' cyclohexylalanine 
with t-butylglycine. This group has also been used successfully by Roche U.K. in 
the development of their collagenase inhibitor, Ro31-9790. The bioavailability 
and pharmacokinetics of such inhibitors were tested in mice and rats. CT1746, 
CT1847 and Ro31-9790 all exhibited similar concentration-time profiles after i.v. 
and p.o. administration to mice. Half-lives (i.v.) were in the range of 34 - 38 
minutes which represents a two-fold improvement over comparable 
cyclohexylalanine inhibitors. Percentage oral bioavailability was typically 
between 35 and 45%, three orders of magnitude improvement over most 
cyclohexylalanine compounds. The overriding influence of the t-butylglycine is 
apparent from the similarity of the in vivo profiles produced by CT1746, CT 1847 
and Ro31-9790.
CT1746 was also compared to Ro31-9790 in the rat. The i.v. profiles 
showed a rapid distribution of both compounds which was followed by a shallow 
extended p elimination phase. The corresponding half-lives were 55 minutes 
and 81 minutes for Ro31-9790 and CT1746, respectively. These are longer than 
would be predicted from the poor stability of these compounds in rat blood. This 
suggests that the liver plays a more important role in their clearance than blood 
borne esterases. Extensive liver metabolism is also indicated by the poor oral 
bioavailability (5 - 7%) of both compounds in this species. Rat gut perfusion 
studies have shown that CT1746 is efficiently absorbed without modification (Dr. 
G. Curtiss, personal communication) and therefore the low figure for oral 
bioavailability is a consequence of first pass metabolism.
In summary, the development of methods for measuring inhibitors in 
biological fluids permits the stability and pharmacokinetics of these compounds 
to be investigated. The subsequent generation of biological structure-activity 
relationships, in turn, allows the identification of chemical features that are 
responsible for these properties. Inhibitors possessing Pg' cyclohexylalanine 
have relatively poor in vivo characteristics in mice and rabbits. Half-lives are of 
the order of 15 - 20 minutes and oral bioavailability is negligible. Replacement of
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this group with a t-butylglycine produces a doubling in the systemic half-life and 
significant improvements in bioavailability. Removal of the Pg' group allowed the 
large aryl group to be retained at the P i' of CT1746. A combination of these 
features produced orally active compounds that are potent and selective 
inhibitors of gelatinase.
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CHAPTER 8
DISCUSSION
The first part of this thesis (Chapters 3 and 4) examines mechanisms 
involved in the activation of three MMPs, gelatinase-A, gelatinase-B and 
fibroblast collagenase. This process has been investigated by a number of 
groups but such studies have often been limited by the small amounts of partially 
processed enzyme that are available from natural sources. Access to milligram 
quantities of purified proenzyme through recombinant protein technology and the 
subsequent development of sensitive and easily manipulated assay systems has 
allowed their biochemical properties to be examined in more detail. The second 
part of this thesis describes the use of kinetic assays to identify potent selective 
inhibitors of gelatinase-A. These studies are extended in Chapter 7 to the 
measurement of their pharmacokinetic properties and to the subsequent 
identification of potential clinical candidates.
Since each chapter contains a detailed discussion of the relevant findings, 
this discussion will be limited to a general summary of the results. It also 
provides an opportunity to comment on the broader implications highlighted by 
this work.
Matrix metalloproteinase activation
The over-expression of an enzyme may be used as an indication of its role 
in disease. That stromelysin and collagenase contribute to the outcome of joint 
inflammation may, for example, be suspected because their levels are 
significantly increased by inflammatory mediators. The evidence for elevated 
levels of progelatinase-A at sites of tumour invasion is less clear. In fact, there is 
some experimental evidence to support the proposal that invasion correlates, not 
so much with increased expression of progelatinase-A but with an increase in the 
proportion of the activated form (Dr. T. Baker, personal communication). The 
activation of gelatinase-A is, therefore, of considerable interest and the 
mechanisms by which it is achieved are only now being elucidated. In this 
context, the recent description of a potential cellular activator (Sato et al., 1994) is 
of significant interest. Chapter 3 reports the findings of a study on the activation 
of progelatinase-A by APMA and proteinases. Although this work was aimed 
towards establishing mechanisms of in vitro activation, the results of these
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studies may contribute to our understanding of the activation of progelatinase-A 
in vivo.
APMA induction of progelatinase-A self-cleavage results in the removal of 
the 80 amino acid propeptide to produce a single, active form with an N-terminus 
Y81 (Stetler-Stevenson et al., 1989). The steps involved in this activation process 
were investigated using inhibitors and by measuring its dependence on enzyme 
concentration to discriminate between intra- and intermolecular events. The 
reaction proceeds via a transient intermediate which proved to be too unstable 
for N-terminal sequencing. By homology with stromelysin (Okada et ai., 1988) 
this intermediate is probably the product of a cleavage that occurs a few residues 
upstream of the conserved propeptide cysteine. That the first step is 
intramolecular was shown by the fact that the rate of propeptide cleavage was not 
dependent on the enzyme starting concentration and by the inability of inhibitors 
to halt it. Presumably, this region of the propeptide lies within the substrate 
binding cleft and it is cleaved when the displacement of the cysteine from the 
catalytic zinc by APMA, allows the entry of water to render the enzyme 
catalytically competent. The remainder of the propeptide is then rapidly removed 
to produce the mature enzyme. The concentration dependence of this second 
cleavage and its sensitivity to inhibitors establishes that this is an intermolecular 
event.
The action of APMA is presumed to be artificial because a physiological 
counterpart has not yet been identified. A possible candidate for this role was 
proposed by Weiss et al. (1983). Endothelial cell-stimulating angiogenesis factor 
(ESAF) is a low molecular mass product of cloned lymphoma cells which 
activates fibroblast procollagenase and possibly progelatinase-A. Interestingly, 
its activity is enhanced by heparin which has also been shown to increase the 
rate of gelatinase-A self-activation (Crabbe et al., 1993). Presumably, the 
mechanism behind the two processes is similar and results from the ability of 
heparin to concentrate the reactants on its surface.
In vivo it is probable that MMP activation is initiated by other proteinases 
which are capable of removing the first 30 to 40 amino acids of the propeptide 
(Nagasi et ai., 1991). Cleavage occurs at a “bait region”, the sequence of which 
determines the class of endopeptidase capable of activating the MMP in 
question. Progelatinase-A, however, has proved resistant to in vitro activation by 
either serine proteinases or stromelysin (Okada et al., 1990). This can be linked
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to the absence of a susceptible peptide bond in the bait region. The discovery 
that progelatinase-A could be activated by cell membranes in the absence of an 
exogenous activator (discussed in Chapter 3), however, indicated that the cell 
may provide a component which is missing from in vitro reactions. It can be 
argued that plasmin may be able to activate progelatinase-A in the presence of 
this cellular component and that this explains why inhibitors of urokinase can 
block the type IV collagenase activity of metastatic cells (Reich et al., 1988). The 
identity of such a component has recently been reported by Sato et al. (1994) 
although it appears to activate progelatinase-A directly, rather than by a plasmin 
cascade. Given the ability of the TIMPs to block cell surface activation (Ward et 
ai., 1991) the activator has, not surprisingly, been shown to be a new member of 
the MMP family, namely, membrane type matrix metalloproteinase (MT-MMP). It 
binds to the plasma membrane by virtue of a lipophilic anchor-region situated 
within its C-terminal domain. MT-MMP contains a sequence at the end of its 
propeptide, which is also present in stromelysin-3, that is known to be cleaved by 
a group of subtilisin-like processing enzymes. Since these enzymes are located 
in the golgi (Misumi et al., 1991), MT-MMP may already be active before it is 
transported to the cell surface.
Work presented in this thesis shows that progelatinase-A can also be 
activated by comparatively high concentrations of soluble MMPs, namely 
matrilysin and interstitial collagenase. The ability of collagenase to process 
progelatinase-A can be significantly enhanced in the presence of heparin, which 
also stimulates gelatinase auto-activation (Crabbe et al., 1993). That this activity 
is mediated by the C-terminal domain of gelatinase-A was shown using a 
deletion mutant (proNGL-A) that lacked this domain. Heparin stimulated 
activation may not be confined to the test-tube as will be discussed later. 
Matrilysin can process progelatinase-A to the mature form, although the 
sequence of events is complicated by the autolytic action of gelatinase-A. 
Collagenase, on the other hand, cleaves only at N37_ which seems to be 
sufficient to allow gelatinase-A to complete the process. The sequence 
containing this bond presumably corresponds to the bait region of other MMPs. 
The same intermediate is produced by the action of stimulated human 
fibrosarcoma cells on progelatinase-A (Strongin et ai., 1993). Significantly, this 
cell-line was reported to produce elevated levels of both collagenase and 
matrilysin (Overall and Sodek, 1990). Since matrilysin and collagenase are often
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co-expressed in cell-lines their individual contributions to progelatinase-A 
activation in vivo may be difficult to establish. This might be facilitated by the use 
of specific inhibitors but as shown in Chapter 5, the two enzymes have similar 
inhibitor selectivities. Moreover, if the cleavage site of MT-MMP proves to be at 
|\j37_|_38 this enzyme may also possess a collagenase-like specificity. Alignment 
of its substrate binding sequence with that of other MMPs (Fig. 1.11) argues 
against this, however, since its S i’ sub-site shows gelatinase-like features.
Although these experiments do not establish a role for any individual MMP 
in the activation of progelatinase-A they do show that it is likely to be a result of 
MMP action. It is also possible that the MMP responsible may vary according to 
the physiological circumstances.
The activation of progelatinase-B has been studied extensively by a 
number of groups but the data emerging is equivocal. Using progelatinase-B 
purified from neutrophils, Triebel et al. (1992) demonstrated that autoprocessing 
of the proenzyme in the presence of APMA occurred by a stepwise truncation of 
the propeptide to M^s. At the same time a three step loss of C-terminal domain 
fragments to A^ OG produced a final species of 73 kDa. The 73 kDa form was 
reported to exhibit full activity despite retaining the part of the propeptide that 
contains the cysteine that is thought to bind to the active site zinc atom. The 
specific activity was not compared, however, with a form processed beyond the 
cysteine. Ogata et al. (1992) showed that stromelysin treatment of progelatinase- 
B produced an 82 kDa active form with pGS at the N-terminus which by homology 
with other members of the family represents the fully active enzyme. In contrast, 
Okada et al. (1992) reported that stromelysin treatment generates a 64 kDa 
species. Goldberg et al. (1992) generated various C-terminal mutants of 
progelatinase-B and found that some mutations produced a proenzyme that 
could not be fully processed by either APMA or stromelysin. They propose that 
the C-terminal domain may be in some way involved in processing.
Data from a comparative study of trypsin, APMA and stromelysin activation 
of progelatinase-B are described in Chapter 3. In response to the reports from 
Goldberg et al. (1992), the contribution of the C-terminal domain was also 
studied using a deletion mutant lacking the entire domain, proNGL-B. The 
resulting data show that, in the presence of APMA or stromelysin, proNGL-B 
generates the same amino-terminus as the full-length enzyme i.e. M^5 and p8 8 , 
respectively. The inability of APMA to induce a cleavage at p8 8  suggests that
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gelatinase-B does not recognise this site. This is somewhat surprising since 
gelatinase-A, which is reported to have a similar substrate specificity does cleave 
itself at this position. In agreement with Ogata et al. (1992), stromelysin 
processing of the wild-type enzyme is confined to removal of the propeptide. The 
64 kDa species, described by Okada, is formed when stromelysin is added to 
progelatinase-B that has been stored for prolonged periods. The reasons for this 
are unclear although collagenase is also known to cleave in its own hinge region 
more readily after storage (unpublished observation). In contrast, exposure to 
APMA causes self-processing at both the N-terminal and C-terminal ends of the 
molecule and the final form is produced at a slower rate than that generated by 
either stromelysin or trypsin. Self-processing and activation of wild-type and 
truncated enzymes occurred at a similar rate. Moreover, there were no significant 
differences in the specific activity of each form against gelatin and a peptide 
substrate. These data suggest that the C-terminal domain of progelatinase-B 
does not determine the autoprocessing specificity of the catalytic domain nor the 
final substrate specificity. The latter observation is consistent with previous 
observations on the role of the C-terminal domains of gelatinase-A and 
stromelysin (Murphy eta!., 1992a; Murphy eta!., 1992b). Surprisingly, the 
continuing presence of the propeptide cysteine in the APMA generated forms had 
no effect on the final specific activity, thereby confirming the observations of 
Triebel et ai. (1992).
Interstitial procollagenase can be partially activated by APMA and trypsin 
(Grant et a!., 1987; Nagase eta!., 1990; Suzuki eta!., 1990), however, full activity 
against collagen requires processing to the N-terminus. This is commonly 
effected by the addition of stromelysin in a process that is called 
"superactivation". This form of the enzyme is 5 - 8  fold more potent against 
collagen (Murphy et a!., 1987; Suzuki et a!., 1990) but its relative specific activity 
against peptide substrates has not been reported. Reinemer et al. (1994) arrived 
at a hypothesis for the role of F®1 by examining its position relative to other amino 
acids in a crystallographic model of the catalytic domain of neutrophil 
collagenase. They propose that a salt-bridge links the amino-terminal 
phenylalanine and an aspartic acid (D232) close to the end of the catalytic 
domain. This interaction results in a structurally more ordered N-terminal 
fragment which, unlike forms that lack this residue can then no longer block the
209
substrate binding cleft of an adjacent molecule. Based on this proposal, 
superactivation should increase the activity of collagenase against peptide 
substrates in addition to collagen. Data presented in this thesis (Chapter 4) 
provide no evidence for this proposal. The presence of F^i at the N-terminus 
conferred no additional activity against peptide substrates although removal of 
the propeptide cysteine appeared to be necessary for full activity. This would 
suggest that the presence of is only required for activity on collagen and that 
the association with the C-terminal aspartic acid (D232) may have a different 
function. On inspection, D232 js seen to lie close to the hinge region linking the 
catalytic domain with the C-terminal collagen binding domain. This is particularly 
short in collagenase and may be important in allowing the C-terminal domain to 
position the catalytic domain in the precise site for collagen cleavage. The 
phenylalanine-aspartic acid interaction may function similarly to maintain the 
correct orientation between the C-terminal domain and the catalytic domain. The 
proximity of F^i and, therefore, the propeptide to the C-terminal domain may also 
explain the observation that collagenase only binds to collagen in the active form 
(Vater et al., 1978; 1986; Murphy et al., 1992b). Presumably, this places the 
propeptide in a position where it can mask the collagen binding exo-site.
The activation of collagenase by stromelysin may be a means of fine 
tuning its activity in vivo, since the expression of both enzymes is significantly 
elevated by inflammatory mediators such as IL-1 and TNF and raised levels of 
both enzymes are observed in joint destruction (Walakovits et al., 1992). The 
presence of highly sulphated proteoglycans in the joint matrix may make the local 
environment acidic. Outside this environment stromelysin would be a far less 
effective activator since it has a pH optimum close to pH 5 (Harrison et al., 1992). 
Indeed, it retains less than 10% of its activity at pH 7.2 - 7.4 (unpublished 
observation). At physiological conditions of neutral pH, the role of stromelysin 
may be taken up by other MMPs such as matrilysin (Quantin et al., 1989).
The possibility that gelatinase-A is also capable of processing collagenase 
was noted whilst studying the activation of progelatinase-A by collagenase. A 
reduction in the size of the collagenase correlated with the appearance of active 
gelatinase-A and N-terminal sequencing of the newly formed collagenase 
revealed its N-terminus to be p8 i. The rate at which collagenase was processed 
was slow compared to processing by stromelysin, even at pH 7.5. The addition of 
heparin, however, significantly enhanced activation by gelatinase but not
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activation by stromelysin. The combination of fully active collagenase and 
gelatinase is a potent collagen degrading force. These observations show that 
gelatinase-A and collagenase may be involved in a reciprocated activation 
process which is enhanced by heparin. This activity may not be limited to the 
test-tube since all of these agents are be present at sites of mast cell action. Mast 
cells participate in a variety of inflammatory processes and are often found in the 
stroma at sites of tissue remodelling. Moreover, mast cells are also a source of 
tryptase and chymase, proteinases that can activate stromelysin (Gruber et al., 
1989) and collagenase (Saarinen et al., 1994; Lees et al., 1994), respectively. 
The presence of these cells at tumour sites before the ingrowth of new capillary 
sprouts (Taylor and Folkman, 1982) suggests that they may also play a role in 
angiogenesis. These authors also show that the release of heparin increases the 
migration of capillary endothelial cells In vitro. The involvement of MMPs in 
angiogenesis has also been demonstrated by the use of inhibitors to these 
enzymes (reviewed in Moses and Langer, 1991).
Reciprocated activation may also explain some of the conflicting 
experimental data that has emerged from studies on the relative contributions of 
serine proteinases and MMPs to basement membrane invasion. Reich et al. 
(1988), for example show that inhibitors of both collagenase and plasminogen 
activators block the invasion of an artificial basement membrane by metastatic 
cells. Reversal of the effects of plasminogen activators by the MMP activator, 
mersalyl (similar to APMA) lead the authors to propose that a plasmin - 
gelatinase cascade is responsible for basement membrane degradation. A 
similar pathway had already been proposed by Mignatti et al. (1986) on the basis 
of their study of proteinases involved in the invasion of amniotic basement 
membrane by B16 melanoma cells. The results in this thesis support an 
alternative mechanism in which plasmin activates collagenase, setting in motion 
the reciprocated activation process described earlier. A summary of possible 
pathways leading to progelatinase-A and procollagenase activation is presented 
in Fig. 1.8.
The requirement for an intact C-terminal domain for collagenolytic activity 
has been demonstrated by several groups (Birkedal-Hansen et a!., 1988; Clark 
and Cawston, 1989; Murphy et al., 1992b). In Chapter 4 the absence of this 
domain in a deletion mutant was shown to abolish collagen degrading activity 
without affecting the peptidase activity of collagenase. The function of the C-
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Figure 8.1 Zymogen activation cascade responsible for matrix breakdown
Fig. 8  summarises the possible pathways leading to the superactivation 
of collagenase and the activation of progelatinase-A and hence, matrix 
breakdown. A hypothetical membrane-dependent cascade is presented in the 
lower part of the figure. This shows the activation of MT-MMP (Sato et al., 
1994) by subtilisin-like enzymes in the Golgi. The active MT-MMP is then 
inserted into the cell membrane where it can initiate the activation of 
progelatinase-A.
The upper part of the figure depicts the involvement of plasmin in MMP 
activation. Procollagenase may be partially activated by plasmin to a species 
which retains the propeptide cysteine but has an exposed superactivation 
cleavage site. Collagenase is known to be cleaved at this site (F^i) by 
stromelysin (Murphy etal., 1987).
The present work has demonstrated that superactivation may also result 
from gelatinase-A action and that this is enhanced in the presence of heparin. 
This activity is reciprocated because active collagenase can process 
progelatinase-A to a form which rapidly undergoes autolytic activation. These 
events may occur at sites of mast cell action since they are a source of heparin, 
in addition to chymase and tryptase which activate procollagenase (Saarinen et 
al., 1994) and prostromelysin (Gruber etal., 1989), respectively. Matrilysin may 
be important in other circumstances, since it can directly activate progelatinase- 
A and superactivate collagenase (Quantin etal., 1989).
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terminal domain in directing substrate cleavage is unique to collagenase. The 
importance of this domain in collagenolysis makes it a potential target for 
collagenase inhibitors. This was tested by screening for monoclonal antibodies 
against collagenase that could block collagenolysis. During the course of this 
study an antibody (MAC065) was discovered which selectively inhibited 
collagenolysis with an IC5 0  of 3 nM, without affecting the peptidase activity of 
collagenase. Since this molecule does not cross-react with other MMPs it may 
provide an exquisitely selective means of blocking collagenase action. 
Moreover, this approach may be extended to other MMPs once the role of their 
potential substrate/matrix binding domains has been established.
The design of matrix metalloproteinase inhibitors
Captopril is widely regarded as the first example of an orally active 
metalloproteinase inhibitor. The design of this drug advanced the now common 
principle of combining a zinc chelating group with a pseudo-peptide structure to 
provide specificity. This principle was subsequently applied to the design of 
collagenase inhibitors by Gray et al. (1981). The resulting compound exhibited a 
relatively poor IC5 0  of 10 |xM against tadpole collagenase. More potent 
compounds were discovered using SARs so that within 5 years of the Gray 
structure, several groups were reporting ICso's for collagenase in the low 
nanomolar range (Dickens etal., 1986; reviewed in Johnson etal., 1987). The 
Searle hydroxamic acid based compound described in Chapter 1 (Fig. 1.9) is 
representative of the structures available at the time. Since then, four major 
issues have been raised, namely,
1. Which enzyme to target?
2. Is a selective inhibitor preferable to a broad spectrum inhibitor for cancer 
treatment?
3. How do you obtain selectivity?
4. How can a peptide based inhibitor be converted into an orally active drug?
Most of the early studies were directed against the best characterised 
MMP of the time. I.e. interstitial collagenase. There were good reasons to think 
that this enzyme was an important target for the treatment of rheumatoid arthritis. 
Loss of the articulating surface of the joint is the major disabling feature in this 
disease and collagenase is the only known mammalian enzyme capable of 
specifically cleaving the bundles of fibrillar collagen which form a large part of the
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joint matrix. Consequently, early inhibitors were based on the collagen cleavage 
site and in keeping with collagenase's specificity for collagen, leucine-like groups 
were invariably incorporated into the P / position.
Attention later turned to the destruction of proteogylcans observed in the 
traumatised joint (Walacovits et al., 1992). The enzyme responsible for this 
matrix breakdown was originally identified as proteoglycanase (Galloway et al., 
1983) on the basis of this activity but has since been renamed stromelysin, in 
recognition of its much broader substrate specificity. The cloning and purification 
of a recombinant form of this enzyme (Whitham et al., 1986; Murphy et al., 1987) 
greatly facilitated the task of designing more selective inhibitors. Another 
significant advance was made by the introduction of synthetic fluorescent peptide 
substrates (Stack and Gray, 1989: Knight et al., 1992). Nonetheless, progress in 
the design of non-collagenase inhibitors remained slow, largely because of a 
general reluctance to move away from the use of a leucine-like group in the P i' 
position. Indeed, there is little evidence of any significant modifications to this 
group prior to the studies undertaken at Celltech.
As reported earlier, access to milligram amounts of recombinant enzymes 
followed by the establishment of easily controlled and sensitive peptide assays 
were key elements in the progression of inhibitor design at Celltech. The main 
findings of this work are discussed in detail in Chapter 5 and so will only be 
covered briefly in this section, together with some observations made during the 
screening process which have not previously been described.
The first Celltech inhibitors to be tested were similar to the structure of 
Compound 5 (Fig. 1.9), described by Di Pasquale et al. (1986). This had three 
features which were retained in subsequent lead molecules namely,
1. It is right-hand side inhibitor.
2. It possesses R,S,S stereochemistry.
3. The zinc binding ligand is a hydroxamic acid.
The strategy applied at Cellech was to design selective inhibitors of the 
target enzyme, initially stromelysin, to minimise the side-effects that might result 
from modifying normal connective tissue turnover. Several broad range inhibitors 
were also designed as tools to probe the contribution of individual MMPs to 
disease progression. The main site of substrate recognition is the S i' pocket. 
The realisation that stromelysin self-cleaved at an aromatic residue eventually
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led to the introduction of a phenylpropyl group into the corresponding Pi' position 
of inhibitors. As predicted this fulfilled the dual role of increasing activity against 
stromelysin whilst discriminating against collagenase. This distinction was 
maintained when the target was switched to gelatinase-A because of its putative 
role in the metastasis (Chapter 1). Like stromelysin, gelatinase-A self-cleaves at 
the amino-terminal side of an aromatic residue. This choice of enzyme target 
proved to be fortuitous for inhibitor design, since it later became evident that 
selectivity for gelatinase over collagenase could readily be achieved. The 
converse is recognised as being far more difficult, an observation which can now 
be rationalised on inspection of their substrate-binding clefts. Fig. 1.11 shows 
how enzyme homology can be used to predict which amino acids are involved in 
forming enzyme binding pockets (Gooley etal., 1994). Gelatinase-A is thought to 
possess a large Si' sub-site which can easily accept the leucine preferred by 
collagenase. In contrast, the smaller Si' pocket of collagenase would not tolerate 
the bulky aryl groups favoured by gelatinase-A. Identification of the phenylpropyl 
Pi' group was a significant step in the effort towards discovering a selective and 
potent gelatinase inhibitor. This effort was maximised by screening inhibitors 
against a panel of MMPs, the results of which allows the following conclusions to 
be drawn. Essentially, gelatinase-A, gelatinase-B and stromelysin appear to 
have similar recognition sites characterised by a preference for a large Pi ’ and 
P3VP4' group. Matrilysin, like collagenase, cannot tolerate such a Pi' group and 
neither of these enzymes appear to form significant interactions with other 
inhibitor side-chains. As described above, these conclusions may be 
rationalised from modelling data based on X-ray crystallography and NMR 
(discussed in Chapters 1 and 5). In addition to post-rationalisation of SAR data, 
the work of Gooley et al. (1994) shows how inspection of the residues involved in 
Pi' binding can be used to predict enzyme selectivity. This was tested using 
neutrophil collagenase for which there is little available SAR data. Surprisingly, 
since collagen is a major substrate for this enzyme, it possesses an S\ pocket 
which bears more resemblance to that of gelatinase-A than to that of interstitial 
collagenase. On this basis it was predicted that it would accept inhibitors with 
aryl groups at the P i' position. This proved to be the case (unpublished 
observation) and, indeed, aryl based inhibitors may be as potent against this 
enzyme as gelatinase-A.
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Both SAR and structural evidence indicate that the Sg' and S3' sub-sites 
are shallow and the corresponding inhibitor side-chains face away from the bulk 
of the enzyme toward the solvent. Whilst this limits the potency and selectivity 
that can be incorporated into these positions it does present the opportunity to 
modify the physiochemical properties of the inhibitor. Incorporation of a biotin 
into the P3' position, for example, produced a compound similar to CT733 (Table 
5.4) that was subsequently used for localising MMP activity on breast cancer cells 
(Dr.T.Baker, personal communication). Modifications at the P2' residue 
contributed towards oral bioavailability (see later). The general requirements for 
gelatinase inhibition are summarised in Fig. 5.2.
Given that many different classes of zinc metallopeptidase reside on the 
extracellular surface of plasma membranes and are, therefore, highly accessible 
it was important that SARs were not confined to the study of MMPs. It emerged 
from these studies that aminopeptidase N, neprilysin and a mouse enzyme, 
meprin, did not accept the extended aryl group at the Pi'. In the case of 
neprilysin this is unexpected, since inhibitors such as thiorphan (Fig. 1.8) 
possess a phenylalanine analogue in this position (Roques etal., 1980). The 
lack of activity against ACE is somewhat less surprising since this enzyme is a 
carboxypeptidase and interacts with the C-terminal carboxylic acid of its 
substrates. Moreover, ACE is reported to prefer (S)-stereochemistry at the Pi ' 
chiral centre (reviewed in Johnson etal., 1987).
It is apparent that the kinetic properties of the inhibitors described in this 
thesis are very similar to those reported for ACE, including Ki's in the picomolar 
range. In such cases the rate of establishment of the equilibrium between the 
reactants and the complexes must be slow relative to those involving the 
substrate. Morrison and Stone (1985) summarised the consequences of this as 
follows. Low Ki values may derive from a low dissociation rate or a high 
association rate or both. Since there is an upper diffusion controlled limit of 10^ 
M-^s’i for the second order rate constant {kon) and Ki = ^off/kon, this means that 
an inhibitor with a Ki of 10“12 m will exhibit a dissociation half-time of at least 11.5 
minutes (see Table 6.1 for details). Furthermore, the rate of enzyme-inhibitor 
complex (El) formation would also be slow since the first order rate constant kon\ 
includes a term for free inhibitor, which in an inhibitor study is varied at 
concentrations in the region of its Ki value. The effects arising from slow
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establishment of equilibria can be avoided by preincubating the inhibitor with 
enzyme and then performing a steady-state analysis using the general equation 
for tight-binding and competitive inhibition described by Morrison and Walsh 
(1988).
From the argument outlined above we can see that such inhibitors may be 
studied using slow-binding kinetics even if their association rates approach 
diffusion limits. This is particularly valuable for analysing the individual 
contributions of kon and koff to the Ki value. Baici (1988) points out that for an 
inhibitor to be effective it must be able to bind to the target enzyme at a rate 
greater than that of its natural substrate, othen/vise significant substrate turnover 
would occur before equilibrium of the enzyme-inhibitor complex. MMPs are 
surrounded by an abundance of substrate which may have a significant effect on 
the delay time for inhibition. Consequently, the kon value of an inhibitor should 
ideally be large. Measurement of this value was facilitated by the high turnover 
rate of QF24, by gelatinase-A. This allows the enzyme concentrations to be kept 
low so that slow-binding equations can be applied. Methods for determining kon 
are discussed in Chapter 6. Briefly, this value was determined either indirectly by 
linear regressiori of kobs (apparent first order rate constant for establishment of 
equilibrium) on the inhibitor concentration or directly using X, a term relating the 
kon to the total inhibitor and enzyme concentration. The linearity of the former 
plot can be interpreted as an indication that enzyme-inhibitor complexes arise 
from a simple bimolecular collision. In most instances kon was above the limit of 
10® M‘is'1 proposed by Bartlett and Marlow, (1987) for slow binding inhibition. 
The broad range inhibitor, CT435 (Table 5.2), proved to be an exception, 
although its association rate constant was not significantly below the threshold 
cited above. Dissociation half-times, on the other hand, were consistently of the 
order of minutes to hours (Table 6.1). This shows that slow rates of dissociation 
are largely responsible for the slow establishment of equilibrium and a 
combination of this and a relatively rapid association rate result in inhibitors with 
Ki's in the picomolar range. The studies provide some indication of the 
relationship between inhibitor structure and association and dissociation rates. 
Surprisingly, both features appear to correlate with the size of the P3' group. An 
increase in kon. for example, was observed upon replacement of this group with 
an amide (CT1746), whereupon, incorporation of a large group in this position 
eg. sulphamylurea (CT1166) or arylsulphonamide (CT989) significantly
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decreased the rate of dissociation resulting in inhibitors with Ki's of less than 10 
pM against gelatinase-A. In another example, extension of the P3’ chain of 
CT543 by a single carbon (CT962) resulted in a ten fold decrease in the 
dissociation rate. Other groups may, however, make a significant contribution. 
Given that association rates are generally of the same order it is probable that 
any modification leading to a significant decrease in potency will be reflected in a 
higher koff value. Replacement of the hydroxamic acid of CT989 with a 
carboxylic acid (CT976), for example, leads to a thirty fold increase in koff (Fig. 
6.2). Obviously, the small sample size of this study precludes a more detailed 
analysis of the relationship between inhibitor structure and rates of association 
and dissociation with gelatinase-A.
There are comparatively few peptide based drugs in the clinic and this 
may be a consequence of their poor pharmacokinetic properties (Humphrey and 
Ringrose, 1986). That this is the case in the MMP area is reflected in the paucity 
of literature on the subject. Despite this obstacle, oral availability was a major 
goal in the design of the MMP inhibitors described in this thesis.
The published results may be summarised as follows (mainly from Singh 
et al., 1993). The sytemic half-life in rats is generally of the order of 6 - 40 
minutes. There are no reports of oral bioavailabilities greater than 10% and in 
most cases it appears to be negligible. Compounds appear to be subject to 
considerable first pass elimination. Analysis of the bile has identified the 
presence of parent compound and metabolites arising from modifications of the 
hydroxamic acid. Roche report a systemic half-life of about 1 hour in the rat and 
bioavailabilities of 7% and 17% in the rat and marmoset, respectively for Ro31- 
9790, which incorporates a tertiary butyl group in the P2' position. This is a broad 
spectrum MMP inhibitor, which is currently being developed for the treatment of 
arthritis.
British Biotech have adopted a different strategy in which the hydrophobic 
properties of their lead compound (BB94;Batimastat) have been maintained. Not 
unexpectedly, this makes the drug orally non-bioavailable but it imparts a long 
lasting depot effect when administered intraperitoneally. This formulation is 
reported to show beneficial effects in resolving tumour ascites (Beattie et al., 
1994).
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As a consequence of the specificity of the enzyme-inhibitor interaction a 
considerable reduction in potency may be expected after the incorporation of 
features aimed at improving bioavailability. The Celltech strategy is to develop 
inhibitors efficient enough to withstand this predicted drop in potency without 
significantly modifying their ability to target the enzyme. The development of 
methods to measure the activity of these inhibitors in vivo has been a key 
element in the progression of this work.
Two major questions were addressed,
1. How to rapidly screen inhibitors for improved pharmacokinetic properties?
2. How to measure the plasma levels of compounds that possess very poor 
chromophores?
The first issue was overcome by the development of the pleural cavity 
assay. This screen is based on a model described by Lark et al. (1990). In that 
model, stromelysin and radiolabelled transferrin were injected into the pleural 
cavity of rats and the effect of TIMP-1 administration was observed by analysing 
the contents of the pleural cavity. Transferrin is a very poor substrate for 
gelatinase-A (unpublished observation) and so it was substituted with 
radiolabelled gelatin. The assay was transferred to the mouse since efficacy 
models were established in this species. This assay was used to screen a 
number of inhibitors, initially following iritravenous (i.v.) or intraperitoneal (l.p.) 
administration. Activity after i.v. dosing tended to correlate with In vitro potency, 
implying that inhibitors had very similar systemic properties. Particularly 
hydrophobic compounds such as CT989 exhibited more prolonged activity after
i.p. administration, which indicates that this compartment can be used to provide 
a slow release mechanism. Similar properties were described for Batimastat 
(see above).
When studies were extended to the oral route none of these early 
compounds exhibited significant bioavailability. Results in Chapter 7 show that 
small improvements in oral bioavailability were effected by the introduction of a 
basic group into the P3' position (Fig. 7.5). The subsequent incorporation of a 
tertiary butylglycine group in the P2' position led to a dramatic improvement when 
it was combined with the removal of the P3' residue. Retention of the aryl Pi ' 
group meant that such inhibitors remained selective against collagenase and 
retained a significant level of potency (20 - 40 pM) for gelatinase-A.
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The pleural cavity assay was useful for providing SAR data but it could not 
be applied to the determination of pharmacokinetic properties. Accordingly, a 
range of extraction and detection methods were developed to determine the 
concentration of inhibitors in biological fluids. These were tested initially in a 
limited study of the stability of lead compounds in blood or plasma. The results 
indicate that inhibitors may be unstable in rodent blood although there is only 
evidence of serious instability in rat blood (Dr. G. Curtiss, personal 
communication). The good stability of a prototype compound, CT420, in human 
blood has since been established for other compounds (unpublished 
observation).
Methods developed for measuring blood stability were subsequently 
applied to pharmacokinetic studies. Titration of the inhibitory activity was 
generally employed for this purpose after an appropriate extraction step. One 
drawback is the inability of this method to discriminate between parent and 
metabolites of similar activity. Since, however, the hydroxamic acid is predicted 
to be the major site of metabolism, the major metabolites are not expected to be 
particularly active. Nonetheless, wherever possible analytical techniques were 
used to confirm the data and to identify the parent compound.
Early studies identified the arylsulphonamide series as having superior 
systemic properties in the mouse. Further investigation indicated that the 
hydroxamic acid was not the major determinant of their clearance. The atypical 
blood profile seen in the mouse was not displayed in the rabbit. Analysis of 
rabbit bile and organs associated with elimination accounted for only 3% of the 
administered dose. Other studies suggest that a large proportion of this dose 
may enter the Gl tract in the glucuronide form (Dr. O. Epomolu, personal 
communication).
Half-lives in the mouse were generally of the order of 15 - 20 minutes for 
cyclohexylalanine-type compounds. This figure was doubled by replacing this 
group with tertiary butyl. A ti/2 of approximately 35 minutes was determined for 
three such compounds, CT1746, CT1847 and a control compound Ro-31 9790. 
Most strikingly, oral bioavailability was raised from less than 1 % to greater than 
30%. The flat oral concentration curve observed in this species suggested that 
drug was only slowly absorbed. Since the rate of absorption across the G.l. tract 
is fairly consistent amongst different species and there is no evidence of slow 
absorption in the rat this may reflect a long residency time in the stomach.
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possibly as a result of precipitation. The oral bioavailability of CT1746 and Ro31- 
9790 was significantly reduced in the rat despite an apparent increase in the 
systemic half-life to over an hour. This may be interpreted as rapid first pass 
elimination since gut perfusion studies show that inhibitors are effectively 
absorbed (Dr. G. Curtiss, personal communication). The aggressive metabolism 
of the rat might not translate to higher species and so these compounds may be 
candidates for evaluation in humans.
In summary, this study has extended our knowledge of the mutual 
activation pathways which may orchestrate the activity of these enzymes in 
normal physiology and pathology. The measurement of the activity of these 
enzymes against fluorescent peptide substrates, allowed a range of SARs to be 
established that culminated in the synthesis of inhibitors with Ki's of less than 10 
pM against the target enzyme, gelatinase-A. The discrimination of these inhibitors 
against collagenase and members of other zinc metalloproteinase families 
should be reflected in a high tolerance to their presence in the body. At the same 
time it should be emphasised that a consequence of the activation of MMPs by 
one another is that even selective inhibitors may have an Indirect effect on the 
activation and hence activity of other MMPs.
This is the first study to report the kinetics of complex formation between a 
hydroxamic acid based MMP Inhibitor and an MMP. The results suggest that they 
exhibit many of the properties associated with the more potent inhibitors of 
peptidyl-dipeptidase A.
Finally, the development of methods to measure the in vivo activity of these 
inhibitors has resulted in the identification, of orally bioavailable compounds 
which may be used to provide treatment of tumour growth and metastasis in man.
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